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Abstract 
Lung cancer causes high mortality because most people present late with advanced disease 
that is not amenable to curative treatment.  Screening high-risk groups with low dose CT 
imaging of the thorax has been shown to reduce lung cancer mortality by 20%, but at the 
cost of a high false positive rate.  Population stratification with molecular biomarkers could 
improve the cost-benefit of lung cancer screening programmes and reduce false positives. 
 
Tumour cells shed DNA into the blood, enabling tumour-derived genetic alterations to be 
detected non-invasively by analysing circulating cell-free DNA (cfDNA).  The aim of this study 
was to determine the screening and prognostic potential of total cfDNA levels and two 
genomic instability scores based on the detection of copy number aberrations in cfDNA 
samples of lung cancer cases and controls collected in the ReSoLuCENT study (A Resource for 
the Study of Lung Cancer Epidemiology in North Trent).  Controls were identified as low or 
high risk for the development of lung cancer over five years using the Liverpool Lung Project 
risk model. 
 
CfDNA was extracted from the plasma of 52 untreated lung cancer cases, 32 high risk controls 
and 10 low risk controls and quantified total cfDNA levels by SYBR green real-time qPCR.  Low 
coverage whole genome sequencing with Illumina HiSeq 2500 was completed for a subset of 
cases (N=62) and controls (N=40).  Two published genomic instability scores were adapted 
and tested; the plasma genomic abnormality (PGA2) and the copy number aberration (CNA) 
score.  Screening potential was evaluated by performing Receiver Operating Characteristic 
(ROC) curves to assess the ability of the test to discriminate between lung cancer cases and 
controls by calculating area under the curve (AUC).  Logistic regression was used to further 
assess the ability of total cfDNA levels and genomic instability scores to predict case or 
control status.  Prognostic value was determined by Kaplan Meir and Cox regression survival 
analyses. 
 
In this preliminary study, there was no difference in total cfDNA levels between early stage 
lung cancer cases and high risk controls.  The PGA2 score was higher in high risk controls 
compared to lung cancer cases and was not further evaluated.  In comparison, the CNA score 
had good discriminatory ability for high risk controls compared to all lung cancer cases (stage 
I-IV) with an AUC of 0.74 but poorer discriminatory ability for early stage cases (I-IIIA) with 
an AUC of 0.60. 
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Although total cfDNA levels and CNA scores above the median value were associated with 
poor survival, both were statistically significant in univariable but not multivariable cox 
survival regression analyses.  Therefore, total cfDNA levels and the CNA score had limited 
prognostic value when other factors were taken into account.  Total cfDNA levels are not 
recommended as a screening tool because total levels lack specificity for cancer.  The 
screening performance of the CNA score may be improved by targeting recurrent copy 
number aberrations and by combining the score with alternative tumour-derived genetic 
alterations in cfDNA such as point mutations or methylation changes. 
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1 Introduction 
1.1 Introduction to lung cancer 
 Background 
Cancer is a major worldwide health problem.  Lung cancer is the second most common 
cancer in the United Kingdom and causes the highest number of cancer deaths (1, 2).  The 
five-year age-standardised survival rate for lung cancer is 9% (2).  This rate is low and 
treatment advances have had a minimal impact in improving survival outcomes (3).  Non-
small cell lung cancer (NSCLC) patients diagnosed with stage I or II (early disease) can be 
treated surgically with curative intent and have a one year survival rate of 71% and 59% 
respectively (4).  However, most patients with NSCLC are diagnosed with stage IV (advanced 
disease) and the one-year survival rate is significantly lower, 16% (4). 
 
 Lung cancer screening 
Early detection of lung cancer has been shown to reduce lung cancer mortality.  In the 
National Lung Screening Trial (NLST), high risk individuals aged 55 to 74 years (current 
smokers or ex-smokers having stopped < 15 year prior to study participation with at least a 
30 pack year history of smoking) (N=53,454) were randomised to be screened by low dose 
CT (LDCT) imaging of the thorax or chest radiography.  In this study, lung cancer mortality 
was reduced by 20% with LDCT imaging compared with chest radiography (5).  However, this 
benefit was at the cost of a high false positive rate and consequently a number of participants 
had unnecessary invasive interventions and follow-up tests.  Nearly 25% of screening LDCT 
scans were positive, with 96.4% of detected nodules being false positives and 320 people 
needing to be screened to prevent one cancer death.  Furthermore, the probability that a 
LDCT abnormality represented an indolent tumour was 18%, leading to concerns regarding 
over-diagnosis (6).  Three European LDCT screening randomised studies for lung cancer 
reported non-significant mortality reductions (DANTE, MILD, Danish Lung Cancer screening 
trial), but were criticised for small numbers of participants and the short length of follow up 
in a systematic review (7).  In the NELSON study (N=15,822), of the 7155 participants 
randomised to LDCT, 3% were diagnosed with lung cancer and <1% had interval cancers (8).  
The negative predictive value (NPV) was high (99.8%) and the positive predictive value (PPV) 
was 40.4%.  In comparison, in the NLST study the NPV was >99% and the PPV after one round 
 
 
2 
 
of screening was 2.4% and 5.2% after two rounds (9).  However, it is difficult to compare 
these studies because there were different criteria for a positive test and different study 
designs.  Mortality outcomes are still awaited for the NELSON study.  Lung cancer screening 
would be more cost-effective if the identification of high risk individuals was improved so 
that both the number of patients requiring LDCT imaging and the false positive rate were 
reduced. 
 
1.1.2.1 Risk prediction models to improve lung cancer screening 
Various risk prediction models have been developed to enrich the screened population and 
identify people at highest risk of developing lung cancer, based on family history and 
environmental risk factors (10, 11).  The application of risk prediction models in lung cancer 
screening programmes aims to identify a higher number of lung cancer cases for a set 
screened population (10).  However, there is variability in the effectiveness of risk prediction 
models.  In a recent systematic review of risk prediction models, the ability of models to 
distinguish between cases and controls measured by the areas under the receiver operating 
curve was between 0.57 and 0.88 (12). 
 
1.1.2.1.1 The Liverpool Lung Project risk model 
The Liverpool Lung Project (LLP) risk model was developed from data collected in a case-
control study combined with lung cancer age-incidence data (11).  The LLP model estimates 
the absolute risk of developing lung cancer over a 5-year period for both smokers and non-
smokers (11).  The model includes the most important lung cancer risk factors of age, sex 
and smoking (pack years), as well as other risk factors such as occupational exposure to 
asbestos, pneumonia, prior malignant cancer (other than lung cancer) and family history of 
lung cancer (11).  The LLP risk model has been validated in three large Western independent 
populations (two large case-control studies and one prospective cohort population study) 
with good discriminatory ability demonstrated by areas under the receiver operating curves 
of 0.76, 0.67 and 0.82 respectively (13).  The LLPv2 has been updated to include chronic 
obstructive airways disease and tuberculosis (14, 15).  A cut off of a ≥5% 5-year risk of 
developing lung cancer in the prospective cohort study had a sensitivity of 57.4% and 
specificity of 81.1% compared to a cut off of ≥2.5% that gave a higher sensitivity of 74.3% 
but lower specificity of 67.4% (13). 
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Using the LLP risk model, the United Kingdom Lung Cancer Screening (UKLS) programme 
recruited participants aged 50-75 years and randomised those with a ≥5% risk over 5-years 
of developing lung cancer to observation or CT screening (16).  Of 2028, participants that 
underwent CT screening, 42 (2.1%) had lung cancer.  The false positive rate was 3.6% and 
23% of participants required interval CT scans to follow up lung nodules (16).  In comparison, 
the cumulative risk of a false positive biopsy result over 10 years was 7.0% for mammography 
screening for women aged 40 years (17). 
 
Risk-prediction models such as the LLP risk model are very useful to identify individuals at 
higher risk, but the use of molecular biomarkers has the potential for greatly improved 
diagnostic accuracy (15).  For clinical utility, such a molecular biomarker test should be based 
on a sample that is easy to obtain, (e.g. blood), easy to perform in an NHS lab, reproducible, 
cost-effective, and have high sensitivity and specificity.  Currently available tests do not meet 
these criteria (see Section 1.5). 
 
 Histology and staging 
There are two main types of lung cancer.  NSCLC accounts for approximately 80% of cases, 
and small cell lung cancer (SCLC) 20% of cases (4, 18).  There are several subtypes of NSCLC, 
and the two most common types are squamous cell carcinoma and adenocarcinoma (19).  
The histological subtype determines chemotherapy options and the recommended genetic 
tests to identify patients that may benefit from molecular targeted treatments.  Lung cancer 
is staged according to the tumour, node, metastases (TNM) staging system, and the eighth 
system superseded the seventh edition in January 2017 (20). 
 
 Risk factors 
1.1.4.1 Acquired risk factors 
Smoking is a major risk factor for the development of lung cancer and causes 85% of cases 
(21).  Other acquired risk factors include exposure to radon, asbestos, heavy metals, diesel 
exhaust, silica (22) and ionising radiation (23).  Furthermore, there is an increased risk of lung 
cancer with benign pulmonary disease (24) and HIV infection (25). 
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1.1.4.2 Inherited risk factors 
The risk of developing lung cancer is 50% greater if an individual has an affected first degree 
relative (parent or sibling) compared to having no affected relative (Odds ratio (OR)= 1.51, 
95% confidence interval (CI): 1.39-1.63) (26).  Inherited genetic syndromes can predispose 
patients to cancer, including lung cancer.  Inherited RB1 (27) and TP53 mutations (28) are 
rare, but associated with a high risk of lung cancer at an early age (29) and an increased risk 
in subjects who smoke (27, 30). 
 
1.1.4.2.1 Inherited susceptibility loci 
Other than rare inherited syndromes, the majority of the inherited predisposition to lung 
cancer is believed to be caused by alterations in a number of low penetrance susceptibility 
genes (31). 
 
A variety of genome wide association studies (GWAS) have been carried out.  Studies that 
have analysed more than 100,000 single nucleotide polymorphisms (SNPs) are catalogued 
online by the National Human Genome Research Institute (32).  Susceptibility loci have been 
identified at chromosome loci 15q25 (33), 5p15 (34) and 6p21 (35).  These findings were 
replicated by The International Lung Cancer Consortium (ILCCO) in a large study of nearly 
fifty thousand subjects for 15q25 and 5p15 but not 6p21 (36).  In this study, the odds ratios 
for one susceptibility variant were low even for the strongest associations, for example a 
variant at 15q25 was found to have an odds ratio of 1.26 for the development of lung cancer 
in white subjects (95% CI 1.21-1.32).  However, the odds ratio increased to 2.64 (95% CI 1.86-
3.74) when three variants were considered (two variants for 5p15 and one variant for 
15q25).  Interestingly, the three main loci identified (15q25, 5p15, 6p21) account for less 
than 10% of familial risk, and further large genome wide studies are required to identify rare 
low risk variants and structural variations, which are also thought to contribute to lung 
cancer susceptibility (37).  Furthermore, genetic susceptibility loci can differ depending on 
subject ethnicity and histological subtype of the tumour (38, 39).  In a meta-analysis of four 
GWAS, the presence of a rare variant of BRCA2 approximately doubled the risk of developing 
squamous cell lung cancer (odds ratio 2.47), which is the strongest reported genetic 
association thus far in lung cancer (40). 
 
By exploring regions identified by GWAS, genes that may be important in the aetiology of 
lung cancer can be identified (39).  For example, 15q24-25.1 contains a candidate gene 
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coding for nicotinic acetylcholine receptor subunits and this region is strongly associated 
with lung cancer development in smokers (33, 36, 41).  A very recent GWAS has identified 
ten additional loci and highlighted seven genes that may be important in the development 
of lung cancer (39).  For example, three variants associated with the development of lung 
adenocarcinoma were located near genes related to telomere length (39).  As well as aiding 
understanding of the development of lung cancer, the identification of loci that increase the 
inherited risk of lung cancer could enable individuals inheriting a combination of risk alleles 
to be targeted for screening or smoking cessation programmes (41). 
 
 Genetic changes in lung cancer 
1.1.5.1 Carcinogenesis  
The development of lung cancer is a stepwise process from normal bronchial epithelium into 
regions of metaplasia, dysplasia, carcinoma insitu and invasive carcinoma (42).  Progressive 
histological changes are associated with increased genetic alterations.  Supported by the 
tumour microenvironment, the increased genetic alterations lead to the acquirement of 
different cancer hallmarks (43).  These hallmarks include, the induction of angiogenesis, 
sustainability of growth signals, evasion of growth suppressors, resistance against cell death, 
as well as developing capability to invade and metastasise and escape the immune system 
(43). 
 
In squamous cell carcinoma changes in the chromosome loci 3p are among the earliest 
changes of carcinogenesis with loss of alleles at different sites (3p21, 3p22-24, 3p25) (42, 
44).  Eventually changes occur in 9p21 (CDKN2A/p16), 8p21-23, 17p13 (TP53) and 13q14 
(RB1) (42)(Figure 1-1).  3p alterations are also early changes seen in adenocarcinoma and 
small cell lung cancer and therefore may be useful in the early detection of lung cancer (44). 
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Figure 1-1 The histological development of squamous cell carcinoma and accumulative 
genetic changes. 
Adapted from Wistuba 1999 (42) with permission. 
 
1.1.5.2 Genomic instability 
Genomic instability is an ‘enabling characteristic’ of cancer development that can lead to 
clonal cell proliferation (43).  There are many forms of genetic instability, which increase the 
mutation rate and therefore the chance of cancer. 
 
Somatic alterations that arise from genomic instability include: 
 point mutations: substitution of a nucleotide  
 insertions/deletions: addition/removal of a single or multiple nucleotides leading to 
a shift in the reading sequence 
 allelic losses/gains (such as those mentioned above)  
 structural chromosomal rearrangements caused by inversion, duplication, 
translocation (balanced variants), deletion or amplification (unbalanced variants 
that lead to a change in the number of base pairs in the genome and are also known 
as copy number aberrations (CNAs)) 
 epigenetic changes including the modification of DNA by methylation 
 
Mutations can be silent and have no consequence or there can be loss or gain of gene 
function (45).  Silencing of tumour suppressor genes and activation of oncogenes promotes 
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autonomous stimulation of growth signalling pathways and cell proliferation that can lead to 
the development of cancer (46-48). 
 
In lung cancer, patterns of somatic mutation differ depending on tumour histology, ethnicity 
and smoking habits (49-53).  Driver oncogenes, although mostly rare, have been identified in 
lung cancer to be important therapeutic targets, such as EGFR, ALK, HER2 and BRAF, in 
adenocarcinoma, and DDR2, FGFR in squamous cell carcinoma (47, 54-58).  More recently, 
108 of 110 SCLC tumours sequenced harboured mutations in both of the tumour suppressor 
genes TP53 and RB1 (53).  This high incidence indicates that mutations in these genes are 
essential to the pathogenesis of SCLC (51, 53).  Other important genes that are deregulated 
in SCLC are the oncogenes PIK3CA, EGFR and MET, and tumour suppressor genes CDKN2A 
and PTEN (59, 60). 
 
Large collaborative efforts to understand the cancer genome, epigenome, transciptome and 
proteome by processing tumour DNA, RNA and protein have resulted in a greater 
understanding of the mutational landscape of tumours including lung cancer (61, 62). 
 
1.1.5.2.1 Copy number aberrations in lung cancer 
The human genome is diploid and consists of two copies of each chromosome; a change to 
the total number of chromosomes is called aneuploidy (63).  Copy number aberrations 
(CNAs) are variations in the number of copies of one or more regions of DNA (63).  CNAs can 
vary in size from around 50 bp to several megabases (64), or be as large as a chromosomal 
arm or whole chromosome (65).  Duplication of DNA results in copy number gain, usually 
termed amplification if more than one copy is gained, and deletion of DNA is termed copy 
number loss, or deletion if both copies are lost (63). 
 
In lung cancer, CNAs are common, occur early in carcinogenesis (53, 66), are progressive and 
are present in both SCLC (53) and NSCLC (67).  Mostly, focal amplifications and deletions are 
reported because this level of resolution enables the identification of candidate genes and 
potentially actionable mutations for therapeutic manipulation (68-70). 
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1.1.5.2.1.1 Copy number aberrations identified in non-small cell lung cancer 
1.1.5.2.1.1.1 Squamous cell lung cancer 
In a study of squamous cell lung cancer, there was an average of 323 segmental CNAs 
identified per tumour, when tumour DNA from 178 surgically resected (76% stage I-II) 
specimens were profiled for CNAs with Affymetrix 6.0 SNP arrays (>900,000 probes)(68).  In 
the same study, the average number of focal aberrations per tumour was 47 and the average 
number of broad (defined as ≥50% of a chromosomal arm) aberrations was 23.  Novel and 
previously identified cancer-related genes were noted to occur at peaks of significant 
amplification and deletion.  These data were combined with SNP array data from a further 
306 (N=484, 94% stage I-IIIA) tumour-normal pairs.  In this combined study, 49 focal deletions 
and 33 focal amplifications were reported as significant aberrations based on their amplitude 
and frequency across samples (q value <0.05) (69).  The top ten focal amplifications were 
3q26.33 (SOX2), 8p11.23 (FGFR1), 11q13.3 (CCND1), 8q24.21 (MYC), 7p11.2 (EGFR), 4q12 
(PDGFRA, KIT,KDR), 2p16.1 (REL, BCL11A), 9p13.3, 19q13.2, 1q21.2 (MCL1) and the top ten 
focal deletions were 9p21.3 (CDKN2A), 8p23.2, 2q22.1, 10q23.31 (PTEN), 5q11.2, 1p13.1, 
3p13, 19p13.3, 3p25.3, 18q23 (69).  Low coverage copy number profiling identified 
significant copy number gains (copy number ratio >0.25) for more than 50% of tumour 
samples from patients with early stage squamous cell carcinoma for chromosomal regions, 
3q, 5p, 7p, 7q, 8q and 19q, and significant copy number loss (copy number ratio <0.25) for 
region 3p (71). 
 
Gain or amplification of chromosome 3q is one of the most common CNAs described for 
squamous cell carcinoma (68).  More specifically, amplification of the chromosomal region 
3q22-29 has been reported to be critical for progression of metaplasia to carcinoma (72, 73).  
There was a higher number of CNAs identified in squamous metaplastic lesions that 
progressed to carcinoma (N=6) compared to those that regressed (N=23) (73).  The presence 
of three CNAs (loss of 3p26.3-p11.1 and gain of 3q23-28, and 6p25.3-24.3) identified by array 
CGH predicted the development of squamous cell lung cancer from metaplastic lesions in an 
independent group of high risk patients with an accuracy of 92% (74).  Another study of 23 
cases described gains of 1q25-32, 12q23-24.3 and 17q12-22 as important for progression to 
carcinoma (72). 
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1.1.5.2.1.1.2 Adenocarcinoma 
Lung adenocarcinoma and lung squamous cell carcinoma tumours have different copy 
number profiles (69).  Affymetrix 6.0 SNP copy number profiles of 660 (89% stage I-IIIA) 
tumour normal pairs from patients with lung adenocarcinoma had just 25% of focal 
aberrations in common with profiles obtained from 643 squamous cell carcinoma tumours 
(69).  Fifty-two significant (q value <0.05) focal deletions and 30 focal amplifications were 
detected.  The top ten most significant regions of focal deletion were 9p21.3 (CDKN2A), 
9p23, 4q35.1, 22q13.32, 1p13.1, 15q11.2, 16q23.1, 11q25, 9q21.11 and 13q12.11.  The top 
ten most significant regions of focal amplification were 14q13.3 (NKX2-1), 8q24.21 (MYC), 
5p15.33 (TERT), 1q21.3 (MCL1), 12p12.1 (KRAS), 12q14.1 (CDK4), 11q13.3 (CCND1), 12q15 
(MDM2), 3q26.2 (MECOM/TERC) and 7p11.2 (EGFR) (69). 
 
1.1.5.2.1.2 Copy number aberrations identified in small cell lung cancer 
In SCLC, CNAs are generally over larger segments such as chromosomal arms, compared to 
CNAs detected in adenocarcinoma and squamous cell carcinoma that are more focal (66, 75).  
One-hundred and ten SCLC tumours were processed by Affymetrix 6.0 SNP array to identify 
CNAs (53).  Copy number amplifications greater than 1 Mb in size were detected for 
chromosomes 3q (SOX2, PIK3CA) 5p, 8q (MYC) and 1p and amplifications less than 1 Mb in 
size for 1p (MYCL1), 2p (MYCN), 13q (IRS2), 4q and 8p (FGFR1).  Copy number deletions of 
size greater than 1 Mb were identified for chromosomes 3p (FHIT, ROBO1), 3q, 13q (RB1), 
17p (TP53) with deletions less than 1 Mb for chromosomes 5q, 9p (CDKN2A), 15q and 4q. 
 
1.1.5.3 Identifying genetic mutations  
The molecular analysis of lung tumour tissue is important in order to identify potential 
treatment options for patients with advanced lung cancer.  The minority of patients (<20%) 
with lung adenocarcinoma (76) with tumour samples positive for EGFR mutations or ALK re-
arrangements may respond to targeted therapies with Gefitinib (77), Erlotinib (78), Afatinib 
(79), Osimertinib (80) or Crizotinib (54).  Further targeted therapies are in development in 
clinical trials, and to be eligible a patient’s tumour sample may require genotyping to identify 
somatic alterations (76, 81).  Because most patients with lung cancer present when the 
tumour has progressed beyond surgical resection, only a small diagnostic biopsy may be 
taken.  This tissue sample can be inadequate for detailed molecular analysis (82) and also 
limits further research.  Biopsies can be repeated but this is an invasive procedure with 
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potential risks.  Alternative approaches are required and circulating cell-free DNA (cfDNA) 
may provide means to give indirect access to the tumour DNA. 
 
1.2 Circulating cell-free DNA 
 Background 
Extracellular nucleic acids are identified in serum, plasma and lymph as well as non-
circulating fluids such as ascites, urine and saliva (83).  They comprise cfDNA, microRNA 
(miRNA) and messenger RNA (mRNA).  First described in blood by Mandel and Metais in 1948 
the field has significantly developed over the last 20 years as the use of circulating nucleic 
acids as potential biomarkers across different diseases and in prenatal medicine has been 
realised (84).  Circulating cfDNA describes double stranded DNA (dsDNA) fragments in the 
blood, either circulating freely, linked to proteins or encapsulated (85). 
 
 Circulating cell-free DNA in pregnancy 
Cell-free fetal-derived DNA is detected in the maternal circulation from the 7th week of 
gestation and levels increase as pregnancy progresses (86).  Low fractions of fetal-derived 
cfDNA are present in the maternal circulation, varying from 0.4%-11.9% in early pregnancy 
to 2.3-11.4% in late pregnancy (86).  Fetal genetic abnormalities have been detected in 
maternal blood non-invasively by analysing cfDNA samples (87).  Next-generation 
sequencing methods have increased the sensitivity for detecting fetal genetic abnormalities 
in maternal blood when circulating fetal DNA fractions are low (87, 88).  Fetal aneuploidy 
was detected non-invasively by whole genome next generation sequencing of maternal 
cfDNA (88), even with a fetal DNA fraction ≤10% (87).  This has facilitated the translation of 
non-invasive prenatal testing into clinical practice. 
 
In a large prospective screening study (N=15,841), non-invasive prenatal diagnostic testing 
of fetal aneuploidies (trisomies 21, 13, 18) in maternal blood by highly parallel next-
generation sequencing had higher diagnostic sensitivity and PPV and lower false positive 
rates compared to the standard screening methods of nuchal translucency ultrasound and 
serum biochemical analytes (89).  Furthermore, the number of invasive diagnostic tests that 
can potentially harm the developing fetus such as amniocentesis were reduced (90).  
Nonetheless, testing can fail if the fraction of fetal-derived cfDNA in the blood is too low (91).  
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Yet, this can be overcome by repeat testing at a later gestational date when circulating fetal 
fractions are expected to be higher in the blood (92). 
 
In addition to detecting fetal aneuploidies, the complete fetal genome has been sequenced 
(93) and sub-chromosomal abnormalities have been identified non-invasively (94, 95).  Thus, 
expanding the potential diagnostic role of non-invasive prenatal tests to identify micro-
deletions (94), copy number variants (95) and single gene disorders (96).  An additional 
application of prenatal cfDNA testing may be to screen for cancer to aid early detection (97).  
In the minority of pregnant women with multiple aneuploidies detected by cfDNA whole 
genome copy number analyses, seven of 39 had an underlying malignancy (97).  However, 
the challenge remains to develop a cost-effective test and the use of non-invasive prenatal 
testing in the NHS is currently limited (98, 99). 
 
 Circulating cell-free DNA in cancer  
The plasma concentration of cfDNA (measured in ng/ml) is higher in patients with cancer 
compared to healthy controls (100, 101).  However, raised cfDNA levels are not specific to 
cancer and have been observed in many other illnesses and after exercise (102-105).  Similar 
genetic and epigenetic changes have been demonstrated in tumour and cfDNA for many 
tumour types including breast cancer, lung cancer, colorectal cancer and melanoma (84).  
This has generated much interest in cfDNA as a potential cancer biomarker, particularly in 
lung cancer where there is limited tumour tissue available. 
 
CfDNA is readily obtained from a simple blood test and there is potential for repeated 
sampling at different points in the patient pathway.  Moreover, cfDNA may be more 
representative of tumour heterogeneity than a needle biopsy, as it comprises DNA from 
different clonal populations of tumour cells (106).  Recently, clonal and subclonal mutations 
were detected with variant allele frequencies varying from 0.15% to 23.3% in the plasma of 
cases with stage I and stage II NSCLC, demonstrating intratumour heterogeneity non-
invasively (107). 
 
1.2.3.1 Structure of circulating cell-free DNA 
CfDNA can circulate in the blood stream linked to proteins, be encapsulated within 
exosomes, microparticles or apoptotic bodies or circulate freely as nucleosomes, virtosomes, 
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or DNA traps (85).  CfDNA in the blood is highly fragmented in both cancer cases and controls 
(108).  In healthy controls, cfDNA fragments are characteristically small measuring less than 
200 base pairs (bp) with a peak fragment size of approximately 164 bp (109).  In cancer 
patients, cfDNA fragments can range in size from 1kb to just 100 bp but they are typically 
small measuring from 160 bp to 200 bp (93, 110, 111).  CfDNA fragments of 166 bp in length 
are commonly reported (93, 112-114).  This is the length of DNA that is wrapped around a 
histone protein (142 bp) combined with a linker fragment (24 bp) and is known as a mono 
nucleosome (109, 115). 
 
Tumour-derived DNA has been noted to be shorter or more fragmented than non-tumour 
derived DNA (85, 114).  A greater abundance of shorter DNA fragments (<145 bp) have been 
observed in plasma from colorectal cancer cases compared to controls (108).  More than 
50% of colorectal cancer cases had fragments less than 100 bp compared to 25% of controls 
(108).  Fragments less than 166 bp have been noted to be smaller in size by multiples of 10 
bp (109, 112, 114).  Ten base pairs is the equivalent length of a turn of the DNA helix around 
a histone protein that could resist nuclease activity and account for the observed 
distributions (116) (109).  Understanding the structure and origin of cfDNA in cancer cases 
and controls is important to enhance clinical utility (85). 
 
1.2.3.2 The origin of circulating cell-free DNA 
CfDNA in healthy controls originates primarily from haemopoetic cell death (lymphocytes 
and myelocytes) rather than solid tissue cell death (109).  In comparison, cfDNA in cancer 
patients originates mostly from the death of host tumour micro-environment and tumour 
cells rather than haemopoetic cells (85), with tumour proportions varying widely from 3% to 
93% (110). 
 
Nucleosome positioning varies between different cell types due to epigenetic differences 
(109).  These differences were exploited to identify the origin of the primary tumour by deep 
sequencing cfDNA from cancer cases and correlating patterns of fragmentation and 
nucleosome spacing to published datasets of human cell lines and primary tumour tissues 
(109). 
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1.2.3.3 Mechanism of release of circulating cell-free DNA 
The fragment size of cfDNA can infer its structure and mechanism of release from cells (85).  
Apoptosis is believed to be a major mechanism for the release of cfDNA for both cancer cases 
and controls yielding a mono-nucleosome size of 166 bp (114).  Small fragments in multiples 
of 166 bp have been observed as a ‘DNA ladder’ pattern on gel electrophoresis of cfDNA 
(110).  This pattern was similar to the ‘DNA ladder’ pattern caused by apoptotic cell death 
(110).  Phagocytosis of necrotic cells by macrophages can also lead to the release of small 
DNA fragments of size 185 bp to 926 bp into the circulation (117).  The presence of very small 
cfDNA fragments in the blood (<145 bp) may result from further cfDNA degradation following 
phagocytosis, or by nucleases in the blood after release of DNA from cells (108).  Larger, less 
degraded cfDNA fragments of more than 10,000 bp are attributed to the direct release of 
DNA from necrotic cells (110, 118, 119).  In addition, large cfDNA fragments could be actively 
released from tumour cells.  Leukaemic cells incubated in anti-apoptotic conditions released 
high levels of extracellular DNA despite low caspase activity (118).  Figure 1-2 summarises 
different release mechanisms of cfDNA into the blood. 
Figure 1-2:  The postulated mechanisms for cfDNA release into the blood and identified 
genetic and epigenetic alterations.   
LOH: loss of heterozygosity, MSI: microsatellite instability 
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Small membrane bound cell fragments called microvesicles that contain tumour DNA are 
secreted by tumour cells into the circulation, including exosomes, apoptotic bodies and 
microparticles (85).  The numbers of microvesicles are increased in the blood of cancer 
patients (120, 121).  Apoptotic bodies released from cells undergoing apoptosis are engulfed 
by phagocytes and release their DNA into the blood, thus contributing to levels of circulating 
cfDNA.  Exosomes (30-100nm) and microparticles (200-1000nm) contain protein, DNA and 
RNA and may function as intracellular messengers (85, 122).  Exosomes can be isolated in 
order to extract DNA and RNA for biomarker analyses (123, 124).  It has been suggested that 
exosomes may directly release their DNA into blood and that they are a ‘rich’ store of cfDNA 
(125). 
 
Another postulated mechanism for generation of cfDNA is circulating tumour cell (CTC) lysis.  
However, a single CTC contains 6 pg of DNA therefore, thousands of CTCs per ml of plasma 
would be required to obtain the typical cfDNA levels greater than 17 ng/ml seen in advanced 
cancer (126).  In fact, less than ten CTCs are often present in 7.5 mls of plasma in advanced 
cancer cases and therefore CTC lysis is not likely to make a significant contribution to the 
levels of cfDNA in the blood (126, 127).  Although, the number of CTCs detected in the blood 
of cancer cases can vary depending on the cancer subtype and stage (127). 
 
1.2.3.4 Elimination of circulating cell-free DNA from the body  
The half-life of fetal derived cfDNA in maternal plasma was found to be 16 minutes after 
delivery of the baby (86).  In comparison, the half-life of cfDNA in a colorectal cancer patient 
after surgery was 114 minutes (128).  Plasma nucleases degrade cfDNA but renal and hepatic 
clearance may also be important in the elimination of cfDNA from the circulation (86). 
 
In cancer patients, the rapid clearance of cfDNA enables real-time monitoring of tumour 
dynamics in response to chemotherapy (129) and targeted treatments (130).  A reduction in 
the levels of tumour-derived cfDNA or circulating tumour DNA (ctDNA) are early markers of 
tumour response in different cancer types (129, 131). 
  
 
 
15 
 
1.3 Characterisation of circulating cell-free DNA 
The three steps in processing cfDNA are blood sampling and processing, DNA extraction and 
analysis.  Many techniques are in use, some poorly validated, making comparisons between 
studies difficult, and limiting reproducibility of results (132).  All studies require detailed 
standard operational procedures (SOPs).  There are many potential factors that can affect 
the yield of cfDNA and these are shown in Figure 1-3  along with recommendations for blood 
collection, processing and storage. 
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Figure 1-3: Important pre-analytical and analytical factors and recommendations for optimal 
cfDNA processing (133-135).   
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 Pre-analytical processing  
1.3.1.1 Plasma vs Serum  
CtDNA is present at very low concentrations (ng/ml) so contamination with lymphocyte 
genomic DNA must be minimised to reduce false readings.  Serum cfDNA levels are higher 
than those in plasma due to the lysis of white blood cells during the clotting process, which 
causes the release of genomic DNA into the serum (136, 137).  There was a strong correlation 
between total cfDNA levels and white cell counts in serum but not plasma samples (138).  
Consequently, most cancer studies now focus on extracting cfDNA from plasma rather than 
serum. 
 
1.3.1.2 Blood sampling and processing 
Blood for cfDNA analysis is collected in tubes with anti-coagulants or preservatives that aim 
to prevent clotting and reduce cell lysis.  The type of anti-coagulant used can effect cfDNA 
yield when blood processing is delayed (139).  Blood collected in tubes containing heparin or 
citrate had significantly higher cfDNA levels at 24 hours compared to blood collected in tubes 
containing ethylenediaminetetraacetic acid (EDTA) (139).  EDTA blood collecting tubes are 
relatively cheap, readily available and in routine use in the NHS. 
 
The length of storage of blood prior to processing is a critical pre-analytical factor.  Prolonged 
storage of blood collected in EDTA tubes led to progressive increases in total cfDNA levels at 
four, seven and 25 hours compared to one and two hours (140).  Other studies have shown 
no difference in total cfDNA levels until after six hours of storage (135).  Increased cfDNA 
levels after prolonged storage is due to the lysis of white blood cells, which results in 
increased genomic DNA (141). 
 
It is recommended that blood collected in EDTA tubes is processed by double centrifugation 
(134, 135).  A slow spin (800g-2000g) separates plasma from other blood components.   
Followed by a further faster spin (2000-16000g) to remove all cells and debris whilst avoiding 
cell lysis (133, 134).  Plasma should be frozen and stored at -80°C and repeat freeze/thaw 
cycles avoided (133). 
 
Although more expensive than EDTA tubes, alternative blood collecting tubes with different 
cell preservatives have been tested (141-144).  CellSave (144) and Cell-Free DNATM BCT 
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(Streck) tubes have enhanced the clinical utility of cfDNA analyses by enabling longer storage 
periods prior to blood processing without affecting cfDNA yields (145) or ctDNA profiling 
(141).  Thus enabling a more practical and flexible approach to blood collection to facilitate 
greater clinical utility. 
 
CfDNA yields, single nucleotide variant (SNV) genotyping and copy number aberration 
profiles were unchanged when blood collected in CellSave tubes were compared to blood 
collected in EDTA tubes that were processed within four hours of blood collection, but were 
significantly altered when EDTA tubes were processed after four days (144).  There were no 
significant differences between CellSave and Cell-Free DNATM BCT (Streck) tubes after 96 
hours of storage for DNA quality, somatic variant detection and mutant allele frequencies 
(141).  With CellSave tubes, whole blood can be processed four days after blood collection, 
there is no requirement for centrifugation and samples can be sent in the post to a central 
laboratory (144).  Furthermore, with CellSave tubes CTCs can be analysed from the same 
blood sample as ctDNA advocating combinatory analyses (144). 
 
1.3.1.3 Circulating cell-free DNA extraction from plasma 
The low concentration of cfDNA in the blood necessitates efficient extraction methods.  The 
DNA yield, its purity for PCR analysis (absence of protein, EDTA and ethanol contaminants) 
and the ability to detect small fragments 50-100 bp are all important factors that affect the 
accuracy of downstream results (137, 146, 147).  CfDNA yield can vary greatly dependent on 
the extraction method (140, 146-148).  Maximising the quantity of extracted DNA is 
important to increase the sensitivity of downstream mutation analysis. 
 
For a DNA extraction method to be useful, the results must be reproducible between 
laboratories (132, 149).  Many DNA extraction methods have been used and some have been 
compared (137, 140, 147, 149).  Qiagen commercial kits are most frequently used for DNA 
extraction from plasma (135, 150).  Cells are lysed to release their contents and DNA is 
captured on a silica-gel membrane.  Thereafter, a number of washing steps are performed 
and finally the DNA is eluted from the silica-gel membrane.  Advantages of the Qiagen blood 
kit include that it is simple to use, it produces results quickly, and has the potential for robotic 
automation (151).  Disadvantages are that there is loss of small fragments <150bp, because 
they are filtered through the membrane instead of adsorbing to it (146).  For example the 
QIAamp® blood kit (Qiagen) yielded significantly less cfDNA from spiked serum (50ng/ml) 
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compared to the triton/heat/phenolchloroform method, 18.6% (SD±4.34%) and 38.6% 
(SD±7.15%) respectively (140).  It is difficult to compare techniques across studies due to 
local modifications of protocols and different methods for establishing cfDNA quantity and 
integrity. 
 
It is important to standardise methods of cfDNA extraction because there are a wide number 
of methods in use resulting in varied cfDNA yields.  As part of the European SPIDA-DNAplas 
collaboration, plasma was sent to fifty-six different laboratories in Europe, cfDNA was 
extracted using local methods and returned for quantification (150).  CfDNA yield varied 
between 2.87 pg/µl and 224.02 pg/µl, but there was less variability when extraction methods 
designed specifically for cfDNA were used (150). 
 
 Analytical processing  
1.3.2.1.1 Quantification of total cfDNA levels 
A variety of methods are in use to quantify total cfDNA levels, which are summarised in Table 
1-1.  Amplification of a single gene such as hTERT (152) or GAPDH (140) by quantitative 
polymerase chain reaction (qPCR) is most commonly used.  The choice of target gene may 
influence absolute DNA yields.  Higher levels of cfDNA were reported in the same patient 
plasma samples with single copy β-globulin gene than GAPDH, but this may have been due 
to false positive amplification by the primer and poor primer design (149).  CfDNA is highly 
fragmented and therefore higher molecular weight amplicons give lower estimation of 
cfDNA yield because fragments smaller than the amplicon are not quantified (133).  Accurate 
quantification is important to ensure adequate levels of cfDNA prior to further genetic 
analyses.  The impact of DNA fragmentation was assessed in one study, which reported that 
Picogreen and qPCR were less accurate in determining the concentration of smaller DNA 
fragments but more sensitive than (Nanodrop) spectrometry (153). 
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Method of total cfDNA quantification Detection 
Limit 
Advantages Disadvantages 
Fluorescent qPCR    
A reference gene can be amplified using 
specific primers from just a few copies to 
thousands/millions.  Emitted fluorescence is 
measured.  Examples of reference genes 
include GAPDH, β-actin, hTERT, Alu sequences 
 SYBR green: intercalating dye binds to 
dsDNA and fluoresces 
 Taqman probe: binds to predetermined 
sequence and fluorescent signal is 
emitted upon probe hydrolysis 
0.01 ng/ml 
(SYBR 
green) (154) 
Robust 
Reproducible 
Automated 
No post-PCR processing 
required 
Taqman probe: primer-dimers 
and nonspecific PCR products 
are not detected (155) 
Risk of introducing contaminants 
Accuracy can be affected by DNA 
fragmentation (153) 
SYBR green is less specific, as also 
measures primer dimers and 
contaminants.  Samples cannot be 
multiplexed in SYBR green assays (156) 
Taqman probe: selective amplification 
dependent on primer specificity 
Picogreen    
Direct fluorescent nucleic acid dye that binds 
to dsDNA 
0.025 ng/ml Less expensive than qPCR 
Quick 
No PCR required 
Detects all DNA fragments- less specific 
Accuracy can be affected by DNA 
fragmentation (153) 
Qubit® fluorometer     
Direct fluorescent nucleic acid dye that binds 
to dsDNA 
0.1 ng/ml Quick, no PCR required Low sensitivity 
Nanodrop spectrophotometry    
Calculate concentration by UV light 
absorbance 260nm 
1000 ng/ml 
(153) 
 
Simple and very quick 
260/280nm ratio gives measure 
of DNA purity 
Low sensitivity 
Nonspecific* 
Affected by contaminants such as protein 
Commercial DNA dipstick kits    
1 µl DNA quantified by comparison to DNA 
standards 
100 ng/ml 
(157) 
Simple 
Fast-minutes 
Nonspecific*, poor reproducibility 
Limited range of detectable 
concentrations, very low sensitivity 
Table 1-1:  Methods for determining cfDNA yield. 
*Measures single- and double-stranded DNA, RNA, oligonucleotide
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1.3.2.1.2 Detection of tumour-derived alterations in circulating cell-free DNA 
Tumour-derived cfDNA or ctDNA can be analysed to reveal both genetic and epigenetic 
changes (158).  The presence or absence of genetic alterations can be investigated and ctDNA 
can be quantified to track tumour evolution and response to treatment in real-time with 
longitudinal samples (159).  The ctDNA mutant allele fraction describes the fraction of 
mutant alleles compared to the total number of alleles (mutant plus wild-type alleles) (160).  
CtDNA mutant allele fractions correlate with tumour burden and ctDNA is more likely to be 
detected in cancer patients with advanced compared to early stage disease (161).  To 
quantify levels of ctDNA in patients with low tumour burden or to detect small changes in 
allele fractions highly sensitive and specific methods are required. 
 
A variety of methods are in use to determine cfDNA genetic alterations and examples are 
summarised in Table 1-2.  Initial methods to detect cfDNA genetic alterations relied on PCR 
amplification of a predetermined sequence and real-time quantification to determine the 
presence of mutant alleles, with some studies validating detected genetic mutations by 
direct sanger sequencing (162, 163).  More recently, reduced costs and technological 
advances have enabled the precise genetic make-up of a region to be determined by next 
generation highly parallel sequencing (164-166).  This has also improved the sensitivity of 
mutation detection in cfDNA samples.  In contrast to sequencing of targeted regions of 
known mutations, the complete plasma cfDNA genome or exome has also been intensively 
scanned to identify copy number changes, point mutations and re-arrangements (106, 131, 
160, 167).  Highly parallel sequencing, remains expensive but has the advantage of 
sequencing unknown DNA aberrations and is sensitive and quantitative (165, 168).  
Sensitivity and specificity can vary depending on a number of factors, including methods of 
DNA preparation, type of sequencing platform, depth of coverage and bioinformatics 
analyses.  How many times a genomic region is read is known as the depth of coverage and 
is a strong determinant of analytical sensitivity (160).  A higher coverage increases analytical 
sensitivity as there is more certainty of detecting a true mutation at low allele fraction, but 
increasing coverage increases cost.  Reducing the proportion of the genome sequenced can 
reduce cost and enable very high coverage (>10,000X).  Targeted panels for high coverage 
next generation sequencing can range from testing a few selected genes to hundreds of 
genes.  Primers can be designed to target amplicons for enrichment (166) or prior to 
sequencing prepared DNA library fragments with regions of interest can be captured and 
 
 
22 
 
enriched, for example by hybrid capture using biotinylated DNA oligonucleotides that target 
regions of interest (160). 
 
In lung cancer, ctDNA mutant allele fractions have been detected as low as 0.02% by high 
coverage targeted Illumina sequencing (10,000X) (CAPP-Seq) (160), 0.004% when the same 
method was used with additional PCR error suppression techniques (iDES-enhanced CAPP-
Seq) (169), and 0.01% by ddPCR (170).  By confirming the presence of a point mutation on 
the complementary DNA strand, mutations were detected at an even lower allele fraction of 
0.00004% (171). 
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Method Advantages Disadvantages 
Real-time quantitative polymerase chain reaction (RT-qPCR) (172) 
Allele specific 
PCR products amplified in real-time and quantified 
Examples of methods to enhance analytical sensitivity 
 Scorpion ARMs (scorpion amplification refractory 
mutation system) (163)-self- probing (reduces 
amplicons binding together) and fluorescent 
detection   
 Mutation enriched PCR (162)-2 step PCR using 
intermittent restrictive digestion to selectively 
eliminate WT genes 
Distinguish between mutant and WT allele by 
difference in only one single nucleotide.  
Screen ‘hot spot’ region where mutation known to be 
so tumour analysis not needed 
Detection sensitivity 0.5% mutant alleles 
Selective amplification dependent on primer 
specificity  
Only detects mutations that primers are designed 
for 
May miss mutations if only ‘hot spot regions’ are 
screened 
Bead based digital PCR in emulsion (BEAMing) (173) 
Allele specific 
PCR products amplified then tag WT and mutant alleles with 
different fluorescent probes, which can then be counted by 
flow cytometry 
Quantitative-can count fraction of positive alleles   
Can determine fraction of activating mutations that 
have switched to resistant type  
Detect rare mutant alleles 
Detection sensitivity 0.01%-1% mutant alleles 
Personalised assay so may need tumour sample 
Can only assess known mutations 
 
 
Denaturing high-performance liquid chromatography (DHPLC) (174) 
Allele specific 
PCR product is heated and fragment mobility assessed by 
observation of the chromatogram by UV light (2 
peaks=heterozygous, 1 peak=homozygous)  
Simple quick and cheap compared to sequencing 
analysis 
  
Selectivity dependent on primer sensitivity 
Less sensitive compared to other methods  
Detection sensitivity 3% mutant alleles (78)  
Can only assess known mutations 
Digital droplet PCR (ddPCR) (170)   
Allele specific  
Positive and negative fluorescent signals read by flow 
cytometer and used to calculate mutant allele 
concentration 
Quantitative-can determine concentration of mutant 
alleles 
Detection sensitivity 0.001% mutant alleles  
Quick 
Cost effective 
Selectivity dependent on primer sensitivity 
Can only assess known mutations 
Only one or a few mutations can be tested 
 
Direct Sequencing (172, 175)  
Sanger sequencing 
Chain termination sequencing- 
Irreversible chain termination after incorporation of a 
fluorescently labelled nucleotide followed by fragment size 
separation by electrophoresis.  Laser excitation causes 
fluorescence to be emitted and coloured chromatography 
peaks enable the identification of nucleotides and their 
ordering  
 
A) Simultaneously detect tumour specific 
alterations: chromosomal rearrangements, 
chromosomal copy number variations, single 
nucleotide polymorphisms in all known cancer 
genes.  Detects new mutations. No need for 
tumour sample 
B) High single base accuracy.  Long read lengths 
can be obtained 700-900bp (aids sequencing of 
repetitive regions) 
Less specific/mutation missed if high background of 
WT cfDNA ie. rare mutation or small amount of DNA 
Poor detection sensitivity 10%-30% mutant alleles  
Long run time for single assay 
Expensive  
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Method Advantages Disadvantages 
Second-generation sequencing- MPS/NGS/Highly parallel (164, 166, 167)  
Whole genome/Whole exome or Targeted sequencing 
Direct detection of each nucleotide base incorporated into 
a newly synthesised DNA strand in real time. 
Precise method depends on the technological platform eg. 
Illumina, Ion Torrent  
Examples of methods to enhance analytical sensitivity of 
targeted sequencing 
 TAm-Seq- detection sensitivity 2% with 
sensitivity and specificity >97% (166) 
 CAPP-Seq-detection sensitivity 0.02% (detection 
sensitivity 0.1% with 100% sensitivity and 99% 
specificity (160) 
 M-PCR- detection sensitivity 0.1% with sensitivity 
and specificity >99% (159) 
As above (A) 
Simultaneously analyse hundreds or thousands of 
bases (MPS) 
High throughput  
Quantitative- can determine allele fraction 
Increased sensitivity by targeting regions: exomes, 
amplicons of oncogenes or tumour suppressor genes  
  
Variable expense depending on proportion of the 
genome sequenced and coverage, costs are 
reducing 
Bioinformatic infrastructure required 
MPS: risk of over sampling but can be limited by 
error rate of sequencer 
 
 
 
 
 
Table 1-2 : Methods to detect tumour-derived cfDNA genetic alterations in lung cancer. 
MPS: massively parallel sequencing.  NGS: next generation sequencing.  TAm-Seq: tagged amplicon deep sequencing (target and amplify long genomic regions 
(1000s of bases) from just one DNA fragment by PCR prior to library preparation and sequencing).  CAPP-Seq:  cancer personalised profiling by deep 
sequencing (targeted hybrid capture of prepared DNA library fragments using biotinylated DNA oligonucleotides to select regions known to be recurrently 
altered in NSCLC). M-PCR: multiplex PCR (personalised PCR assay based on tumour-detected mutations to target regions of library DNA fragments prior to 
sequencing). 
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1.3.2.1.2.1 Tumour-derived copy number aberrations have been identified in circulating 
cell-free DNA 
In 2012, Leary et al. identified CNAs and re-arrangements in cfDNA of colorectal and breast 
cancer patients by whole genome sequencing with an average genome coverage of 9X (167).  
CNAs have also been identified in cfDNA of cancer patients by array CGH (113, 176, 177) and 
low coverage whole genome sequencing (178).  CfDNA CNAs have been reported in plasma 
samples of prostate cancer patients (N=9) (0.1X coverage) (178), patients with hepatocellular 
carcinoma (N=4) (17X coverage) (168) and patients with metastatic breast cancer 
(N=58)(0.1X coverage) (179).  Using array CGH, resistance mechanisms to androgen receptor 
targeted agents were explored in cfDNA samples of castrate resistant prostate cancer cases 
(176).  However, whole genome amplification was required to obtain adequate quantities of 
cfDNA (2.5 µg) for array CGH analyses (176). 
 
1.4 Circulating cell-free DNA and lung cancer 
There are many potential clinical applications of cfDNA in cancer and Figure 1-4 summarises 
the potential benefits for patients with lung cancer (128, 180, 181).  Particularly in lung 
cancer, the small amounts of available tumour tissue and potentially low tumour cellularity 
from diagnostic biopsy specimens obtained by bronchoscopy and endobronchial ultrasound 
transbronchial needle aspiration (EBUS-TBNA) warrants an alternative approach to the 
detection of tumour genetic alterations for genotyping and research (182).  
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Figure 1-4: The potential applications and benefits of cfDNA technologies in lung cancer. 
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 Detection of biomarkers to predict and monitor treatment response  
Genotyping in lung cancer is vital to identify patients that may benefit from targeted 
therapies to improve disease free survival and survival outcomes (183).  EGFR mutation 
status was not identified in nearly one in five lung cancer patients due to insufficient tissue, 
poor performance status and long turnaround time (184).  Genetic testing of cfDNA by means 
of a simple blood test is non-invasive and facilitates genetic analyses at multiple points in the 
patients pathway, without the need for an invasive tissue biopsy (158). 
 
Studies of cfDNA in lung cancer patients often focus on the ability to detect oncogenic driver 
mutations that are potential clinical therapeutic targets in patients with advanced disease 
(Appendix A).  There is varied concordance between mutations identified in tumour tissue 
and cfDNA from 59% to 100% (185, 186).  Discrepancies could occur for several reasons.  
Poor assay sensitivity can cause false negative results in cfDNA (174, 187, 188).  In a large 
study of 1162 patients with locally advanced or metastatic disease and matched tumour and 
cfDNA samples, the false negative rate for EGFR testing was 10% (188).  Concordance can 
vary between studies due to differences in patient factors as well as technical differences in 
laboratory methods for pre-analytical and analytical processing of cfDNA (189).  In addition, 
if plasma cfDNA collection and the biopsy were not taken at the same time, the tumour may 
have evolved in the interval resulting in loss of some mutations and gain of others (190).  
Furthermore, cfDNA may be more representative of tumour heterogeneity because DNA in 
the blood has come from multiple tumour cell clones rather than a small sample of cells 
taken at biopsy (159, 168). 
 
Currently, non-invasive cfDNA EGFR testing is recommended only when tumour tissue is not 
available, because a tumour could harbour a sensitising mutation not detectable in plasma 
(190, 191).  If a cfDNA sample tests negative for a mutation then a repeat tumour biopsy 
must be re-considered because genotyping plasma is less sensitive then tumour tissue (189). 
 
 The FDA have approved the RT-PCR cobas® EGFR Mutation Test v2 to detect plasma EGFR 
sensitising mutations (exon 19 deletion and exon 21 L858R substitution mutations) in 
patients too unwell for biopsy (192).  Gefitinib an EGFR tyrosine kinase inhibitor is licensed 
for patients with EGFR sensitising mutations detected in plasma when no tumour tissue is 
available.  In our local cancer centre, T790M cfDNA testing is soon to be available for patients 
unable to have a biopsy or with insufficient tumour tissue for processing, to establish 
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whether treatment with the third generation EGFR TKI Osimertinib may be of benefit.  
However, a tumour biopsy is still recommened in patients with negative T790M plasma 
results due to a 30% false negative rate compared to tumour genotyping (193). 
 
Serial measurements of mutations may be an alternative method to imaging to assess 
tumour response to treatment (129, 194).  The dynamic changes of ctDNA levels are 
demonstrated by targeted approaches and highly sensitive techniques.  Due to the non-
specific nature of measuring total cfDNA levels, small changes in ctDNA levels may not be 
detected as a change to total cfDNA levels and therefore would not be reliable for measuring 
tumour response to treatment. 
 
 Detection of resistance mechanisms 
CfDNA biomarkers have been incorporated into early phase clinical trials for predictive and 
prognostic assessment as well as to identify resistance mechanisms.  Resistance mechanisms 
to first generation (e.g Gefitinib, Erlotinib) and third generation (eg. Osimertinib) EGFR TKIs 
have been studied in cfDNA samples (Apendix Table A).  These studies have revealed tumour 
heterogeneity and a multitude of intra and inter-patient resistance mechanisms to include 
gene amplifications and point mutations, which may have been missed by tumour biopsy 
due to sampling bias (195).  Understanding response and tumour resistance mechanisms is 
vital to designing new drugs and treatment strategies to maximise clinical impact (195, 196). 
 
 Detection of disease relapse and minimally invasive disease 
Following potentially curative treatment, the presence of ctDNA may indicate minimally 
residual disease and may therefore represent a higher risk of disease relapse (197).  In the 
NSCLC TRACERx (TRAcking Cancer Evolution through therapy) study, cfDNA extracted from 
pre and post-surgical plasma samples of early lung cancer cases were profiled using 
personalised multiplex-PCR (mPCR) next generation sequencing assays based on individual 
tumour mutation profiles (159).  The presence of ctDNA was confirmed if at least two SNVs 
(clonal or subclonal) were detected in plasma.  Study participants had clinical assessments, 
blood profiling and CXRs performed every three to six months.  The detection of ctDNA was 
associated with disease relapse in 13 of 14 cases following surgery for early stage lung cancer.  
The median time between the detection of ctDNA and CT imaging confirmation of disease 
relapse was 70 days (range 10-346 days).  Furthermore, in three cases the proportion of 
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ctDNA increased during adjuvant chemotherapy suggesting resistance, and all three cases 
relapsed within one year of surgery. 
 
In addition to lung cancer, the presence of ctDNA has been associated with disease relapse 
in early stage breast (198) and colon cancer (197).  In breast cancer, serial blood samples 
were collected following neo-adjuvant chemotherapy and surgery for 55 cases (198).  CtDNA 
was detected by a personalised ddPCR assay (based on clonal somatic mutations identified 
in matched tumour samples) and the presence of ctDNA was predictive of disease relapse 
with a hazard ratio of 25.1 (95% CI 4.08-130.5, p<0.0001).  The median time that ctDNA was 
detected prior to clinical relapse was eight months.  Although case numbers were few, 
further genetic analysis of ctDNA with highly parallel sequencing identified somatic 
alterations more in keeping with alterations identified in metastatic deposits rather than the 
primary tumour. 
 
For 230 stage II colon cancer cases, targeted sequencing of tumour DNA was carried out for 
15 genomic regions known to be recurrently mutated (197).  Then, the somatic mutation 
with the highest allele fraction (compared to the mean allele fraction of a group of healthy 
controls) was used to create a personalised assay for ctDNA detection with high coverage 
targeted sequencing.  The detection of ctDNA after the completion of adjuvant 
chemotherapy was predictive of disease relapse with a hazard ratio of 11 (95% CI 1.8-68, 
p=0.001). These findings could lead to the development of personalised therapeutic 
strategies to target and eradicate micro-metastases (159, 198). 
 
1.5 Non-invasive biomarkers to potentially aid early lung cancer detection 
 Circulating cell-free DNA 
The identification of ctDNA in the blood may aid early lung cancer detection (160).  Although, 
it is more difficult to detect cfDNA tumour-derived genetic alterations in early stage 
compared to advanced stage cancer due to lower tumour burden (161).  Despite a high 
analytical sensitivity of 0.02% for detecting 139 recurrently mutated genes, the sensitivity 
for detecting ctDNA in stage I lung cancer cases was 50% compared to 100% for stage II-IV, 
specificity for both sup-groups was 96% (160). 
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1.5.1.1 Total circulating cell-free DNA levels 
Total cfDNA levels have been reported to distinguish early lung cancer cases (I-IIIA) from 
healthy controls, cases with benign nodules and cases with chronic inflammatory lung 
disease with a Receiver Operating Characteristic (ROC) area under the curve (AUC) of 0.80 
(199), AUC 0.90 and AUC 0.78 (101) respectively.  Further studies to demonstrate the 
potential screening or diagnostic tool in lung cancer are shown in Table 1-3.  The role of 
cfDNA levels in screening for lung cancer remains undefined, and poor sample handling as 
well as methodological differences could contribute to differing results between studies. 
 
Prospective studies are more informative than case-control studies for biomarker 
assessment because bias and reverse causation are reduced.  In a prospective study of 1035 
former or current heavy smokers attending for CT screening, there was no significant 
difference in median total cfDNA levels in participants found to have lung cancer compared 
to those who did not (4.8 ng/ml (N= 38, IQR 3.4-8.0 ng/ml) and 3.9 ng/ml (N= 947, IQR 2.1-
6.1 ng/ml respectively) (200).  In this study the median value for lung cancer patients was 
relatively low in comparison to a case-control study by the same group utilising the same 
methods (152).  It was then noted that over 40% of samples were analysed three years after 
being frozen and that nearly a third of DNA was lost annually due to degradation in storage 
(201). 
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Study Method of DNA Subjects 
(NSCLC unless stated) 
Total cfDNA level ng/ml 
(Range)( ± SD) 
Cut-off 
ng/ml 
Sensitivity 
Specificity 
AUC-ROCa 
(95% CI) Extraction Quantification 
Szpechcinski  
2016(199) 
QIAamp 
DNA blood 
midi kit 
RT-qPCR 
β actin 
 
Stage I-IIIA N=65 
Benign lung noduels N=28 
(Healthy controls N=16) 
Mean 4.00 ± 1.60  
Mean 3.06 ± 1.37 p=0.0009 
(Mean 1.01 ± 0.90 p<0.0001) 
2.8 86.4% 
61.4% 
0.80  
(0.70-0.84) 
Szpechcinski  
2015(101) 
QIAamp 
DNA blood 
midi kit 
RT-qPCR 
β actin 
 
Stage I-IIIA N=50 
Healthy controls N=40 
Mean 8.0 ± 7.8 (Median 5.9, 
range 1.12-41.0) 
Mean 2.3 ± 1.5 (Median 
1.87, range 0.72-6.49) 
p<0.0001 
2.8 90% 
80.5% 
0.90  
(0.81-0.95) 
 
Chronic inflammatory lung disease 
N=101 
Mean 3.36 ± 1.8 
p<0.0001 
5.25 56% 
91% 
0.76 
(0.68-0.83) 
Ulivi  
2013(202) 
QIAamp 
DNA blood 
mini Kit  
RT-qPCR 
GAPDH 
 
Stage I-IV  N=100  
Healthy controls N=100 
Median 47.2 (0.7–251)  
Median 9.2   (2.2–184) 
p<0.0001 
25 80% 
91% 
0.90  
(0.86-0.93) 
 
Catarino 
2012(203) 
QIAamp 
DNA blood 
mini Kit  
RT-qPCR 
hTERT 
Stage I-IV N=104 
Healthy controls N=205 
Mean 270 (-) 
Mean 122 (-) 
p<0.0001 
20 79% 
83% 
0.88 
(0.84-0.92) 
Van der Drift 
2010(204) 
MagNA Pure 
LC Total 
Nucleic Acid 
Isolation Kit  
RT-qPCR 
β globin 
 
Stage I-IV N=46 
Respiratory clinic attendees with lung 
cancer excluded (52% COPD) N=20 
Median 52 (5-3597) 
Median 29 (0-175) 
p=0.03 
32  
 
67% 
52% 
0.66  
(0.53-0.80) 
Kumar 
2010(205) 
QIAamp 
DNA blood 
mini kit  
Picogreen 
dsDNA kit  
Stage III, IV N=100 
Benign lung disease N=100 
Mean 122.7 ± 47.4 
Mean 74 ± 19.8  
p<0.001 
104.5 
 
52% 
95% 
0.83 
(0.77–0.89) 
Szpechcinski 
2009(206) 
QIAamp 
DNA blood 
midi kit  
RT-qPCR 
β actin 
 
Stage I-IIIA N=30 
Healthy controls N=16 
Mean 12.0 (1.5-64.4) 
Mean 2.7 (0.9-7.0) 
p<0.001 
7 50% 
100% 
0.87 
(0.74-0.95) 
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Yoon*(207) 
 
 
QIAamp 
DNA blood 
mini kit 
 
qRT PCR 
β actin 
 
NSCLC+SCLC (8.8%) Stage I-IV and 
ED/LD N=102  
Controls attending for lung cancer 
screening  mostly smokers N=105 
Median 22.6 (3.1-730.5) 
Median 10.4 (1.6-89.9) 
p<0.0001 
- - 
 
0.86 
(0.81-0.91) 
Paci 
2009(132) 
QIAmp DNA 
blood mini 
Kit 
qRT PCR 
hTERT 
Stage I-IV (most early) N=151 
Healthy controls N=79 
 
Mean 12.8 (-) 
Mean 2.9 (-) 
p<0.001 
2 85% 
47% 
0.79 
(0.71-0.83) 
Ludovini 
2008*(208) 
Qiamp blood 
kit** 
RT-qPCR 
hTERT 
Stage I-III N=76 
Healthy smokers N=66 
Mean 60 ± 99.8 
Mean 5 ± 8.8 
p<0.0001 
3.25 
 
80% 
60% 
0.82 
(0.75-0.88) 
Herrera 
2005 (209) 
QIAamp 
DNA blood 
mini kit 
RT-PCR 
β actin 
 
Surgical candidates N=25 
Healthy controls N=11 
Mean 14.6µg/l (3-30µg/l) 
Mean 10.6µg/l (7-14µg/l)  
p=0.18 
- - 0.63 
(0.44-0.82) 
Guan-Shun 
2004(210) 
QIAamp 
DNA blood 
midi kit 
PICOgreen 
dsDNA kit 
NSCLC+SCLC (24%) stage I-IV (mostly 
advanced) N=67 
Benign lung disease N=36 
Healthy controls N=44 
Median  110.7 (10th -90th 
percentile, 22.9-383.5) 
Median 45.5 (7.5-121.0) 
Median 11.6 (2.5-31.8) 
p<0.001 
53.8 
 
 
 
70% 
80% 
 
cancer vs all 
controls 0.86  
(0.80-0.91) 
 
Sozzi* 
2003(152) 
QIAamp 
DNA blood 
mini kit  
RT-qPCR 
hTERT 
 
NSCLC I-IV (most early stage) N=100 
High risk attended for screening 
N=100 
Median 24.3 (-) 
Median 3.1 (-) 
No p value  
25 
 
46% 
99% 
 
0.94  
(0.91-0.97) 
Sozzi 
2001(157) 
QIAamp 
DNA blood 
mini kit 
DNA DipStick 
TM kit  
NSCLC stage I-III N=81  
Healthy controls N=32  
Mean 318  
Mean 18 
No p value 
26-125 86% 
100% 
0.84 
(0.77-0.90) 
 
Table 1-3: The utilisation of cfDNA levels as a potential screening or diagnostic tool in lung cancer. 
aAUC-ROC: area under the curve – receiver operator characteristics, a measure of discriminatory power, a value of 1 has excellent discriminatory power where 
as a value of 0.5 has no discriminatory power.  All studies in this table were conducted with plasma samples.  *matched cases to controls.**specific type of 
kit not stated.
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Most recently, six genes from The Cancer Genome Atlas known to be commonly methylated 
in squamous cell and adenocarcinoma lung cancer were investigated in matched sputum and 
cfDNA samples in a case-control study of early stage lung cancer (stage I and IIA) and controls 
with histologically confirmed benign lung nodules.  With an optimised method to minimise 
DNA loss, the best combination of three genes had a sensitivity and specificity of  98% and 
71% for sputum and 93% and 62% for plasma with AUC 0.89 and AUC 0.77 respectively (211).  
Prior to this study, the sensitivity and/or specificity of cfDNA methylation analyses were too 
poor to be useful for screening, or studies focused on cases with advanced lung cancer (212-
214), or compared cases to healthy rather than high risk controls (215). 
 
Alternative blood biomarkers have been investigated in lung cancer to aid early detection to 
include circulating tumour cells (CTCs) (216, 217), microRNAs (218) and proteins (219, 220). 
 
 Circulating tumour cells 
An advantage of detecting somatic alterations in CTCs are that they are specific to cancer, 
and are not identified in genomic DNA or caused by other disease processes (221).  Similar 
to cfDNA, CTCs are present in minute quantities in the circulation and have to be isolated 
from blood constituents (222).  CTCs can be enriched by identifying their epithelial cell 
markers or physical characteristics (size or deformability) or all blood cells can be analysed 
(223).  Once isolated (223), CTCs can be quantified (by the number of cells per volume of 
blood), single cell components (DNA, RNA, protein) can be extracted and analysed (224) and 
the morphology of CTCs can be studied (225).  Furthermore, CTCs can be grown in vitro or 
injected subcutaneously to create CTC derived xenograft (CDX) models.  The CDX models 
carry the same genetic signature as the primary tumour, model response to therapeutics and 
enable the identification of tumour resistance mechanisms (226). 
 
The FDA have approved a cell search system that selects and counts CTCs by an epithelial cell 
marker for prognostic monitoring, in certain types of cancer but not lung cancer (227).  This 
method in early stage lung cancer patients only identified one or more CTCs in approximately 
one third of patients studied (N=125) and had poor diagnostic ability (217).  With epithelial-
mesenchymal transition, CTCs may lose their epithelial cell markers and escape capture 
(228).  In a study of patients with COPD (N=168), CTCs were isolated by size and identified by 
defined cytopathological features (229).  In this study, 3% of COPD patients had between 19 
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to 67 CTCs detected between one to four years prior to the identification of a lung lesion on 
annual CT screening and subsequent diagnosis of stage IA NSCLC.  No COPD patient without 
CTCs detected subsequently developed cancer (median follow up 60 months) and there were 
no CTCs detected or cancer diagnoses for smoking (N=42) or non-smoking healthy controls 
(N=35) with a mean follow up of five years.  However, due to limited data CTCs cannot be 
recommended to aid early lung cancer detection.  Furthermore, the technology is relatively 
expensive and if robust standardised methods for cfDNA were validated, this would be a 
simpler, more widely applicable and cheaper methodology.  In addition, for CTC genome 
analyses whole genome amplification is required to obtain adequate DNA quantities for 
sequencing that can lead to the introduction of artefacts (230)  
 
 Circulating RNA 
Cell-free miRNAs circulate in the blood and evade degradation by RNAses by attachment to 
protein complexes, or containment within exosomes/microvesicles, apoptotic bodies or HDL 
structures (231, 232).  As regulators of gene expression, levels of miRNA are deregulated in 
cancer (231) and certain miRNAs are associated with lung cancer development and 
aggressiveness (218, 233).  Tumour-derived RNA includes miRNA (non-coding small RNAs) 
and long non-coding RNA.  Due to their small size, miRNAs are more stable than long non-
coding RNA and they can be detected by relatively simple assays (233).  MiRNAs can be 
detected by RT-qPCR, microarray hybridisation (233) or more recently sequencing (124). 
 
In lung cancer, miRNA have most frequently been studied as diagnostic and prognostic 
biomarkers (218, 234).  A 13 miRNA panel was validated in a large LDCT screening study of 
high risk individuals (heavy smokers aged ≥50 years, N=1,115), the diagnostic sensitivity and 
specificity for lung cancer were 78% and 75% with an AUC of 0.85 (234).  A 24 miRNA panel 
was validated prospectively in a large screening study (current or ex heavy smokers aged ≥50 
years, N=939) and diagnostic sensitivity and specificity were 87% and 81% (218).  In this 
study, the combination of detecting a lesion by LDCT and a positive miRNA test reduced the 
false positive rate from 19.4% for LDCT alone to 3.7%.  In a different study, miRNA was 
isolated from tumour-derived exosomes of early stage NSCLC cases and sequenced, the 
presence of a panel of miRNA had an AUC of 0.94, indictaing excellent discriminative ability 
(124).  However, in lung cancer studies there is great variability between published miRNA 
panels with different numbers and types of miRNAs reported.  These differences are most 
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likely due to patient factors, a lack of standardised methods for collecting, processing and 
quantifying/normalising miRNA expression, as well as variability in the material studied eg. 
whole blood, serum, plasma, and exosomes. 
 
 Proteins  
In response to tumour-antigens, the immune system produces autoantibodies that circulate 
in the blood and can be identified in serum by enzyme-linked immunosorbent assays (ELISA), 
a relatively straightforward assay that can be performed in most clinical laboratories (235).  
A six-panel autoantibody test was technically (236) and clinically validated in three matched 
(for age, sex and smoking history) early lung cancer case-control groups with reported AUC 
of 0.63-0.71 and a diagnostic sensitivity of approximately 40% and specificity of 90% (220).  
Diagnostic specificity was increased to 93% by the addition of a seventh autoantibody to the 
panel (p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE, SOX2) to create the Early CDT®-Lung test 
(Oncimmune Ltd., Nottingham, United Kingdom)(237).  This test has been audited in clinical 
practice (N=1,600) (238) and discriminated between people with benign and malignant 
detected lung nodules (N=296) with similar values of sensitivity and specificity (239).  A 
randomised prospective clinical trial to evaluate the ability of the Early CDT®-Lung test to 
identify high risk individuals is ongoing with the primary aim to reduce the number of stage 
III and IV lung cancer cases diagnosed (240).  So far, 10,000 ex-smokers or smokers aged 50-
75 years have been recruited in Scotland out of a planned 12,000 participants (241). 
 
Blood Levels of pro-surfactant B are increased in NSCLC compared to high risk controls and 
can be identified by ELISA (219, 242).  The ability of Pro-surfactant B levels to distinguish 
between high risk controls and lung cancer cases was tested in a large prospective screening 
study (N=2,485) that recruited individuals with a 2% risk of developing lung cancer in a 3-
year period by using risk prediction models (219).  In this discovery set, there was good 
discriminative ability with an AUC of 0.69 and 0.74 when adjusted for lung cancer risk factors.  
In a validation set, with samples from a different study the AUC was 0.68.  Levels of pro-
surfactant B were found to be higher than matched controls for cases with adenocarcinoma 
but not squamous cell carcinoma.  Reliance on single biomarkers that vary by the histological 
subtype of lung cancer is not recomended.  A screening test needs to differentiate between 
all histological types of lung cancer and high risk controls to reduce the false negative rate. 
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The combination of pro-surfactant B levels and N1,N12-diacetylspermine (a serum 
metabolite) differentiated between cases that developed lung cancer (N=108) and matched 
healthy controls (N=216) in a validation set with an AUC of 0.81 for cases with serum samples 
collected 0-6  months prior to diagnosis and an AUC of 0.73 overall (243).  A combinatory 
biomarker approach is therefore advocated. 
 
 Other non-invasive biomarkers in lung cancer 
Urine can be collected non-invasively and is an abundant source of biomarkers.  Urine 
metabolites were evaluated by liquid chromatography-mass spectrometry and four 
metabolites differentiated between lung cancer cases stage I-II (N=213) and matched 
population controls (N=536) (age, sex, race) with AUC 0.71 (244).  For 178 cases and 351 
controls (matched on age, sex, race, date of sample collection), the AUC was improved when 
two of the four urinary metabolites were combined with lung cancer risk factors (from 0.78 
to 0.80) (245).  However, the occurrence of these metabolites in other cancer subtypes is 
unknown; metabolism can vary with dietary and drug intake and levels of metabolites can 
be affected by renal function (244).  Alternatively, the detection of volatile organic 
compounds in exhaled breath show promise for early lung cancer detection but there is a 
lack of standardised validated methods (246). 
  
 
 
37 
 
 
1.6 Aims and objectives of the project 
Lung cancer is a genetic disease caused by inherited and acquired genetic changes.  The 
hypothesis of my PhD is that the identification of acquired genetic changes of lung cancer in 
the blood will enable the development of clinically useful biomarkers.  There is a significant 
need to improve the overall survival of people with lung cancer by detecting asymptomatic 
individuals with early stage disease.  Molecular stratification of people at high risk of lung 
cancer may reduce the number of people needing CT imaging and minimise the false positive 
rate, thereby improving the cost-effectiveness of a lung cancer-screening programme. 
 
To improve diagnostic accuracy it is important that a test has high diagnostic sensitivity.  
Current proposed non-invasive biomarker tests report sensitivity of 40%-87% (218, 220).  
High diagnostic sensitivity was reported for specific miRNA panels but there was poor 
consensus between different studies because the numbers and types of miRNAs tested 
differed (218, 220, 234).  It was proposed to further investigate the use of cfDNA as a non-
invasive blood biomarker to aid early lung cancer detection by using blood samples collected 
in the ReSoLuCENT study (A Resource for the Study of Lung Cancer Epidemiology in North 
Trent) study (247) (see Section 2.2.2).  Previously, sequencing methods have focused on a 
single gene or a panel of genes, to reduce cost and increase test sensitivity.  Low coverage 
molecular profiling of cfDNA represents a cost effective, unbiased approach to identify 
somatic copy number alterations across the whole genome. 
 
 Optimising plasma DNA extraction and evaluating total circulating-cell free DNA levels 
as a potential screening tool (Chapter 3) 
The initial aim of my PhD project was to optimise the quantity of extracted plasma cfDNA to 
enable sensitive downstream genetic analysis of samples collected in ReSoLuCENT.  Method 
standardisation is an important step towards national standardisation and future clinical 
implementation (84).  This facilitates appropriate blood handling and processing, plasma 
cfDNA extraction and analysis, in order to further biomarker development in lung cancer. 
 
The first aim and objective was: 
 To identify the most efficient cfDNA extraction method by comparing the percentage 
recovery of tumour formalin fixed paraffin embedded (FFPE) DNA from healthy 
volunteer plasma. 
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Many studies have demonstrated that total cfDNA levels can discriminate between lung 
cancer cases and controls (see Section 1.3.2.1.11.5.1.1).  Most recently, total cfDNA levels 
had excellent discriminative ability to distinguish between early lung cancer cases (I-IIIA) and 
healthy controls with AUC 0.90 (101).  However, no study has assessed the discriminatory 
ability of total cfDNA levels to distinguish early lung cancer cases and high risk controls 
identified by a risk prediction model.  It was hypothesised that total cfDNA levels would be 
higher in lung cancer cases compared to high risk controls.  Quantification of total cfDNA 
levels is a simple and cheap test that could be carried out in any laboratory able to perform 
RT-qPCR assays and is therefore a cost-effective approach warranting further evaluation. 
 
The second aim and objective was: 
 To evaluate total cfDNA levels quantified by SYBR green RT-qPCR as a potential 
screening tool for lung cancer by comparing total cfDNA yield for lung cancer cases 
and high risk controls. 
 
 Low coverage sequencing to identify copy number aberrations in circulating cell-free 
DNA (Chapter 4) 
Copy number aberrations (CNAs) occur early in lung carcinogenesis, are progressive and 
occur in both NSCLC and SCLC.  The hypothesis was that due to the release of tumour DNA 
from cancer cells, lung cancer cases would have more cfDNA CNAs compared to high risk 
controls and therefore the detection of CNAs may serve as a screening and prognostic tool 
for lung cancer.  A genomic instability score can quantify the magnitude and number of CNAs 
and it would be expected that lung cancer cases would have higher genomic instability scores 
compared to high risk controls. 
 
  
 
 
39 
 
 
The aims and objectives were 
 To evaluate analytical performance and to validate the detection of tumour-derived 
CNAs by low coverage whole genome sequencing of cfDNA samples 
a. To optimise DNA library preparation for cfDNA samples by comparing library 
quantities and detection of copy number ratios with different input amounts 
of cfDNA ng/ml and PCR cycles as well as two different PCR mastermixes. 
b. To determine the lower limit of detection for identifying CNAs by low 
coverage whole genome sequencing of cfDNA samples by adding tumour 
FFPE DNA in known quantities to extracted cfDNA from the pooled plasma 
of healthy volunteers. 
c. To determine test reproducibility across sequencing runs by comparing the 
detection of copy number ratios in cell line DNA 
d. To demonstrate the identification of tumour-derived CNAs in cfDNA samples 
of lung cancer cases collected in the ReSoLuCENT study by low coverage 
whole genome sequencing.  The objectives were to compare cfDNA CNAs to 
those detected in matched tumour FFPE DNA.  In addition, to compare 
cfDNA CNAs to CNAs known to be common to the three main subtypes of 
lung cancer. 
 To evaluate the clinical validity of low coverage whole genome sequencing to identify 
CNAs in selected lung cancer cases and controls  
a. To explore the sreeening and prognostic value of two genomic instability 
scores based on the number and magnitude of CNAs identified in cfDNA 
samples.  The objectives were to compare scores between lung cancer cases 
and high risk controls to assess screening value and to aseess the 
relationship between score and overall survival to assess potential as a 
prognostic tool. 
 
 
40 
 
 
2 Materials and Methods 
2.1 Materials 
 General laboratory equipment and consumables 
Laboratory equipment Supplier 
AB104-S Balance Mettler, Toledo 
ABI 7900 Genotyping Platform Applied biosystems 
Benchtop Micro Centrifuge Heraeus Pico 17  Thermo Fisher Scientific 
Benchtop Rotamixer HATI 
Benchtop Temperature Controlled Centrifuge MSE Sanyo 
Class II Microbiological Safety Cabinet Envair 
CO2 Incubator MCO175  Sanyo 
Covaris® S220 Focused-ultrasonicator Covaris 
Heating Block Grant Boekel BBA 
Ice machine Scotsman Ice Machine 
Magnet stand-96 Thermo Fisher Scientific 
Nanodrop Spectrophotometer ND-1000 Labtech International 
P2, P10, P20, P100, P200, P1000 Gilson Pipettes Fisher Scientific 
Power pack Bio-Rad 
QBD4 Incubator for Eppendorfs Grant Boekel BBA 
Thermal cycler: GeneAmp PCR system 96 well Applied Biosystems 
Thermal cycler: Light Cycler 480 96 well Roche  
Thermal cycler: PTC-200 96 well MJ Research 
Titramax 1000 Incubator and Shaker Heidolph 
UV Sterilisation Cabinet Bignet 
Vortex Genie 2 Scientific Industries 
Water Purification Unit Lab Technologies 
Water bath Grant Instruments 
Western Gel Mini Protean II Cell Bio-Rad 
 
Laboratory consumables Supplier 
0.2ml Microcentrifuge Tubes Starlab 
0.5ml, 1.5ml, 2ml Microcentrifuge Tubes Fisher Scientific 
1.5 ml DNA Lo-bind Microcentrifuge Tubes Eppendorf 
1.5 ml Cryovials Scientific laboratory suppliers (SLS) 
15 ml Sterile Conicol Tubes BD Falcon 
50 ml Sterile Conicol Tubes BD Falcon 
96 Well PCR Plates Applied Biosystems 
384 Well PCR Plates Starlab 
6 ml EDTA Blood Phlebotomy Tubes BD  
GIBCO Distilled DNase/Rnase Free Water  Life Technologies 
Graduated 10µl Microfilter Tips Starlab 
Nitrile Powder Free Gloves Fisher Scientific 
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Pipette Tips  Starlab 
Plate Seals Biorad 
 Laboratory solutions 
All laboratory solutions were made up with ddH2O, were purchased from Sigma-Aldrich Co. 
unless stated otherwise and were of molecular biology grade. 
 
TAE buffer (10x, pH8.0): 0.4 M Tris-base, 200mM glacial acetic acid, 10 mM EDTA (pH 
adjusted to 8.0). 
Phosphate Buffered Saline (PBS)(Dulbeccos A, 1x): Sodium chloride 0.137M, Potassium 
Chloride 0.003M, Disodium Hydrogen Phosphate 0.008M, Potassium Dihydrogen Phosphate 
0.0015M. 
6X Sample loading buffer: Glycerol 60%, Tris-HCL pH 7.6 10mM, EDTA 60mM, Bromophenol 
blue 0.03%, Xylene Cyanol FF 0.03%. 
 Buffers and reagents for molecular biology techniques 
2.1.3.1 DNA processing 
Xylene (Fisher Scientific) 
Absolute Ethanol (Fisher Chemical) 
Isopropanol 99.5% extra pure (ACROS organics) 
Nuclease free distilled water (Gibco by Life Technologies) 
Ready to use TE (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) X1 buffer (Thermo Fisher Scientific)  
NaOH 2M (Illumina)  
2.1.3.1.1 Phenol choloform method: 
Triton X-100 (BDH Prolab) 
Phenol chloroform isoamyl alcohol mixture (Sigma Life Science) 
Sodium acetate trihydrate (Fisher Scientific) 
2.1.3.1.2 Commercial kits purchased for DNA extraction: 
QIAamp® DNA FFPE Kit (Qiagen) 
Chemagic DNA Buffy Coat Kit (Perkin Elmer) 
QIAamp® Blood Mini Kit (Qiagen) 
QIAamp® Circulating Nucleic Acid Kit (Qiagen) 
FlexiGene DNA kit (Qiagen) 
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2.1.3.1.3 Commercial kits purchased for Illumina whole genome sequencing: 
NEBNext® Ultra DNA library Prep Kit (NEW ENGLAND BioLabs®Inc.) 
NEBnext® multiplex oligonucleotides (NEW ENGLAND BioLabs®Inc.) 
Dual lane HiSeq Rapid PE Flow Cell (Illumina) 
TruSeq Rapid PE Cluster kit (Illumina) 
TruSeq Rapid Duo cBot Sample Loading Kit (Illumina) 
Truseq rapid SBS 200 cycle kit (Illumina) 
2.1.3.2 PCR 
PCR water 
Nuclease free distilled water (Gibco by Life Technologies) 
2.2 Plasma samples 
 Healthy volunteer study 
Healthy volunteers from the University of Sheffield were recruited to the study ‘Optimisation 
of plasma nucleic acids’.  Up to 50 mls of blood were withdrawn from each participant, and 
if required further samples were taken after a minimum four-week interval as per protocol.  
Peripheral whole blood samples were processed as described in Section 2.3 then plasma and 
lymphocyte buffy coats were stored in 1.5 ml cryovials.  This study had ethical approval from 
South Yorkshire Research Ethics Committee (08/H13010/40) and was authorised by Sheffield 
Teaching Hospitals NHS Foundation Trust (STH14669) (Appendix B).  Written informed 
consent was obtained from all participants. 
 
 The ReSoLuCENT study  
The aim of the ReSoLuCENT study (A Resource for the Study of Lung Cancer Epidemiology in 
North Trent) (247) was to collect high quality detailed epidemiological and biological samples 
and data from lung cancer patients with a strong family history or early onset disease, and 
family based controls.  This multi-centre national institute for health research (NIHR) 
portfolio study was opened in 2006 after ethical approval from West Midlands Research 
Ethics Committee (05/MRE07/72) and was authorised by Sheffield Teaching Hospitals NHS 
Foundation Trust (STH13872) (Appendix C).  Recruitment to the study completed in August 
2016.  The Chief Investigator of the study is Professor Penella Woll. 
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Participants with lung cancer were eligible for the study if they had active disease and were 
either aged 60 or less at diagnosis or had a strong family history of lung cancer (1st degree 
relative with lung cancer aged ≤ 60 years or ≥ 2 1st or 2nd degree relatives with lung cancer at 
any age).  Recruited controls were either co-habiting partners or 1st degree relatives of the 
case.  All participants had a blood test and samples were processed using optimised SOPs (as 
described in Section 2.3) to obtain plasma and lymphocyte buffy coat layer so that 
contamination and degradation of cfDNA was minimised.  In addition, permission was sought 
from cases to obtain surplus tumour FFPE tissue sections.  All participants completed a highly 
detailed questionnaire to include smoking, occupational, and medical histories. 
 
Each participant in the study was allocated a unique number that identified the recruiting 
centre, enabled the matching of cases and controls, and linked samples and data.  All 
participants were registered with the Health and Social Care Information Centre (HSCIC) and 
lung cancer development, disease recurrence and cause of death were recorded. 
 
2.2.2.1 Allocation of a Liverpool lung cancer risk score 
Cases and controls aged 40-80 years were allocated a score based on the LLP Model (11)(see 
Section 1.1.2.1.1).  A score of ≥2.5% was chosen to define high risk controls because a study 
of 4900 lung cancer cases and 1703 healthy controls found that a score of ≥2.5% identified a 
higher proportion of lung cancer cases compared to a score of ≥5.0%.  The identification of 
lung cancer cases improved from 45.5% with score ≥5.0% compared to 66.7% with score 
≥2.5% (248).  Although, this was at a cost of increasing the number of controls incorrectly 
identified as lung cancer from 15.1% to 33.4% (248). 
 
2.3 Blood processing and sampling 
Blood processing was optimised to minimise lymphocyte DNA contamination of plasma 
(140).  Peripheral whole blood was withdrawn by venepuncture into EDTA blood collecting 
tubes to prevent blood clotting.  Blood samples were kept on ice and processed within one 
hour of venepuncture by double centrifugation.  The first centrifugation at 800 g, 4 oC for 10 
minutes in a benchtop centrifuge formed three separate layers of plasma, lymphocytes and 
red blood cells.  The plasma layer was removed into a 15 ml conical tube leaving at least 2 
mm depth of plasma above the lymphocyte (buffy coat) layer in order to avoid contamination 
of the plasma with genomic DNA.  The lymphocyte layer was stored at -80oC in a 1.5ml 
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cryovial.  A second centrifugation of the plasma at 1600g, 4oC for 10 minutes allowed removal 
of any remaining cells whilst avoiding cell lysis.  The resulting pellet consisting of platelets, 
cells and cellular debris was left in the tube, and the plasma supernatant was aliquoted into 
1.5 ml cryovials for storage at -80oC.  Small aliquots were utilised to avoid repeat thawing of 
plasma, as cfDNA levels can be affected (134). 
 
Prior to further processing, thawed plasma was centrifuged at 1000g 4 oC for five minutes, 
to remove DNA contaminants or any precipitated material (249). 
 
2.4 DNA extraction from tumour tissue 
Tumour genomic DNA was isolated from FFPE tissue sections both to spike healthy volunteer 
plasma for the evaluation of cfDNA extraction methods, and to determine somatic mutations 
with highly parallel sequencing. 
 
The protocol for the QIAamp® DNA FFPE kit (Qiagen, West Susex UK) was followed with the 
introduction of an overnight incubation step to ensure complete lysis of plasma proteins and 
contaminants.  This commercial kit extracts DNA from plasma by adsorption of DNA onto a 
silica membrane. 
 
Using a fresh scalpel for each sample, tumour tissue was scraped into a 2 ml tube.  To 
eliminate the paraffin, 1 ml of xylene was added and the mixture was vortexed and 
centrifuged (17 000 g for 2 minutes).  After removing the supernatant by pipetting, 1 ml of 
absolute ethanol was added to the pellet to extract any residual xylene followed by a repeat 
centrifugation.  The supernatant was discarded and the remaining pellet was air dried to 
evaporate residual ethanol.  Once dry, to lyse proteins and contaminants the pellet was re-
suspended in 180 µl of buffer ATL and 20 µl of proteinase K (20mg/ml).  The mixture was 
incubated at 56 oC in a Titramax 1000 Incubator and Shaker (Heidolph, Germany) and left 
overnight.  An additional 20 µl of proteinase K was then added, and the mixture was 
incubated at 56 oC for one hour and then at 90 oC for a further hour.  The very high 
temperature enabled the partial reversal of formalin induced nucleic acid crosslinking.  Two-
hundred microliters of buffer AL was added and 200 µl of absolute ethanol.  After thorough 
mixing, the solution was transferred to a QIAamp MiniELute column.  Upon centrifugation of 
the column (6000 g for 1 minute), DNA became bound to the silica membrane across the 
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bottom of the column whilst contaminants passed through the membrane into the collection 
tube to be discarded.  Residual contaminants were washed away by two sequential 
centrifugation steps (600 g for 1 minute) with 500 µl of wash buffer AW1 and AW2.  To dry 
remaining buffer, the column was centrifuged at 17 000 g for 4 minutes.  Afterwards, DNA 
bound to the membrane was eluted into a clean 1.5 ml aliquot by adding 50 µl of elution 
buffer ATE (10mM Tris-Cl, pH 8.3, 0.1mM EDTA, 0.04% NaN3 (sodium azide)) for a 5 minute 
incubation followed by centrifugation at 17 000 g for 2 minutes. 
 
2.5 DNA extraction from plasma 
 Phenol-chloroform method  
An organic solvent extraction method based on phenol-chloroform has been reported by our 
group to give higher DNA yields than the Qiagen® Blood Midi Kit (Qiagen) (140).  Therefore, 
this method was evaluated. 
 
Up to 1 ml of thawed plasma was separated equally into two, 2 ml tubes.  A solution of PBS 
(20% of the sample volume) and the detergent Triton X-100 (2% of the sample volume) was 
added to each tube to reduce the surface tension of the mixture.  The mixture was incubated 
at 98 oC for 5 minutes to denature proteins and then cooled on ice.  The resulting solid was 
transferred to a 15 ml falcon tube.  An equal volume of phenol-chloroform was added to 
extract the protein.  The mixture was vortexed and separated into two 1.5 ml aliquots.  
Centrifugation at 17,000 g for 15 minutes caused three layers to form.  The bottom yellow 
liquid layer was phenol-chloroform, the semi-solid white middle layer was protein and the 
top clear aqueous layer contained the DNA.  The aqueous layer was transferred to a clean 2 
ml tube.  Sodium acetate 3M stored at -20 0C was warmed to room temperature and added 
to the DNA supernatant at 10% of the supernatant volume, followed by 1 ml of ice-cold 
absolute ethanol to precipitate DNA.  The samples were left overnight at -20 oC to allow full 
precipitation of longer length DNA. 
 
The next day, samples were centrifuged at 17,000 g for 15 minutes.  The supernatant was 
discarded leaving an invisible pellet of DNA.  The pellet was washed with 1 ml of 70% ice-cold 
ethanol and centrifuged at 17,000 g for 10 minutes.  The ethanol was removed and the pellet 
was air dried for over an hour.  Once dry, the pellet was re-suspended in DNA/RNAase free 
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water at 4% of the original plasma volume and left at 4oC for one week to ensure that the 
DNA had fully dissolved. 
 
 Qiagen QIAamp commercial kits 
Qiagen QIAamp® kits adsorb DNA onto a silica membrane within a column and are the most 
widely used commercial kit for the extraction of DNA from plasma.  The QIAamp® Circulating 
Nucleic Acid Kit (Qiagen) was evaluated in comparison to the QIAamp® Blood Mini Kit 
(Qiagen). 
 
Standard operating procedures (SOPs) for the QIAamp® Blood Mini Kit centrifugation 
method and QIAamp® Circulating Nucleic Acid Kit vacuum method were followed for the 
extraction of DNA from 1 ml and 1-3 mls of plasma respectively.  These protocols were 
previously validated in Prof J. Shaw’s laboratory at the University of Leicester. 
 
2.5.2.1 QIAamp Blood Mini Kit method 
One ml of thawed and centrifuged plasma was added to 100 µl of Qiagen protease (24 
mg/ml) in a 15 ml conical tube and vortexed for 15 seconds.  If less than 1 ml of plasma was 
available, then the volume was made up to 1 ml by the addition of PBS.  One ml of the lysis 
buffer AL was added and the solution was vortexed for 15 seconds.  The mixture was 
incubated at 56oC for 10 minutes, to allow enzymatic digestion of protein contaminants, 
inactivation of DNases and release of nucleic acids from bound proteins, lipids and vesicles.  
After incubation, 1 ml of absolute ethanol was added, this improves the binding of DNA to 
the silica membrane.  Up to 600 µl of the plasma mixture was added at a time to the column, 
which was then centrifuged for 1 minute at 6000 g.  During centrifugation, DNA in the plasma 
mixture binds to the silica membrane and contaminants pass through the membrane to be 
discarded.  Residual contaminants were removed in two wash steps by adding 500 µl of 
buffer AW1 and AW2 followed by centrifugation at 6000 g for 1 minute and 20,000 g for 3 
minutes respectively.  The purified DNA was separated from the column membrane by 
incubating with elution buffer AE for 5 minutes followed by centrifugation at 6000 g for 1 
minute.  Buffer AE (10mM Tris-Cl, 0.5mM EDTA, pH 9.0) was added to the column in two 
steps of 70 µl and 30 µl, in order to maximise DNA yield whilst maintaining adequate DNA 
concentration by maintaining a low volume. 
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2.5.2.2 QIAamp® Circulating Nucleic Acid Kit method 
In brief, 1, 2 or 3 mls of thawed plasma were added to a 50ml falcon tube with 100 µl, 200 µl 
or 300 µl of Qiagen proteinase K and 0.8 ml, 1.6 ml or 2.4 ml of the lysis buffer ACL, depending 
on the input plasma volume respectively.  After vortexing for 30 seconds, the mixture was 
incubated at 60 oC in a water bath for 30 minutes.  Either, 1.8 ml, 3.6 ml or 5.4 ml of the 
binding buffer ACB (for 1ml, 2ml or 3ml plasma respectively) was added and after vortexing 
for 30 seconds, the mixture was incubated on ice for 5 minutes. 
 
Instead of using centrifugal force to enable the passage of liquids through the silica 
membrane (described in Section 2.5.2.1) a vacuum method was used to increase efficiency 
and reduce labour time.  This was particularly important for larger plasma volumes greater 
than 1 ml.  The mixture was poured into a column inserted in a vacuum manifold (QIAvac 24 
plus, Qiagen) (the columns had extenders to accommodate higher plasma volumes).  The 
recommended vacuum pressure of -800 mbar was applied and the mixture was slowly pulled 
through the column.  DNA became bound to the silica membrane and salt and pH conditions 
ensured that proteins and contaminants flowed through the column to be discarded.  Once 
the mixture had passed through the column, residual contaminants were removed by 
applying a vacuum during sequential washes of 600 µl ACW1, 750 µl of ACW2 and 750 µl of 
absolute ethanol.  The columns were removed from the vacuum manifold and placed in a 2 
ml collection tube, which was then spun at 13,100 g for 3 minutes to remove residual liquid.  
To ensure the removal of all ethanol, the column was dried in a new 2 ml collection tube with 
the lid open on a heat block at 56 oC for 10 minutes.  The column was then placed in a 1.5 ml 
Lo-Bind tube.  The amount of AVE elution buffer added to the column was dependent on the 
plasma input volume.  For 1 ml, 2ml or 3ml of plasma, 50 µl, 100 µl or 150 µl respectively of 
AVE elution buffer was applied for 3 minutes prior to centrifugation at 13,100 g for 1 minute 
to elute the nucleic acids. 
 
2.6 DNA extraction from cell lines 
The 250 ml FlexiGene DNA kit (Qiagen) was used to extract genomic DNA from cell lines with 
cell count 1-2 x106 cells.  Following the manufacturer’s instructions, cell pellets were re-
suspended in 300 µl of buffer FG1.  For each sample, 300 µl of buffer FG2 and 3 µl of Qiagen 
protease were mixed and 300 µl of this mixture was added to the re-suspended cell pellet.  
After briefly vortexing, the mixture was incubated in a water bath at 65 oC for 10 minutes to 
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facilitate cell lysis and DNA release.  DNA was precipitated by further mixing with 600 µl of 
isopropanol followed by centrifugation at 10,000 g for 3 minutes.  The tube holding the pellet 
was inverted to remove excess liquid, and 600 µl of absolute ethanol were added to wash 
the pellet.  After another centrifugation step of 10,000 g for 3 minutes the supernatant was 
removed and the tube was inverted again for 5 minutes to dry the DNA pellet.  Three hundred 
microlitres of buffer FG3 were added and the mixture was incubated for at least 30 minutes 
at 65 oC to dissolve the DNA pellet. 
 
2.7 DNA extraction from peripheral blood mononuclear cells 
To determine somatic mutations cfDNA was compared to peripheral blood mononuclear 
cells (PBMC) genomic DNA to allow inherited variants to be excluded.  The 2 ml Chemagic 
DNA Buffy Coat Kit (Perkin Elmer, Baesweiler Germany) and Streptavidin M-PVA magnetic 
beads (Perkin Elmer) were used with the Chemagic Magnetic Separation Module I robot 
(Perkin Elmer) to allow high sample throughput.  In this automated process, PBS was added 
to buffy coats prepared as described in Section 2.3, to give a final volume of 2 mls in 50 ml 
conical tubes.  White blood cells were lysed to release DNA with the addition of 20 µl of 
protease and 5 ml of lysis buffer.  After 20 minutes of mixing, 12 ml of binding buffer and 0.8 
ml of re-suspended magnetic beads were added.  In the presence of the binding buffer, DNA 
bound to the carboxyl group attached to the magnetic beads.  A magnetic rod was inserted 
and the beads with the attached DNA bound to the rod.  To wash off impurities, the magnetic 
rod was transferred from one wash buffer to another for a total of 3 washes.  The DNA was 
eluted from the beads after a 10 minute incubation in 500 µl of TE buffer pH 8.0 (Thermo 
Fisher Scientific, Loughborough UK). 
 
2.8 Extracted DNA storage 
DNA was aliquoted and stored at 4 oC if it was to be processed within six months of 
extraction.  However, all cfDNA samples were processed within seven days of plasma 
extraction.  For long-term storage, DNA was frozen at -20 oC. 
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2.9 Quantification of extracted DNA 
 Quantification of cell line, tumour and genomic DNA 
2.9.1.1 DNA quantification with the Qubit® 2.0 fluorometer 
Cell line, tumour FFPE and genomic DNA were quantified with the Qubit® 2.0 fluorometer 
(Thermo Fisher Scientific) using the Qubit® dsDNA BR Assay (Thermo Fisher Scientific).  The 
intercalating dye in this assay emits fluorescence when bound to dsDNA, enabling specific 
and accurate quantification in the range 100 pg/µl to 1000 ng/µl.  The manufacturer’s 
instructions were followed. 
 
For each sample, 1 µl of Qubit® dsDNA BR Reagent was added to 199 µl of Qubit® dsDNA BR 
Buffer to form a Mastermix.  In 0.5ml Qubit® assay tubes, 2 µl of the DNA sample was added 
to 198 µl of Mastermix, and 10 µl of each Qubit® dsDNA BR standard S1 and S2 were added 
to 190 µl of Mastermix in separate tubes.  After vortexing and an incubation of at least 2 
minutes, the assay tubes were inserted into the Qubit® 2.0 fluorometer.  The Quant-IT dsDNA 
BR assay protocol was chosen and the Qubit® 2.0 fluorometer was calibrated with the freshly 
prepared standards 1 (0 µg/ml) and 2 (100 µg/ml) prior to each quantification.  The 
concentration of DNA in a sample was calculated by the fluorometer with the equation 
below. 
 𝑆𝑎𝑚𝑝𝑙𝑒 𝐷𝑁𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑄𝑢𝑏𝑖𝑡 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒 𝑋 (
200
𝑖𝑛𝑝𝑢𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 µ𝑙
) 
 
 Quantification of plasma cell-free DNA 
2.9.2.1 DNA quantification with conventional PCR 
In the polymerase chain reaction (PCR), a segment of DNA is amplified from just a few copies 
to millions of copies during a sequence of heating and cooling reactions.  There are three 
main steps to a PCR reaction or cycle.  The first step heat denatures dsDNA to form single 
strands.  Second is the annealing step, whereby primers bind selectively to the 
complementary target DNA sequence.  Finally, DNA polymerase synthesises a new DNA 
strand in the extension step.  These steps are repeated and the quantity of DNA between the 
primers is doubled with each PCR thermal cycle. 
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2.9.2.1.1 SYBR Green RT-qPCR  
To accurately quantify low levels of amplifiable cfDNA fragments prior to sequencing, SYBR 
green RT-qPCR was performed.  Quantitative PCR reactions were carried out with the Real-
Time PCR system from Applied Biosystems 7900HT and results were analysed with the 
Sequence Detector Software version 2.4 (Applied Biosystems Thermo fisher Scientific, 
Loughborough UK). 
 
2.9.2.1.1.1 Absolute quantification with a standard curve 
Fluorescence caused by the binding of SYBR green to dsDNA can be measured in ‘real time’ 
during PCR cycling, this is demonstrated by an amplification curve (Figure 2-1).  The Ct or 
threshold cycle is the PCR cycle at which the fluorescence from the amplification reaches the 
threshold line.  The Ct value of the test sample can be compared to a standard curve 
consisting of Ct values from known template DNA concentrations and the concentration of 
the test sample can thus be calculated.  A 10,000 pg/µl standard of mixed individual human 
genomic DNA (Promega, Madison USA) was serially diluted 1:10 to create a total of five 
standards down to 1 pg/µl.  A non-template negative control of distilled nuclease free water 
was included to allow exclusion of contamination of water and assay reagents. 
 
To accurately quantify DNA using a standard curve assay quality controls were as follows.  
The standard curve correlation coefficient R2 had to be greater than 0.99, and the efficiency 
of the PCR reaction between 90-105% (slope -3.0- -3.6).  The efficiency of the PCR reaction 
was calculated from the slope of the curve by the equation: efficiency = (10 -(1/slope) -1) x 100%.  
In addition, a minimum of three replicates of each standard with standard deviation <0.167 
was preferable (Figure 2-2). 
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Figure 2-1: An amplification curve for serially diluted DNA standards. 
Cycle number (x-axis) is plotted against ΔRn (y-axis) (fluorescence normalised to the passive 
reference dye minus the baseline).  An amplification curve has several phases: A) Background 
B) Exponential C) Linear D) Plateau E) Baseline.  The red line in the exponential phase denotes 
the threshold at which the Ct value is determined.  The threshold was set to be in the middle 
of the exponential growth phase of the samples. 
 
 
 
Figure 2-2: An example of an acceptable standard curve. 
R2=0.996, slope = -3.34.  Y-axis represents Ct value and the x-axis DNA quantity. 
 
  
A 
D 
C 
B 
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2.9.2.1.1.2 GAPDH primer and SYBR green mastermix 
Primers for the 81 bp housekeeping gene GAPDH (Glyceraldehyde-3-phosphate 
Dehydrogenase) were used to generate the quantified PCR product.  GAPDH primers were 
purchased from Sigma-Aldrich Co. Aldrich (Ebersberg, Germany) and were re-suspended in 
sterile nuclease free water as per manufacturer’s recommendation to attain a solution of 
concentration 100 picomoles per 1µl (Forward primer: 5’ AACAGCGACACC CATCCTC 
(SY080702259-039).  Reverse primer: 5’ CATACCAGGAAATGAGCTTGACA (SY080702268-
007)).  A short amplified region (amplicon) was important to minimise the risk of non-
amplification of small DNA fragments typical of cfDNA.  The primer concentration in the 
mastermix reaction was optimised by a member of our group.  The final 7 µl mastermix 
constituents are displayed in Table 2-1. 
 
Mastermix reaction X 1 well 
2x SYBR Green Mastermix (Applied Biosystems Thermo fisher)  
contains SYBR® Green I Dye, AmpliTaq Gold® DNA Polymerase, dNTPs with 
dUTP, Passive Reference, and optimized buffer components 
5µl 
GAPDH 10 pM forward + reverse primer (Sigma-Aldrich) 0.3µl +0.3µl 
Nuclease free distilled water 1.4µl 
Table 2-1: Components of the mastermix reaction for SYBR green RT-qPCR. 
dNTPs: deoxynucleotides.  dUTP: 2’-deoxyuridine, 5’triphosphate. 
 
2.9.2.1.1.3 PCR plate preparation 
A 384 microwell plate was prepared in the PCR preparation room in a ultra violet (UV) 
cabinet.  To degrade potentially contaminating DNA in the cabinet the UV light was turned 
on for 5 minutes before and after plate set up (250).  Each DNA sample was prepared in 
triplicate with five replicates of standard.  The total volume in each well was 10 µl and 
consisted of 7 µl of the mastermix reaction solution and 3 µl of the DNA standard or 1:5 
diluted test DNA sample.  Once the plate preparation was complete, it was sealed and briefly 
centrifuged prior to RT-qPCR. 
 
2.9.2.1.1.4 Thermocycling conditions and melting curve analysis 
The recommended thermocycling conditions were 50 °C for 2 minutes, 95 °C for 10 minutes 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute.  A final step of 95 °C, 
60 °C and 95 °C each for 15 seconds was carried out to check for non-specific amplification 
by forming a melting curve.  Melting curves map temperature against change in fluorescence 
due to SYBR green dye interacting with dsDNA.  The melt curve of the amplicon was 81 oC, 
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which was defined by the sequence of the primer GAPDH.  A peak outside of this 
temperature represented primer-dimer formation or the amplification of non-specific 
products and the resulting DNA quantity was invalid due to the presence of fluorescence 
arising from other DNA species (Figure 2-3). 
 
 
A) Unacceptable melting curve     B) Acceptable melting curve 
Figure 2-3: Melting curve analysis for the amplicon GAPDH with a melting point of 81 oC. 
The y-axis shows change in fluorescence (known as derivative) and the x-axis shows 
temperature (°C). 
 
2.10 Quality assessment of extracted DNA 
 Quality assessment of genomic, cell line and tumour DNA 
2.10.1.1 Agarose Gel Electrophoresis 
Tumour FFPE DNA samples were run on a 1.5 % agarose gel to determine DNA fragment size.  
To make the gel, 2.25 g of acarose powder (Sigma-Aldrich) were added to 150 mls of 1 x TAE 
buffer in a 500 ml conical flask.  After heating in a microwave for 2 minutes to dissolve the 
acarose powder, 6 µl of the intercalating dye ethidium bromide 10 µg/µl was added.  Once 
the mixture was cooled it was allowed to set to form a gel in a casting tray with inserted 
comb to create indents in the gel for sample loading.  The gel was loaded with 3 µl of each 
tumour DNA sample mixed with 2 µl of 5 x loading buffer.  For each gel, 5 µl of a Hyperladder 
(Bioline, London UK) were loaded, to allow the size of DNA electrophoresis bands to be 
determined.  The running buffer was 1 x TAE and the gel was run at constant voltage 100 
volts for 1 ½ hours using a BioRad Power Pac. 
  
Primer-
dimer 
No 
primer-
dimer 
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2.10.1.2 Nanodrop Spectrophotometry 
DNA purity and quantity was evaluated by Nanodrop Spectrophotometry with the Nanodrop 
Spectrophotometer (ND-1000, Labtech International, East Sussex UK) and ND-1000 software 
for the detection of nucleic acids.  The ratio of light absorbed by DNA at wavelength 260nm, 
and light absorbed at 230nm by carbohydrates, salts and phenol or 280nm by proteins were 
calculated.  A 260nm:280nm ratio and a 260nm:230nm ratio between 1.7 and 2.2 
demonstrated satisfactory DNA purity.  Nanodrop Spectrophotometry lacks specificity for 
dsDNA quantification because single stranded DNA (ssDNA), RNA and free nucleotides all 
absorb UV light at 260nm. 
 
 Quality assessment of plasma cell-free DNA 
2.10.2.1 Agilent TapeStation 2200 
The 2200 TapeStation (Agilent Technologies, Cheshire UK) detects fluorescent stained dsDNA 
fragments that have been size separated by capillary gel electrophoresis to form bands. 
 
The manufacturer’s instructions were followed.  In brief, 2 µl of high sensitivity D1000 sample 
buffer containing the intercalating fluorescent dye (Agilent Technologies) was added to 2 µl 
of cfDNA or 2 µl of high sensitivity D1000 ladder (Agilent Technologies), in a 96 well plate.  
The plate was vortexed to ensure the coating of all DNA fragments with the dye, centrifuged 
to remove droplets from the sides of wells, and inserted into the Agilent Tapestation with a 
high sensitivity D1000 ScreenTape (Agilent Technologies).  The ScreenTape is a gel with 16 
independent channels and each sample is automatically loaded into one channel prior to 
electrophoresis.  A high quality camera captures the gel image and analysis software (version 
A.01.04) determines the position and fluorescence intensity of each band to assess fragment 
size, and sample molarity by calculating area under the curve.  Fragments ranging in size from 
35 bp to 1000 bp are detected with a quantitative range from 10 pg/µl to 1000 pg/µl and 
accuracy of ± 20%. 
 
2.11 DNA spiking of plasma samples 
To allow for the comparison of different methods of cfDNA extraction, tumour FFPE DNA 
quantified by nanodrop spectrometry (see Section 2.10.1.2) was added in known amounts 
to half of the pooled plasma from healthy volunteers.  Tumour DNA is fragmented and 
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therefore somewhat representative of cfDNA in cancer patients. Control plasma and plasma 
spiked with tumour DNA were stored at -80oC, prior to DNA extraction. 
 
 The percentage of DNA recovery 
The amount of DNA extracted from plasma was determined by taking the average quantity 
of DNA in 1 ml of plasma calculated from the Ct values of three qPCR replicates.  The Ct value 
of each replicate was compared to a standard curve to determine the quantity of DNA in 
pg/µl.  The complete workflow is demonstrated in Figure 2-4. 
 
In order to compare methods of plasma DNA extraction the percentage of spiked DNA 
recovered from healthy volunteer plasma was calculated using the equation: 
 
% 𝐷𝑁𝐴 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =  
(𝐷𝑁𝐴 𝑛𝑔/𝑚𝑙 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑠𝑝𝑖𝑘𝑒𝑑 𝑝𝑙𝑎𝑠𝑚𝑎 − 𝐷𝑁𝐴 𝑛𝑔/𝑚𝑙 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑚𝑎𝑡𝑐ℎ𝑒𝑑 𝑢𝑛𝑠𝑝𝑖𝑘𝑒𝑑 𝑝𝑙𝑎𝑠𝑚𝑎)
𝑡𝑢𝑚𝑜𝑢𝑟 𝐷𝑁𝐴 𝑠𝑝𝑖𝑘𝑒 𝑛𝑔/𝑚𝑙
 𝑋 100% 
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Figure 2-4: Sample workflow for SYBR green RT-qPCR plate set up and method for calculating 
the amount of DNA extracted from 1 ml of plasma (ng/ml). 
A standard curve is displayed with R2 >0.996 and slope -3.3.  The red line demonstrates how 
extrapolating the Ct value of a sample leads to a quantitative value relative to the standard 
curve.  The x-axis shows DNA quantity and the y-axis the Ct value. 
  
DNA extracted from 
1ml plasma
DNA eluted in y µl
4 µl added to 16 µl ddH2O
3 µl added to 7 µl mastermix
10 µl added to well
Plasma DNA 
ng /ml 
Amount of DNA in 1 ml of 
plasma= DNA ng/µl x y µl 
DNA ng/µl x 5/1 dilution 
factor
DNA ng/µl x 10/3 dilution 
factor
DNA pg/µl ÷1000 = DNA 
ng/µl
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2.12 Cell lines and cell culture 
Human cancer cell lines to include a colorectal cancer cell line (HCT 116) and lung cancer cell 
lines (H69, A549, H460 and SK-MES-1), were obtained from the American Type Culture 
Collection (ATCC), (Bethesda, USA).  Cell lines were cultured in a 37 oC incubator with 5% CO2 
according to ATCC guidelines in DMEM medium (Lonza, Slough UK) or RPMI 1640 medium 
(Lonza).  Medium was supplemented with 10% fetal calf serum (GIBCO, Thermo fisher).  
Standard aseptic techniques were employed and procedures were carried out in a grade 2 
safety cabinet.  DNA extracted from cell lines (see Section 2.6) was used as a positive control 
for whole genome sequencing runs on the Illumina HiSeq2500. 
 
2.13 Cell line authentication 
STR (short tandem repeat) profiling was carried out by the core genomics facility to assess 
for cell line contamination in accordance with the International Cell Line Authentication 
Committee (ICLAC).  Ten STR loci were amplified by PCR with the GenePrint® 10 System 
(Promega) on a MJ Research PTC-200 thermocycler (GMI, Minnesota USA).  The number of 
tandem repeats at each allele were detected on the 3730 DNA analyser (Applied Biosystems).  
STR profiles for cell lines were compared and matched to reference profiles held in the COG 
Cell Line and Xenograft STR Database (251).  The cell line was confirmed as being from the 
same donor if there was a greater than 80% match.  This allowed for genetic drift with 
increasing passage and variability in testing between laboratories. 
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2.14 Low coverage whole genome sequencing to identify copy number 
aberrations 
Low coverage whole genome sequencing was carried out to identify CNAs in ReSoLuCENT 
samples.  The HiSeq 2500 system (Illumina, Essex UK) is a next generation highly parallel 
sequencing platform with the ability to perform whole genome sequencing.  There are four 
main steps: library construction, template preparation, sequencing and data analyses (Figure 
2-5). 
 
 
Figure 2-5: The four main steps to complete DNA sequencing with Illumina HiSeq 2500. 
  
Library 
construction
•DNA fragmentation
•End repair, 5' phosphorlyation and dA tailing
•Adaptor ligation and USER excision
•Bar coding and PCR amplification of adaptor ligated DNA
Template 
preparation
•Library quality check
•Library pooling
•Library preparation for template generation on the HiSeq
Sequencing
•Isothermal bridge PCR amplification to create clusters of DNA 
fragments
•Sequencing by synthesis  
Data analyses
•Hiseq data analyses 
•CNAnorm to identify copy number variants
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 Library construction 
The NEBNext® Ultra DNA library Prep Kit (NEW ENGLAND BioLabs®Inc., Hitchin UK) was used 
to prepare libraries for Illumina sequencing.  This kit was chosen because it was validated for 
between 5 ng to 1 µg of tumour FFPE DNA, was cost effective and required only 3 hours of 
hands on laboratory time.  Figure 2-6 summarises the processes involved. 
 
 
Figure 2-6: An overview of library construction with the NebNEXT® Ultra DNA library Prep kit. 
Adapted from www.neb.com (2017) and reprinted with permission from New England 
Biolabs, Inc. 
 
2.14.1.1 DNA fragmentation 
Random DNA fragmentation is an important step in library preparation to ensure unbiased 
coverage of the whole genome.  For each DNA fragment, the number of nucleotides that can 
be sequenced with Illumina technology is limited to 2x250 bp for forward and reverse reads 
in bi-directional sequencing, therefore it is important to have short fragments to achieve 
adequate genome coverage.  Furthermore, short fragments are important to avoid 
overlapping reads where by the same fragment is sequenced twice thus reducing sequencing 
efficiency. 
 
Tumour FFPE DNA and genomic DNA were diluted in nuclease free sterile water and 
mechanically sheared by high frequency ultrasonic acoustic waves with the Covaris® E220 
Focused-ultrasonicator (Covaris, USA).  The standard settings were followed for a target 
fragment length of 200 bp except for length of treatment time, which was optimised 
according to DNA concentration (Table 2-2)(252).  A peak fragment size of 200 bp was chosen 
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to give an insert size compatible with sequencing paired end reads of 100 bp.  Shearing cfDNA 
was not indicated because cfDNA fragment size is generally <200 bp (see Section 1.2.3.1).  
Furthermore, it was important to minimise the loss of DNA given the low quantities present 
in cfDNA.  CfDNA and fragmented samples were run on the Agilent 2100 Tapestation to 
evaluate the size distribution of fragments prior to library construction (Figure 2-7)(see 
Section 2.10.2.1). 
 
Covaris® S220 settings for a target peak fragment 
length of 200bp 
100 ng DNA in  
130ul  
1000 ng DNA in 
130ul 
Treatment time in seconds 360  430 
Peak incident power: power emitted during each 
ultrasonic acoustic wave burst 
175 watts 
Duty factor: percentage of time that the covaris 
instrument applied power during each burst 
10 % 
Cycles per burst: number of sound waves/acoustic 
oscillations per burst 
200 
Temperature  7 °C 
Water level 6 
Table 2-2: The Covaris® E220 Focused-ultrasonicator settings utilised to shear genomic and 
tumour DNA. 
 
 
Figure 2-7:  An example of the Agilent Tapestation 2000 output after shearing 1000 ng of 
genomic DNA. 
Sample Intesity (FU) is stated on the y-axis and fragment size on the x-axis.  The peak 
fragment size is 207 bp.  Upper and lower markers are demonstrated. 
 
2.14.1.2 End repair, 5’ phosphorylation and dA tailing 
Shearing DNA produces different sized fragments with inconsistent 3’ and 5’ ends.  
Therefore, recessed ends were filled in and overhung ends were degraded so that all 
fragment ends were uniformly blunt.  After end repair, 5’ ends were phosphorylated and 3’ 
ends were adenylated (dA tailing) to enable adaptor ligation. 
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Three microlitres of NEBNext® End repair enzyme mix and 6.5 µl of NEBNext® End repair 
reaction buffer were added to 55.5 µl of DNA.  The reaction mixture was placed in a 
thermocycler at 20 oC for 30 minutes followed by 65 oC for 30 minutes. 
 
2.14.1.3 Adaptor Ligation and USER excision 
NEBNext® Adaptors have a single ‘T’ overhang and bind specifically to the single ‘A’ overhang 
of the adenylated 3’ DNA fragment end, this minimises detrimental adaptor-adaptor ligation.  
For PCR amplification of adaptor ligated DNA the stem adaptor loop between the 5’ and 3’ 
end is opened by eliminating ‘U’ in the middle of the loop (Figure 2-8). 
 
Fifteen microlitres of Blunt/TA ligase Master Mix, 2.5 µl of 1:10 diluted NEBNext® Stem Loop 
Adaptor (1.5 µM) and 1 µl of Ligation enhancer were added to the reaction mixture.  To allow 
adaptor ligation, the mixture was incubated at 20 oC for 15 minutes.  Three microlitres of 
User enzyme were added followed by a 37 oC incubation for 15 minutes.  A clean up step was 
carried out to eliminate PCR contaminants with the same volume of AMPure® XP beads 
(Beckman Coulter, Inc London UK) as the DNA product as described in Section 2.14.2.  
Therefore, fragments of size > 100 bp were retained and adaptors were eliminated.  Products 
were eluted in 28 µl (with High Fidelity PCR Master Mix) or 17 µl (with Hotstart Q5 PCR 
Master Mix) of 0.1X T.E (Tris-Acetate pH 8.0) and stored at -20◦C prior to barcoding and PCR 
amplification. 
 
 
Figure 2-8:  Adaptor ligation and U excision to open up the stem loop adaptor with USER 
enzyme during DNA library preparation. 
Adapted from www.neb.com (2017) and reprinted with permission from New England 
Biolabs, Inc.  
 
 
62 
 
2.14.1.4 Barcoding and PCR amplification of adaptor ligated DNA 
NEBNext® Master Mix, a unique NEBNext® barcode (NEW ENGLAND BioLabs®Inc.) and the 
Universal primer mix containing the universal primers P5 and P7 were added sequentially in 
quantities displayed in Table 2-3 to thawed adaptor ligated DNA.  Adaptor ligated DNA 
fragments were selectively amplified by PCR with thermocycling conditions shown in Table 
2.4.  During the first few cycles, the barcodes and PCR primers P5 and P7 were ligated to DNA 
fragments.  Universal PCR primers P5 and P7 have complementary sequences to 
oligonucleotides bound to the solid surface of the Illumina flow cell and are therefore 
required for hybridisation of library fragments to the flow cell (Figure 2-6). 
 
 High Fidelity 2X PCR 
MM 
Q5 Hot start HiFi PCR MM 
Adaptor ligated DNA 
fragments 
23 µl 15 µl 15 µl 
Master Mix (MM) containing 
DNA polymerase, dNTPs, Mg2+ 
and a propriety buffer 
25 µl 25 µl 25 µl 
Barcode/Index primer 1 µl (25 µM) 2 µl (10 µM) 10 µl  
(10 µM) Universal PCR primer 1 µl (25 µM) 2 µl (10 µM) 
Sterile nuclease free water 0 µl 6 µl 0 µl 
Total volume  50 µl 
Table 2-3: Reagent quantities utilised prior to PCR amplification of adaptor ligated DNA 
dependent on the DNA polymerase and concentration of primers. 
 
 PCR cycling conditions for the High-
Fidelity PCR master mix 
PCR cycling conditions for the Q5 
Hot Start HiFi PCR Master Mix 
Step Temp ◦C Time in secs No. of 
cycles 
Temp ◦C Time in secs No. of 
cycles 
Initial 
denaturation 
98 30 1 98 30 1 
Denaturation 98 10 8-15* 98 10 7-16* 
Annealing 65 30 65 
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Extension 72 30 
Final 
extension 
72 5 mins 1 65 5 mins 1 
Hold 4 ∞ 
Table 2-4: PCR cycling conditions for the amplification of adaptor ligated DNA with the 
NEBNext® Ultra DNA Library Prep kit. 
*12-16 cycles were utilised for 5 ng cfDNA, 10-12 cycles for 50 ng cfDNA, 8-9 cycles for 100 
ng tumour FFPE DNA and 7-9 cycles for 100 ng genomic DNA (see Section 4.3.1.1). 
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The NEBNext® High-Fidelity PCR master mix contained Q5 Phusion High-Fidelity DNA 
polymerase with 3’ to 5’ directional exonuclease activity.  The NEBNext® Q5 Hot Start HiFi 
PCR Master Mix replaced the NEBNext ®High-Fidelity PCR master mix as an update to the 
NEBnext® Ultra kit.  This resulted in the elimination of DNA polymerase activity at room 
temperature and therefore increased enzyme efficiency 
 
The number of PCR cycles were determined by input DNA quantity and quality (see Table 
4-1).  It was important to avoid over amplification since bias would be introduced by the 
preferential amplification of smaller fragments.  After PCR amplification, a second clean up 
step was carried out with AMPure® XP beads to eliminate PCR contaminants, using the same 
volume of beads as library product as described in Section 2.14.2.  More selective size 
selection of 320 bp fragments (DNA insert + adaptor + primer) was not performed to 
minimise DNA loss given the low quantities of cfDNA.  The final DNA product or library was 
eluted in 33 µl of 0.1X T.E., 29 µl of the final product was removed to avoid bead carryover 
and stored at -20◦C prior to sequencing. 
 
 Reaction clean up with AMPure® XP Beads  
Reaction clean-ups were manually carried out with re-suspended AMPure® XP Beads 
(Beckman Coulter).  The paramagnetic beads are coated in carboxyl molecules that bind 
reversibly to DNA fragments in the presence of polyethyl glycol (PEG) and salt. 
 
The size of DNA fragments that bind to the beads or the size of fragments left in solution is 
dependent on the concentration of PEG, which is determined by the bead: DNA volume ratio.  
The lower the volume ratio of beads to DNA, the larger the DNA fragments that bind to the 
beads and the larger the size of the small fragments that remain in the supernatant.  For 
example, a ratio of one was expected to retain fragments >100 bp and exclude primers, 
which are < 50 bp.  In comparison, a ratio of 0.7 facilitates the elimination of fragments < 150 
bp that remain in the supernatant, and is used to eliminate adaptor dimers. 
 
In a 96 well plate, the DNA sample was pipette mixed ten times with a pre-specified volume 
of paramagnetic beads and incubated for 5 minutes.  DsDNA bound to the beads, and a 
magnet was used to separate the beads from the supernatant during a 5-minute incubation.  
The supernatant containing unincorporated dNTPS and PCR contaminants such as salts, 
enzymes and excess primers was removed.  The remaining DNA-bead pellet was washed 
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twice for 30 seconds with 200 µl of freshly prepared 80% ethanol.  After air drying the pellet 
for 5 minutes to remove excess ethanol, the pellet was re-suspended in 0.1X T.E elution 
buffer by pipette mixing 10 times.  A magnet was applied after a 2-minute incubation, for 3 
minutes, to separate the beads from the eluted DNA and the eluted DNA was removed to a 
clean tube leaving behind a few microlitres to avoid bead carryover. 
 
2.15 Library Quality Control 
 Determination of library quality and quantity with the Agilent Tapestation 2200  
Adaptor barcode ligated dsDNA Libraries were diluted 1:5 and analysed for quality and 
quantity with the Agilent Tapestation 2200 (Figure 2-9).  Each library electrophenogram was 
checked for a shift in the size of the peak fragment size.  A gain in the peak fragment size of 
at least 126-128 bp from baseline indicated successful barcode adaptor ligation. 
 
The presence of a peak at approximately 125 bp indicated adaptor-dimer formation and a 
peak at 60 bp primer-dimer formation.  Significant adaptor-dimer or primer-dimer 
contamination can reduce sequencing efficiency because they form clusters on the flow cell 
and are sequenced.  Adaptor-dimer contamination was avoided by diluting adaptors 1:10 for 
input DNA <100 ng.  The molar concentration (pmol/l) of a library was calculated by the area 
under the curve. 
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Figure 2-9:  Representative Agilent bioanalyser traces of pre and post library cfDNA products. 
The y-axis represents sample intensity (FU) and the x-axis fragment size in bp.  A) cfDNA 
library pre PCR. B) cfDNA library post PCR. C) cfDNA of a different library post PCR with 
presence of adaptor-dimer. 
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2.16 Equimolar pooling of library products 
Accurate library quantification and pooling was vital to obtain the optimal density of clusters 
on the flow cell to ensure high quality base calls and a high number of reads.  An in house 
equation was utilised to calculate the volume of a library for pooling (see below).  This 
equation was based on the molar concentration of multiple pooled genomic DNA libraries 
that had optimal cluster densities to give a final pooled library of 4nM.  The concentration of 
each sample in the final pooled library was 4nM divided by the total number of samples 
pooled. 
 
Step 1:     
𝑇𝑎𝑝𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑒𝑔𝑖𝑜𝑛 𝑝𝑚𝑜𝑙 𝑝𝑒𝑟 𝑙 × 𝑎𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 0.0028 = 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑛𝑀 
Step 2:   
2000 ÷ (𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑛𝑀 
× 𝑎𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 𝑜𝑛 𝑡𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑠𝑎𝑚𝑝𝑙𝑒𝑠) = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 500 µl 
Step 3:   
𝑉𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 500 µl × adjustment factor 1.75 × 3 = adjusted volume in 1500 µl  
Step 4: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑏𝑢𝑓𝑓𝑒𝑟 𝐸𝐵 + 0.1% 𝑇𝑤𝑒𝑒𝑛 = 1500 µl −  ∑ 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 1500 µl  
 
2.17 Whole genome low coverage sequencing 
 Illumina next generation sequencing  
Illumina NGS relies on isothermal bridge PCR amplification of adaptor ligated DNA fragments 
to create clusters of fragments from a single DNA template to enable highly parallel 
sequencing (253).  Reversible dye terminator chemistry and the identification of 
fluorescence signals unique to each nucleotide enables the sequence of nucleotides of a DNA 
template to be identified (253). 
 
The Illumina HiSeq 2500 was prepared for sequencing according to the manufacturer’s 
instructions by Dr Emily Boardman.  Rapid sequencing runs were completed using a single 
flow cell to obtain approximately 300 million reads of length 100 bp, within 27 hours.  Low 
coverage was ensured by multiplexing a maximum of 48 samples so that the expected 
number of reads per sample was approximately 6 million.  The human genome consists of 3 
billion nucleotides and therefore 6 million reads of length 100 bp equates to reading 600 
million nucleotides and a genome coverage of 0.2X (=600 million/3 billion).  Dr Emily 
Boardman loaded the flow cell and pooled library onto the HiSeq and commenced the 
sequencing run. 
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2.17.1.1 Pooled library preparation 
Standard protocols were followed to prepare pooled libraries for sequencing on the Illumina 
HiSeq 2500 (Illumina) with the TruSeq Rapid PE Cluster kit (Illumina).  A PhiX control v3 
(Illumina) was spiked into the pooled sample library as a positive control and to maintain 
library complexity (see Section 2.17.1.3.1). 
 
Five microliters of pooled library and separately 5 µl of diluted PhiX control v3 were 
incubated for 5 minutes with 5 µl of 0.2N NaOH (Illumina) to denature dsDNA.  On an ice-
block to prevent double strands reforming, 990 µl of pre-chilled Illumina buffer HT1 was 
added to each eppendorf to attain concentration 20 pM.  The mixtures were diluted further 
with buffer HT1 dependent on the concentration (pM) required to obtain optimal cluster 
density.  416 µl of the DNA mixture was vortexed with 4 µl of the equivalent concentration 
of PhiX control v3 (1%) to create a final mixture ready for sequencing. 
 
2.17.1.2 Cluster formation  
Figure 2-10 demonstrates how clusters were generated.  The upper and lower glass surface 
of the Illumina flow cell is coated in two types of oligonucleotides that are complementary 
to the universal PCR primers (P5 and P7) ligated to DNA libraries.  This enables hybridisation 
of the ssDNA fragments to the flow cell.  Isothermal PCR bridge amplification generates 
hundreds of thousands of clusters consisting of clonally amplified DNA fragments.  Once 
cluster formation is completed sequencing begins. 
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Figure 2-10: Isothermal bridge amplification to generate clusters for Illumina sequencing. 
dsDNA: double stranded DNA. ssDNA: single stranded DNA.  Adapted with permission from 
Bentley et al 2008 (253). 
 
A 1.5 ml eppendorf holding the final library mixture was placed in the HiSeq 2500 by Dr Emily 
Boardman.  The mixture entered the dual lane HiSeq Rapid PE Flow Cell (Illumina) for on-
board automated cluster generation with the TruSeq Rapid PE Cluster kit (Illumina).  
However, if only one lane of the flow cell was utilised then up to 24 libraries were pooled 
and cluster generation was commenced on the cBot (Illumina) by Dr Emily Boardman with 
the TruSeq Rapid Duo cBot Sample Loading Kit (Illumina) and completed on the HiSeq 2500. 
 
2.17.1.3 DNA sequencing with Ilumina HiSeq 2500 
Fluorescently labelled nucleotides (A, C, G, T) were washed over the flow cell.  The nucleotide 
that was complementary to the nucleotide of the DNA template competed to be 
incorporated into the new strand.  The other nucleotides were washed away and laser 
excitation caused fluorescence to be emitted.  The flow cell was imaged and clusters emitting 
P5 
P7 P5 
P7 
1) Hybridisation of barcode adaptor 
ligated ssDNA to complementary primers 
on the flow cell 
2) A new strand is synthesised by DNA 
polymerase and then the template strand is 
washed away 
3) The new strand hybridises to a 
complementary primer on the flow cell.  A 
new DNA strand is synthesised 
4) The dsDNA is denatured leaving two 
ssDNA fragments.  The process is repeated 
multiple times (from step 2) to generate 
clusters 
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a signal were identified.  The wavelength and intensity of the signal determined the called 
base.  Importantly, only one nucleotide at a time was incorporated into the growing DNA 
strand due to the presence of a blocking 3’-OH group (253), therefore homopolymers were 
accurately detected.  The blocking group and fluorescence group were cleaved after imaging 
to facilitate binding of the next complementary nucleotide as the next cycle began (253).  
The number of sequencing cycles determined the read length.  The Truseq rapid SBS 200 
cycle kit (Illumina) was used for sequencing. 
 
2.17.1.3.1 PhiX control and phasing/pre-phasing errors 
The PhiX control v3 was an adaptor ligated DNA library, established from the well 
characterised small viral genome PhiX.  PhiX has almost equal AT and GC content and 
therefore its addition to a pooled library preserves a balance between AT and GC content.  
This is important because fluorescence signals are more easily differentiated in complex 
libraries, which leads to accurate cluster identification and precise correction of phasing and 
pre-phasing errors.  During sequencing, if a newly synthesised strand within a cluster falls 
behind by one base this is called phasing and if it is ahead by one base this is called pre-
phasing. 
 
2.18 Data analysis 
The interpretation of sequencing data to obtain somatic CNAs requires many different 
analyses steps.  Both Dr Emily Boardmand and Dr Lucy Crooks performed bioinformatics 
analyses to construct the FASTQ files once sequencing was completed.  Dr James Bradford 
took the FASTQ files and processed the data according to agreed instructions to establish 
copy number ratios with the software CNAnorm.  Figure 2-11 summarises the data analysis 
process.  The bioinformatics scripts were supplied by Dr James Bradford and are found in 
Appendix D. 
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Figure 2-11:  A summary of the steps to analyse sequencing data to obtain copy number 
aberrations. 
1) Cluster generation and 
Sequencing
2) Bases called and allocated 
quality scores
•BCL2 (Base Call Binary) files- one for each 
cycle.
3) Reads formed and de-
multiplexed
•FASTQ files- one for the forward read and 
one for the reverse read.  
4) Alignment
•SAM (sequence alignment/map format) files
•SAM files compressed and converted to BAM 
files.
5) Duplicates and poorly mapped 
reads removed
•Final BAM
6) Reads grouped into windows 
and counted
•tab delimited text file
7) Copy number ratios established 
with CNAnorm
•copy number profile graph
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 Cluster identification/template generation and base calling 
Data analysis initially took place on the HiSeq 2500 with software version 2.2.68.  During the 
first 4-7 sequencing cycles, clusters on the flow cell were identified and their positions were 
marked by X and Y co-ordinates.  These co-ordinates were used to determine the colour and 
intensity of emitted fluorescence from each cluster.  Up to cycle 25, clusters were removed 
if the fluorescence intensity was low or if clusters were of poor quality. 
 
Each of the four nucleotide bases emitted fluorescence at a unique wavelength represented 
by four different colour channels.  Base calling occurred in real-time for every cluster in each 
sequencing cycle.  After cycle 12, corrections were applied to the fluorescence intensity if 
two or more bases emitted fluorescence from a cluster in the same cycle (cross talk 
correction).  After cycle 25, phasing and pre-phasing corrections were applied to correct for 
DNA polymerase errors and Phred like quality scores were allocated to called bases.  The 
base quality score took into account a number of cluster parameters to include signal to 
noise ratio and fluorescence intensities.  Once the sequencing cycles were completed all 
clusters had to pass a quality control step to remove unreliable clusters from further data 
analyses.  To pass, the ratio of the brightest base intensity divided by the sum of the brightest 
and second brightest base intensities had to be greater than 0.6 for all but one base calls in 
the first 25 cycles.  The sequencing run was failed if fewer than 80% of clusters passed this 
step. 
 
 Formation of reads and de-multiplexing 
The raw base calls from each cycle were combined to create sequences of bases or reads.  
Adaptors were trimmed and reads were separated by their indices (de-multiplexed). 
 
 Alignment 
The BWA: Burrows-Wheeler Alignment tool was used with default parameters to align reads 
to the reference human genome GRCh38.  This tool was optimal for DNA sequencing and 
short paired-end reads (254).  Each read had a mapping quality score that quantified the 
Phred-scale probability that the alignment was correct. 
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 Removal of duplicates and poorly mapped reads 
PICARD software (version 2.1.0) was utilised  to mark duplicate reads, which had identical 
start and end chromosomal co-ordinates (255).  Duplicate reads were removed to reduce 
PCR bias.  Furthermore, only uniquely mappable reads with mapping quality score >37 were 
retained therefore eliminating reads that mapped to a large number of regions (usually 
within repetitive regions) or those with poor quality base calls. 
 
 Determination of sample coverage 
To determine the amount of the genome of each sample that was sequenced known as the 
coverage it was assumed that no reads overlapped.  The coverage was calculated by 
determining the number of bases sequenced (total number of mapped reads x read length) 
divided by the size of the human genome, 3 billion bases (256).  This calculation was carried 
out after bases in reads, with low mapping quality (<20), marked as duplicates, without a 
mapped mate pair were removed.  Furthermore, after the fore mentioned filtering steps, 
bases were subtracted in the second observation from an insert with overlapping reads. 
 
 Copy number analysis to determine somatic copy number aberrations  
2.18.6.1 Creating read profiles for cell-free DNA/tumour DNA and matched genomic DNA 
Uniquely mapped reads with high quality scores (>37) from matched genomic DNA (control) 
and tumour or cfDNA (test) were separated into windows using the bam2windows.pl PERL 
script (257).  Windows were non-overlapping and of fixed size of 1 Mb, to facilitate 
comparisons across individuals and to reduce signal noise.  The number of reads in each 
window were counted for the test and control, and GC content determined by comparison 
to the reference human genome GRch38. 
 
2.18.6.2 Removal of ENCODE blacklisted genomic regions 
Certain genomic regions can have a misleadingly high number of reads aligned because they 
consist of repetitive regions (peri-centromeric, telomeric ends, satellite regions) or are a 
result of sequencing artefact or poor DNA quality.  To reduce false positives, any window 
that overlapped regions blacklisted by ENCODE (The encyclopaedia of DNA elements) were 
removed prior to input into CNAnorm.  Both ‘DAC’ and ‘DUKE’ ENCODE black listed regions 
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based on hg19 coordinates were downloaded from UCSC and converted to GRCh38 
coordinates using the “liftover’ tool (258). 
 
2.18.6.3 Analysis with CNAnorm to identify copy number gains and losses 
Read copy number profiles were established for each sample in R (3.2.3) (259) using 
CNAnorm (version 1.16.0) (260) from Bioconductor (version 3.2) (261).  This programme was 
chosen because CNAs were detected from just 5 ng of FFPE DNA at low coverage and 
germline aberrations were eliminated by comparison to matched genomic DNA (262).  The 
characteristics of the tested tumour FFPE DNA are similar to those expected for cfDNA, small 
fragments and low quantities.  Furthermore, CNAnorm adjusts for, GC content, 
contamination caused by the presence of non-tumour cell derived DNA, aneuploidy, and 
different levels of coverage between matched test and control samples (260).  Correction of 
GC content is important to eliminate bias introduced by PCR in library preparation and 
sequencing.  Figure 2-12 outlines the steps involved to determine copy number ratios with 
CNAnorm. 
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 Copy number ratios were corrected for GC content 
 Smooth segmentation was carried out to reduce signal noise and random error 
 
 Copy number ratios were determined for each window by comparing read 
counts for matched test and control samples 
                    
 
 
 
 
 
GF 
 Adjustments were made for sample contamination, ploidy and varied coverage 
with ‘closest normalisation’. The plot is shown below.  The peak of the most 
frequent copy number ratio closest to the median is identified, normalised to a 
ratio of 1 and the data is shifted. 
 
 Segmentation of normalised copy number ratios to identify point changes in copy 
number 
 Formation of a copy number profile.  Each dot represents a ‘window’ and black 
lines or segments represents consecutive windows of a similar ratio.  The colours 
orange show copy number gains and blue shows copy number losses.  
 
 
 
 
 
 
Figure 2-12:  The determination of somatic copy number aberrations with CNAnorm. 
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To establish somatic CNAs the following steps were performed by Dr James Bradford.  Firstly, 
read profiles for cfDNA/tumour DNA (test) were normalised against read profiles for genomic 
DNA (control) and corrected for GC content to establish copy number ratios.  GC content was 
calculated by dividing the number of G and C nucleotides in a window by the total number 
of nucleotides in GRCh38 in the same genomic region.  Secondly, these ratios were effectively 
‘smoothed’ to reduce signal noise and eliminate significant outliers (260).  Thirdly, data was 
normalised by ‘closest normalisation’, this corrected for differences in ploidy, genome 
coverage and contamination between matched test and control samples.  Closest 
normalisation identified the most frequent copy number ratio closest to the median ratio 
and shifted the data so that this ratio now defined two copies, which is the expected ploidy 
for a diploid genome.  Finally, segmentation analysis was carried out in CNAnorm with the 
programme DNAcopy (263).  This analysis identified point changes in copy number ratios 
across the genome and grouped genomic regions into segments where copy numbers were 
constant (263).  These data were then plotted against chromosome location to attain a copy 
number profile for each sample. 
 
A copy number ratio of one was equivalent to two copies of DNA and was expected for a 
diploid genome.  A ratio of two was equivalent to four DNA copies and described a copy 
number gain whilst a ratio of 0.5 was equivalent to one DNA copy and copy number loss. 
  
2.18.6.4 A 1 Mb window of fixed size was chosen for copy number analyses  
The use of different window sizes to group reads across the genome were explored in 
collaboration with Dr James Bradford.  A small window size resulted in increased noise and 
a greater number of windows with no reads.  In comparison, a larger window size resulted 
in the loss of small CNAs.  To balance resolution and signal noise, a window size of 1 Mb was 
chosen to define copy number aberrations and to determine a genomic instability score. 
 
A window size was defined as a fixed number of bp rather than by a fixed number of 
sequencing reads.  With window size defined by bp, the number of windows remain the same 
across samples allowing direct comparison of CNAs across samples. 
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2.19 Genomic Instability Score 
The hallmarks that lead to the development of cancer are acquired though successive 
mutational events caused by genomic instability (43).  Therefore, tumour DNA is genetically 
diverse compared to normal host cell DNA.  In cancer, CNAs leading to loss or gain of genome 
segments account for a high proportion of genomic variation (264) and may therefore 
provide a highly specific and sensitive biomarker for the detection of genomic instability.  
Genomic instability scores aim to quantify genetic aberrations by measuring the magnitude 
and/or the number of CNAs. 
 
Based on the detection of tumour-derived CNAs in cfDNA by whole genome sequencing (see 
Section 2.18.6), several tumour genomic instability scores have been tested in cancer 
patients and healthy controls.  Furthermore, cfDNA genomic instability scores have been 
used to differentiate cancer cases and controls (178, 265) and may have prognostic value 
(266).  A score may also be useful to quantify and track serial changes in cfDNA and therefore 
monitor treatment response (168).  Scores measuring the number and magnitude of CNAs 
across the whole genome, chromosomal arms and smaller chromosomal segments have 
been explored (167). 
 
Two published genomic instability scores were adapted to evaluate whether scores 
differentiated lung cancer cases and controls.  Genomic instability scores were calculated 
using copy number ratios of 1 Mb windows after low coverage sequencing of chromosomes 
1-22 (see Section 2.18). 
 
 The Plasma Genomic Abnormality 2 score  
The Plasma Genomic Abnormality score (PGA score) quantifies genomic instability by 
summing the squared log2 copy number ratio values of the most significant CNAs from whole 
genome sequencing data (266).  To create this score, copy number ratios of 1 Mb windows 
were calculated as the ratio of observed read count to the mean number of reads from a 
healthy control group (N=7) for the corresponding window (265).  Then copy number ratios 
were log2 transformed and normalised for GC content (265).  Log2 copy number ratios were 
squared and ranked, and the ratios ranked in the 95th to the 99th percentiles were summed 
(265). 
 
 
 
77 
 
In the study by Xia et al 2015, higher median Plasma Genomic Abnormality (PGA) scores were 
found for eight patients with early stage (I-IIA) lung adenocarcinoma compared to eight 
normal controls (19.5 (range 5.9-64.5) vs 9.3 (range 7.4-11.1) p=0.01) (265)  Approximately 
20 million reads were obtained for each individual, and the genome coverage was reported 
as 0.53X. 
 
The PGA score was adapted to create the PGA2 score, by ranking squared copy number ratio 
Z scores and summing the 95th to 99th percentile scores.  Both scores convert gains and losses 
to positive values to allow both extremes of the distribution to be examined.  For our 
samples, copy number ratios were calculated by comparing the number of reads in a 1 Mb 
window for cfDNA to the number of reads in the corresponding window of matched genomic 
lymphocyte DNA (see Section 2.18.6).  This differs to the PGA score, where cfDNA copy 
number ratios were calculated by comparing the number of reads in a window to the mean 
number of reads in the corresponding window of cfDNA samples from a group of healthy 
controls.  For the PGA2 score, the Z score was calculated by subtracting the mean copy 
number ratio of all 1 Mb windows for the sample from the copy number ratio of the 1 Mb 
window and dividing by the standard deviation of all copy number ratios across the genome 
for that sample. 
 
Z score of a 1 Mb window
=
𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑎 1 𝑀𝑏 𝑤𝑖𝑛𝑑𝑜𝑤 − 𝑚𝑒𝑎𝑛 (𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑎𝑙𝑙 1 𝑀𝑏 𝑤𝑖𝑛𝑑𝑜𝑤𝑠)
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑎𝑙𝑙 1 𝑀𝑏 𝑤𝑖𝑛𝑑𝑜𝑤𝑠)
 
 
Then, copy number ratios were log2 transformed, squared, ranked and the 95th to 99th 
percentile scores were summed (266).  For both the PGA and PGA2 scores, the top 1% of 
squared log2 copy number ratios were discarded (266).  This is because it was observed that 
high magnitude CNAs were caused by low quality sequencing libraries or were located near 
centromeres or telomeres (266).  Regions surrounding centromeres and telomeres contain 
highly conserved and repetitive DNA sequences (267) and therefore it can be difficult to map 
accurately short reads to these regions leading to false positive results (266). 
 
 Copy Number Aberration score 
A less selective approach to measure genomic instability is to sum genetic variation across 
the whole genome.  The whole genome summed Z (WGS) score or ‘global Z score’, sums the 
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Z scores of the copy number ratios across all 1 Mb windows of the genome (178).  A Z score 
statistic establishes whether CNAs in a cfDNA sample are present when compared to a 
reference group of controls.  This is achieved by calculating for the test sample the number 
of standard deviations from the mean of the reference plasma samples for each 1 Mb 
window.  Therefore, a Z score is calculated by the following equation: 
 
Z score of a 1 Mb window =
𝑐𝑜𝑝𝑦 𝑛𝑜.𝑟𝑎𝑡𝑖𝑜 𝑠𝑎𝑚𝑝𝑙𝑒−𝑚𝑒𝑎𝑛 (𝑐𝑜𝑝𝑦 𝑛𝑜.𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝)
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑐𝑜𝑝𝑦 𝑛𝑜.𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝)
    
 
In a study by Heitzer et al 2013, low coverage sequencing (>0.1X) with Illumina MiSeq was 
carried out for cfDNA samples from prostate cancer patients and healthy controls (178).  
WGS scores varied from -1.1 to +2.8 for healthy controls (N=10) and 125 to 1156 for prostate 
cancer cases (N=9).  Prostate cancer patients (N=9) were distinguished from healthy controls 
(N=10) by the WGS score in hierarchical cluster analyses.  A significant CNA was defined as 
being greater than three SDs away from the mean of the copy number ratio of the 
corresponding 1 Mb window of the control set.  In silico analyses simulated different 
mixtures of prostate cancer (N=102) and normal control DNA (N=500), and showed that the 
sensitivity for the detection of CNAs was >80% and the specificity >80% when there was 10% 
circulating tumour DNA (178).  When cell line DNA was mixed with normal control DNA at 
different proportions, samples with 1% cell line DNA remained separate from the healthy 
control group in hierarchical cluster analysis (178). 
 
In another study, Chan et al 2013 normalised reads in cfDNA samples to matched genomic 
DNA and then established Z scores by comparing the log2 copy number ratios of 1 Mb 
windows to a reference from 16 healthy controls (168).  CNAs identified in pre-surgical cfDNA 
samples for four patients with hepatocellular cancer almost disappeared in their matched 
post-surgical samples. 
 
The Copy Number Aberration (CNA) score is a whole genome wide assessment score of 
genomic instability adapted from the Whole Genome Summed Z (WGS)(113).  Z scores were 
calculated for each 1 Mb window by subtracting the mean copy number ratio of the low risk 
control group (N=10) from the copy number ratio of each 1 Mb window and dividing by the 
standard deviation of the copy number ratio from the low risk control group. 
 
 
 
79 
 
Z score of a 1 Mb window
=
𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑚𝑒𝑎𝑛 (𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑙𝑜𝑤 𝑟𝑖𝑠𝑘 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)
𝑆𝐷 (𝑐𝑜𝑝𝑦 𝑛𝑜. 𝑟𝑎𝑡𝑖𝑜 𝑙𝑜𝑤 𝑟𝑖𝑠𝑘 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)
 
 
For each low risk control, the mean and standard deviation for all copy number ratios across 
all 1 Mb windows were calculated.  Then, the average of the mean across the low risk 
controls (N=10) and the standard deviation were taken and these valuses were used to 
calculate the Z score.  CNA scores were not calculated for low risk controls so that they did 
not serve as their own controls.  Z scores were squared and summed to calculate the CNA 
score. 
 
In comparison, Heitzer et al. normalised the number of reads in a cfDNA sample to the mean 
number of reads of a heatlhy control group.  Z scores were then calculated within each 1 Mb 
window by subtracting the mean copy number ratio of the control group from the copy 
number ratio of the sample and dividing by the standard deviation of the control group 
(N=19) (113).  Then, Z scores were squared and summed to create the final score.  Neither 
the PGA score (by Xia et al.) or the WGS score (by Heitzer et al.) normalised the number of 
reads in a window for cfDNA to the number of reads in a window of matched genomic DNA, 
therefore all germline aberrations may not have been eliminated. 
 
2.20 Statistical analysis 
Statistical analysis were carried out with Microsoft Excel 2016, Graph Pad Prism version 6.0 
and StataMP version 12.  A p value <0.05 was deemed to be statistically significant.  All 
statistical tests were two-sided. 
 
 Comparison of independent groups 
In Chapter 3, non-parametric Mann Whitney U tests were used to evaluate methods of DNA 
extraction by comparing the percentage of DNA recovery for tumour FFPE DNA added in 
known quantities to plasma.  For a comparison of distributions across more than two groups, 
a non-parametric Kruskal-Wallis rank test was performed.  The characteristics of unselected 
or selected cases and controls were evaluated by comparing the distribution of continuous 
variables with the Mann Whitney U test.  Categorical variables were compared using the chi-
squared test, chi-squared test for trend (where categorical variables were ranked eg. disease 
stage) or Fisher’s exact test (if there were less than five people in the defined category).  A 
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non-parametric test for trend was carried out to compare cfDNA levels or genomic instability 
scores across disease stages in StataMP version 12 in Chapter 3 and 4 respectively.  In 
Chapter 4, DNA fragment sizes and important sequencing parameters were compared across 
different groups by performing Mann Whitney U tests.  This test was also used to compare 
genomic instability scores between cases and controls. 
 
 Correlations between variables and measures of agreement between tests  
In Chapter 4, Spearman’s Rank Correlation coefficients were calculated to compare copy 
number ratios and/or copy number ratio segments for different quantities of input cfDNA 
and different numbers of amplification cycles during library preparation.  The Bland-Altman 
test was used to compare the degree of agreement between old and new library preparation 
kits as well as the degree of agreement between sequencing runs as a measure of 
reproducibility.  In addition, the coefficient of variance was calculated for H69 cell line DNA 
CNA scores between sequencing runs as a measure of reproducibility.  Spearman’s Rank 
correlation coefficients were calculated for segmental copy number ratios and copy number 
ratios to compare 100% tumour FFPE DNA with descending proportions of tumour FFPE DNA 
spiked into cfDNA extracted from the pooled plasma of healthy volunteers.  Copy number 
ratios and segments were also assessed for correlation to compare tumour FFPE DNA and 
matched cfDNA samples.  Pearson’s correlation coefficients were used to measure the 
correlations between log10 cfDNA levels and log10 genomic instability scores. 
 
 Evaluation of circulating cell-free DNA levels and genomic instability scores as 
potential screening tools  
As cfDNA levels (Chapter 3) and CNA scores (Chapter 4) were positively skewed, a log10 
transformation was applied in an attempt to make the distribution more symmetrical.  The 
analyses described below were carried out in StataMP (version 12). 
 
2.20.3.1 Logistic regression 
Logistic regression analyses were used to compare binary outcome variables.  Each variable 
was tested in univariable analysis and included in multivariable analyses if p ≤0.25 or if it was 
an important a priori factor to adjust the analysis for.  Robust standard errors were calculated 
to better estimate variance. 
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2.20.3.2 Receiver Operating Characteristic curves 
The accuracy of a variable in the ability to distinguish between cases and controls and 
therefore function as a screening tool was summarised by plotting Receiver Operating 
Characteristic (ROC) curves.  The ROC curve is a standard tool for biomarker evaluation and 
graphs diagnostic sensitivity (true positive rate) against 1-specificity (false positive rate or 
proportion of controls with a positive test) (268).  ROC curves were generated based on the 
predicted probability of being a case, derived from the logistic regression analysis for 
univariable and multivariable models.  The area under the curve (AUC) gives a measure of 
test performance and facilitates the comparison of screening tools.  The AUC is the average 
value of sensitivity for all specificity values (268).  A test with an AUC of 0.5 is of no use 
because the proportion of cases and controls with a positive test are equal; AUC values close 
to 1.0 indicate a test with good discrimination.  For different score cut-offs the diagnostic 
sensitivity was estimated by dividing the number of true positives by the number of true 
positives and false positives.  The diagnostic specificity was estimated by dividing the number 
of true negatives by the number of true negatives and false negatives. 
 
 Evaluation of circulating cell-free DNA levels and genomic instability scores as 
potential prognostic tools  
2.20.4.1 Survival analyses to determine prognostic factors 
Kaplan-Meier survival curves were used to compare the outcomes of individuals with scores 
above or below the median value after adjusting for time from diagnosis to blood sample 
collection.  The test for proportional hazards was performed to ensure that the relative 
hazard ratio between the two groups was constant over time. 
 
Cox regression survival analyses was carried out to determine the prognostic value of tested 
variables for all cases after adjusting for time from diagnosis to blood sample collection.  The 
date of study recruitment was the date that the patient was registered for the study on the 
electronic database and occasionally lagged behind the date the blood sample was collected.  
First, all variables were tested in univariable analysis.  Variables with p value ≤0.25 were 
included in the final model or a variable was included if it were an important factor to adjust 
the analysis for.  This value was chosen because it was expected that a variable with p value 
>0.25 would not be predictive of survival in a model with other predictors (269). 
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For cox regression there is the assumption that the factors comparing different groups are 
constant over time.  The test of proportional hazard assumption was performed for the final 
model to test that this assumption was correct by showing that all factors had p value >0.05 
and therefore did not significantly vary over time. 
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3  Optimising plasma DNA extraction and evaluating total circulating 
cell-free DNA levels as a potential screening tool in lung cancer 
3.1 Introduction 
Circulating cfDNA is a potential biomarker in lung cancer because total cfDNA levels are 
raised compared to healthy controls, and the genetic changes in the primary tumour are 
identified in the blood (84).  The challenge is to extract maximal amounts of cfDNA whilst 
minimising contamination with genomic DNA from blood lymphocytes, to enable sensitive 
detection of tumour-related genetic alterations.  This will facilitate the translation of cfDNA 
as a biomarker in clinical practice by minimising false positive and false negative results.  The 
three steps in processing cfDNA are blood sampling; DNA extraction and analysis (see Section 
1.3.1 and 1.3.2). 
 
Many studies have reported the utilisation of total cfDNA levels as a screening or diagnostic 
tool for lung cancer (see Section 1.5.1.1).  However, no study has considered whether cfDNA 
levels can differentiate between high risk controls selected by a lung cancer risk model and 
lung cancer cases.  Early detection of lung cancer is vital to improve patient outcomes and 
current screening strategies use risk models to identify those at highest risk of lung cancer 
(10).  The measurement of total cfDNA levels is a non-invasive, cheap test and therefore wide 
spread clinical use in the NHS would be feasible. 
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3.2 Aims and objectives 
The first aim and objective was 
1) To identify the most efficient cfDNA extraction method by comparing the percentage 
recovery of tumour FFPE DNA after being added to healthy volunteer plasma. 
 
Two cfDNA extraction methods were chosen after a review of the literature.  DNA extracted 
from FFPE tumour specimens was added to healthy volunteer plasma to model the short 
degraded fragments characteristic of cfDNA.  The amount of cfDNA extracted from the 
plasma was quantified by SYBR green GAPDH RT-qPCR and the percentage of recovered 
tumour DNA calculated to allow method comparison. 
 
The second aim and objective was 
1) To evaluate total cfDNA levels quantified by SYBR green RT-qPCR as a potential 
screening tool for lung cancer by comparing total cfDNA yield for lung cancer cases 
and high risk controls. 
 
The hypothesis was that lung cancer cases would have higher cfDNA levels than high risk 
controls and therefore cfDNA levels could aid early lung cancer detection. 
 
A description of the ReSoLuCENT study, followed by a description of the cases selected for 
cfDNA analysis is presented.  Total cfDNA levels of cases and controls were compared and 
levels were also compared between subgroups including treated and untreated cases and 
advanced and early stage cases. 
 
Univariable and multivariable logistic regression were performed to establish whether cfDNA 
levels predicted case or control status.  ROC curve analyses were performed to establish 
sensitivity and specificity of cfDNA levels in distinguishing cases and controls. 
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3.3  Results 
 A comparison of plasma DNA extraction methods 
3.3.1.1 Recruitment of healthy volunteers 
Fourteen healthy volunteers were recruited to the study ‘Optimisation of plasma nucleic 
acids’ from April 2013 to March 2016 to provide negative control plasma and pooled plasma 
for spiking experiments (see Section 2.2.1).  The median age of healthy volunteers was 34 
years (range 24-38 years), seven (50%) volunteers were male and seven (50%) were female. 
 
3.3.1.2 Tumour DNA yield and quality 
DNA was extracted from colorectal tumour FFPE sections (see Section 2.4) to be used for 
plasma spiking experiments to model the short degraded fragments of cfDNA.  Extracted 
tumour DNA was added in known quantities to pooled healthy volunteer plasma at a 
proportion of 65 ng per 1 ml unless otherwise stated.  Plasma DNA extraction methods were 
compared by calculating the percentage of tumour DNA recovered as described in Section 
2.11.1. 
 
The quantity and purity of extracted tumour DNA from two colorectal cancer cases were 
determined by nanodrop spectrophotometry.  The yield of DNA from these cases were 404 
ng/µl and 181 ng/µl in 50 µl. The 260/280nm ratios were 1.99 and 2.03, whilst the 
260/230nm ratios were 2.44 and 2.35 respectively.  Extracted tumour DNA yielded a PCR 
product using BRAF V600E short amplicon (160 bp) and BRAF V600E long amplicon (600 bp) 
primers (Figure 3-1).  These findings were consistent with degraded fragmented DNA 
expected from FFPE tissue sections, and a representative model of the fragmented DNA 
circulating in the plasma of cancer patients.  This DNA was used to spike healthy control 
plasma. 
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                    BRAF V600E short              BRAF V600E long 
 
 
Figure 3-1:  Agarose gel electrophoresis of colorectal FFPE tumour DNA extracted from four 
different cases after PCR for BRAF V600E (short and long exons). 
 
3.3.1.3 QIAamp® Blood Mini Kit compared to the phenol chloroform method 
The first aim was to compare two methods of plasma DNA extraction, the QIAamp® blood 
mini kit (Qiagen) and the phenol chloroform method.  Healthy control plasma samples of 1 
ml were spiked with 65 ng of tumour FFPE DNA.  There was no significant difference in the 
median percentage of DNA recovered between the QIAamp® blood mini kit (Qiagen) and 
phenol chloroform method as assessed by three independent experiments (Figure 3-2).  DNA 
yields were very low with both methods.  A median of 1.8% (range 1.3- 2.7%) of DNA was 
recovered from 1 ml of plasma with the QIAamp® blood mini kit (Qiagen) compared to 2.2% 
(range 2.0- 3.4%) with phenol chloroform (p=0.40 Mann Whitney U test).  The phenol 
chloroform method was time consuming and laborious, therefore the QIAamp® blood mini 
kit (Qiagen) was further evaluated. 
1-positive control, human 
genomic DNA 
 
2-postitive control whole 
genome amplified DNA 
 
Tumour extracted DNA 
3- Case 19706 
4- Case 22220 
5- Case 23066 
6- Case 9812 
7- negative control, water 
 
          1     2     3    4   5   6     7      1    2     3     4      5   6   7    
 
600bp 
 
 
100bp 
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Figure 3-2:  The percentage of DNA recovery from 1ml of plasma spiked with 65ng of tumour 
FFPE DNA for the QIAamp® blood mini kit and phenol chloroform method (N=3) 
Median and interquartile range (IQR) shown.  Median 1.8% (range 1.3- 2.7%) vs 2.2% (range 
2.0- 3.4%) respectively p=0.40 Mann Whitney U test.  Each point represents the percentage 
of DNA recovered from one independent experiment. 
 
3.3.1.4 The QIAamp® circulating nucleic acid kit compared to the QIAamp® blood mini kit 
Plasma DNA recovery remained very low with the QIAamp® blood mini kit (Qiagen) therefore 
the QIAamp® circulating nucleic acid (CNA) kit (Qiagen) designed specifically for the 
extraction of cell-free nucleic acids was tested.  To increase cfDNA yields the quantity of 
plasma was increased from 1 ml to 3 mls.  Plasma samples of 3 mls were spiked with 100 ng 
of FFPE tumour DNA, and the vacuum rather than spin method was used (see Section 
2.5.2.2), to accommodate larger plasma volumes and more efficient sample processing.  The 
median percentage of DNA recovery for the CNA kit (Qiagen) was 20.4% (range 19.1- 20.6%) 
compared to 7.0% (range 4.6- 9.2%) for the QIAamp® blood mini kit (Qiagen) (p=0.10 Mann 
Whitney U test) (Figure 3-3). 
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Figure 3-3:  The percentage of DNA recovery from 3 mls of plasma spiked with 100 ng of 
tumour FFPE DNA with the CNA and QIAamp® blood mini kit (N=1). 
Median and IQR shown.  Each point represents one independent repeat and is the average 
of three qPCR replicates.  Median recovery for CNA kit 20.4% (range 19.1- 20.6%) compared 
to 7.0% (range 4.6- 9.2%) for the QIAamp® blood mini kit, p=0.10 Mann Whitney U test. 
 
 The ReSoLuCENT study 
3.3.2.1 Recruitment of participants to the ReSoLuCENT study 
There were 887 cases and 538 controls recruited to the multicentre ReSoLuCENT study from 
6th April 2006 to 31st August 2016.  An intermediate dataset including recruited participants 
up to the 8th of November 2013 forms the sample set described in this Chapter.  Of these 
1121 participants, 682 (61%) had a diagnosis of lung cancer and 439 (39%) were related or 
unrelated controls.  Of the cases, two were ineligible, after further pathological review 
indicated a diagnosis of metastatic thyroid cancer and mesothelioma.  Sixty-eight percent of 
cases and 80% of controls were recruited in South Yorkshire (Sheffield, Doncaster and 
Rotherham).  Figure 3-4 displays recruitment figures for each site. 
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Figure 3-4:  The number of cases and controls participating in ReSoLuCENT across recruitment 
sites. 
Red: Cases.  Green: Controls. 
 
3.3.2.2 Characteristics of cases and controls recruited  
The characteristics of cases (N=680) and controls (N=439) in the ReSoLuCENT study are 
shown in Table 3-1.  The median age of cases at recruitment was significantly older than 
controls, 56.6 years (range 20.8-83.3 years) compared to 52.1 years (range 19.0-83.2 years), 
p<0.0001 Mann Whitney U test.  There were a higher proportion of females in the control 
group (78% vs 50%) and never smokers (32% vs 7%).  Most participants were White British 
(87%). 
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Table 3-1:  The characteristics of cases (N=680) and controls (N=439) participating in 
ReSoLuCENT. 
 
To be eligible for ReSoLuCENT cases, had to have a confirmed pathological diagnosis of lung 
cancer.  The histological subtype was categorised according to the World Health Organisation 
2004 classification of lung tumours (270).  Five hundred and three cases (74%) were 
diagnosed with NSCLC.  Of these cases, 204 (41%) had adenocarcinoma (AC), 152 (30%) 
squamous cell carcinoma (SQ) and for 120 (24%) the histological subtype was not otherwise 
specified (NOS).  In addition, 27 (5%) of NSCLC cases had less common subtypes.  These 
included 10 (2%) cases with neuroendocrine, 5 (1%) with large cell, 2 (0.4%) with 
bronchcoalveolar, 5 (1%) cases had a combination of NSCLC subtypes diagnosed and there 
were individual cases of adenocystic (0.2%), spindle variant (0.2%), and 
pleomorphic/sarcomatoid (0.2%).  One hundred and sixty-six (24%) cases were diagnosed 
with SCLC and 11 (2%) cases had a mixture of SCLC and NSCLC histology. 
 
Lung cancer research is hampered by the poor availability of tumour tissue.  In this study, 
only 29 (4%) of cases had surgically resected tumour tissue available.  In contrast, 451 (66%) 
of cases had a primary bronchial biopsy, 50 (7%) a loco-regional lymph node biopsy, seven 
(1%) a pleural biopsy, 66 (10%) a biopsy of a secondary metastasis and 72 (11%) had cytology 
specimens.  For five (0.7%) cases the biopsy site was unknown. 
Characteristic Cases  
(N=680) 
Controls 
(N=439) 
P value 
(statistical test) 
Gender  Male 338 (50%) 172 (39%) p=0.0006 
(Chi-squared 2x2) Female 342 (50%) 267 (78%) 
Age at 
recruitment 
Median 
(Range) 
56.6 (20.8- 83.3) 52.1 (19.0- 83.2) p<0.0001 
(Mann Whitney U) 
Age at diagnosis Median 
(Range) 
56.2 
(20.7-83.1, N=678) 
- - 
Ethnicity White British 585 (86%) 386 (88%) p=0.24 
(White British vs 
Non White British 
vs Unknown) 
(Chi-squared 2x3) 
 
Black 
Caribbean 
1 (0.1%) - 
Black African 1 (0.1%) - 
Chinese 3 (0.4%) - 
Other  5 (0.7%) 2 (0.5%) 
Unknown 85 (13%) 51 (12%) 
Smoking Status  Current 187 (28%) 142 (32%) p<0.0001 
(Chi-squared 2x4) Ex 353 (52%) 120 (27%) 
Never 50 (7%) 142 (32%) 
Unknown 90 (13%) 35 (8%) 
Status as of 31st 
November 2015 
Alive 111 (16%) 422 (96%) p<0.0001 
(Chi-squared 2x2) Dead 569 (84%) 17 (4%) 
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At study entry, 295 of 514 (57%) of NSCLC cases had advanced stage IV metastatic disease, 
170 (33%) had stage III, 23 (4%) stage II and 6 (1%) stage I disease.  In comparison, 118 of 166 
(71%) SCLC cases had extensive disease (ED) and 48 (29%) limited disease (LD).  Table 3-2 
summarises disease stage according to histological subtype. 
   
Stage  NSCLC MIXED NSCLC 
AND SCLC 
SCLC Total 
AC SQ NOS OTHER 
Stage I 3 3 - - 1  7(10%) 
Stage II 9 8 5 1 - - 23 (4%) 
Stage III 50 71 38 11 7 - 177 (26%) 
Stage IV 137 66 77 15 3 - 298 (44%) 
Limited - - - - - 48 48 (7%) 
Extensive - - - - - 118 118 (17%) 
Missing 5 4 - - - - 9 (1%) 
Total 204 
(30%) 
152 
(22%) 
120 
(18%) 
27 
(4%) 
11  
(2%) 
166  
(24%) 
680 
Table 3-2:  A summary of the stage and histopathology of lung cancer cases (N=680) recruited 
to ReSoLuCENT. 
AC: adenocarcinoma. NOS: not otherwise specified. NSCLC: non-small cell lung cancer. SCLC: 
small cell lung cancer. SQ: squamous cell carcinoma. 
 
The ECOG (Eastern Cooperative Oncology Group) performance status (PS) is a measure of an 
individual’s physical activity, and is an important prognostic factor in lung cancer (271).  Five 
hundred and seventy-eight of 680 (85%) of cases had a PS of 0 or 1, indicating the ability to 
carry out normal activity or light work respectively.  On the other hand, 71 of 680 (10%) of 
cases had a PS of 2, and 19 of 680 (3%) cases had a PS of 3.  A PS of 2 indicated that the 
individual was mobile for more than 50% of the day and a PS of 3 indicated that an individual 
was mobile for less than 50% of the day, had limited ability to self-care, but was not bed 
bound. 
 
3.3.2.3 Liverpool Lung Project cancer risk score  
As part of another project by Eoin Gray, LLP Risk scores were calculated for both cases and 
controls, and were available for 781 ReSoLuCENT participants between the ages of 40 to 80 
years (Figure 3-5).  The LLP model calculates a predicted risk of lung cancer using risk factors 
such as age; gender and smoking (13)(see Section 1.1.2.1.1).  The median risk score for cases 
(N=521) was significantly higher than the median risk score for controls (N=260), 0.84 (range 
0.012-39.36) compared to 0.42 (range 0.005-13.25), p<0.0001 Mann Whitney U test.  In this 
subset, there was no difference between cases and controls for age (median 56.6 (range 40-
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79 years) vs 56.2 years (range 40-79 years), p=0.86 Mann Whitney U test) or gender (p=0.080 
Chi-squared test). 
 
 
Figure 3-5:  A Box plot to compare available Liverpool lung cancer project (LLP) risk scores for 
lung cancer cases (N=521) and controls (N=260) in ReSoLuCENT. 
Median score -0.84 (range -0.012-39.36, N=521) vs -0.42 (range -0.005-13.25, N=260) 
respectively **** p<0.0001 Mann Whitney U test.  Median, IQR, maximm, minimum values 
and outlier values are shown. 
 
Only 38 controls (15%) had a LLP score ≥2.5% and were thus classed as high risk for the 
development of lung cancer.  Whilst, 110 (21%) of lung cancer cases were classified as high 
risk.  Only 42 cases (8%) and 15 (6%) controls had a LLP score ≥ 5%.  Predicted risk is generally 
low because ReSoLuCENT has recruited young cases and controls and age is a significant risk 
factor in the LLP risk model. 
 
As of March 31st 2016, 22 controls (5%) were reported by the Health and Social Care 
Information Centre (HSCIC) (previously The Office of National Statistics) to have developed 
cancer after study registration (Table 3-3).  Only one control was diagnosed with lung cancer.  
These controls were excluded from molecular analyses and no control analysed 
subsequently developed cancer to our knowledge.  LLP risk scores were available for 18 of 
22 controls.  The median LLP score was 0.57 (range 0.13-3.79) and only three (17%) controls 
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had an LLP risk score ≥2.5%.  There was no significant difference between the LLP score for 
controls that were not known to have developed cancer compared to controls that had 
developed cancer (0.42 (range 0.005-13.25, N=242) vs 0.57 (range 0.13-3.79, N=18), p=0.31 
Mann Whitney U test). 
 
Cancer subtype No. of controls 
Basal cell carcinoma 2 
Bowel 1 
Breast 6 
Cervical 4** 
Lung 1 
Melanoma 3 
Prostate 2 
Skin undefined 1 
Testicular 1 
Undefined 1 
Total 22 
Table 3-3:  The development of cancer in control subjects in ReSoLuCENT according to HSCIC. 
** two controls with cervical cancer subsequently developed breast cancer. 
 
 Plasma extracted circulating cell-free DNA total levels of ReSoLuCENT recruits 
3.3.3.1 Selection of cases and controls for circulating cell-free DNA analysis 
CfDNA was extracted from the plasma of 114 individuals (72 cases and 42 controls) 
participating in ReSoLuCENT to test the use of cfDNA levels as a screening tool for lung 
cancer. Levels of cfDNA were quantified by SYBR green GAPDH RT-qPCR (see Section 
2.9.2.1.1). 
 
Seventy-two of 680 available cases were selected for cfDNA analysis as follows.  Plasma from 
52 of 54 cases that had not received treatment for cancer prior to blood withdrawal were 
chosen.  One case was eliminated because disease stage was unknown and a further case 
was not chosen because the histological subtype was rare (adenoid cystic).  In addition, 
plasma from 20 advanced stage treated cases (of 626 treated cases) were processed for 
which the ctDNA allele fraction had been defined by targeted sequencing with the Ion 
Torrent Platform (see Appendix E) (N=6) or whereby tumour FFPE tissue was available 
(N=14). 
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Plasma from 10 low risk and 32 high risk unrelated controls were chosen from those for 
whom an LLP risk score was available (N=260).  The LLP risk model was used to mimic the 
selection of high risk controls as carried out in the UKLS lung cancer screening study (see 
Section 1.1.2.1.1).  There were 222 low risk controls with an LLP risk score <2.5 %.  There 
were 38 high risk controls with an LLP risk score ≥2.5%, and 32 were chosen.  Low risk and 
high risk controls were selected to have similar age range and gender as selected early stage 
cancer cases, although due to small numbers this was more difficult for high risk controls. 
 
Plasma was utilised from blood samples collected from seven different centres participating 
in the ReSoLuCENT study.  Forty-five percent of blood samples were collected from Weston 
Park Hospital in Sheffield (Figure 3-6).  Each site followed ReSoLuCENT SOPs to collect and 
process blood and to store plasma and genomic DNA.  Plasma and genomic DNA samples 
were couriered, using dry ice to avoid thawing, in batches to Weston Park Hospital for long-
term storage. 
 
 
Figure 3-6: A pie chart to demonstrate the proportion of analysed blood samples collected at 
different centres participating in ReSoLuCENT (N=114) 
WPH: Weston Park Hospital, Sheffield (N=51).  DRI: Doncaster Royal Infirmary (N=32), 
Doncaster. NGH: Northern General Hospital, Sheffield (N=15). CHM: Christies Hospital, 
Manchester (N=8). AGH: Airedale General Hospital (N=3): SGH: Southampton General 
Hospital (N=3): VHC: Velindre Hospital Cardiff (N=2): 
 
WPH DRI NGH CHM
AGH SGH VHC
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3.3.3.2 Comparison of selected subjects to non-selected subjects 
First, it was established that there was no evidence that the cases that were selected for the 
study were not representative of the whole study.  There was no significant difference 
between the characteristics of the chosen subgroup of cases with cfDNA levels (N=72) 
compared to the cases whose plasma was not analysed (N= 608) for, age at diagnosis (p=0.11 
Mann Whitney U test), gender (p=0.86 Chi-squared test) or smoking status (p=0.49 Chi-
squared test for trend).  However, due to the presence of selected high risk controls, the 
control group did differ from those that were not analysed.  The median age of the selected 
control subgroup (N=42) was significantly older than the remaining controls in the 
ReSoLuCENT study (N=397), 61.1 years (range 34.4-79.2 years) compared to 52.1 years 
(range 18.9-83.2 years) respectively, p<0.0001 Mann Whitney U test.  Furthermore, there 
was a significantly higher proportion of females and lower proportion of males in the 
remaining control group (N=397) (62% and 38%) compared to the analysed subset (N=42) 
(43% and 57%) (p=0.02 Chi-squared test).  Smoking proportions were also different between 
the two groups, with more smokers in the control subgroup (N=42) compared to the 
remaining controls in the ReSoLuCENT study (N=397) (p=0.003 Chi-squared test for trend). 
 
3.3.3.3 Comparison of all selected cases with controls and analysis of selected subgroups 
In the following sections, first the characteristics and cfDNA levels of selected cases (N=72) 
and controls (N=42) were compared to establish any differences.  Then, subgroups of 
selected cases and controls were compared.  Further comparisons of subgroups were carried 
out with logistic regression and ROC curve analyses to explore the role of cfDNA levels as a 
potential screening tool. 
 
Subgroups were chosen to enable comparison to the published literature and to determine 
the role of cfDNA as a screening tool to potentially aid patient stratification in a lung cancer 
screening programme.  The subgroups were, untreated cases (N=52) vs controls (N=40), and 
untreated early stage cancer cases (N=21) vs high risk controls (N=30).  For cases, treatment 
subgroups were defined by whether anticancer treatment was administered prior to blood 
withdrawal and disease stage.  Cases were subdivided into early stage lung cancer (stage I-
IIIA) that is potentially curable with treatment, and advanced stage cancer (stage IIIB-IV), 
which is not cured by treatment.  For controls, LLP risk score and age defined subgroups.  
Controls aged 50-75 years were included (with the exception of two high risk patients aged 
>75 years) to mimic the age of participants in the UKLS study (see Section 1.1.2), and were 
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subdivided by their LLP risk score into low risk (<2.5% risk of developing lung cancer over 5 
years) and high risk (≥2.5% risk). 
 
3.3.3.4 Comparison of all selected cases with controls  
The characteristics of cases (N=72) and controls (N=42) whose cfDNA levels were determined 
are summarised in Table 3-4.  There was a significant difference between cases (N=72) and 
controls (N=42) for age (p<0.0001 Mann Whitney U test) and smoking (p<0.0001 Chi-squared 
test).  Not surprisingly, given the selection of high risk controls, controls were significantly 
older and more were current smokers. 
 
Characteristic  Cases  
N=72 
Controls  
N=42 
P value 
(statistical test) 
Gender Male 35 (49%) 24 (57%) p=0.77 
(Chi-squared 2x2) Female 37 (51%) 18 (43%) 
Age at registration in 
years 
Median 
(Range) 
57.3  
(34.6-78.5) 
61.2  
(34.4-79.2) 
p<0.0001 
(Mann Whitney U) 
Smoking Status  Current 23 (32%) 25 (59%) p<0.0001 
(Chi-squared 2x4) Ex 33 (46%) 6 (14%) 
Never 4 (6%) 11 (26%) 
Unknown 12 (17%) 0 (0%) 
Length of plasma storage in years 5.7 
(1.2-8.9) 
6.6 
(2.8-9.6) 
0.05 
(Mann Whitney U) 
Status as of August 
30th 2016 
Alive 10 (14%) 39 (93%) p<0.0001 
(Fisher’s exact) Dead 62 (86%) 3 (7%) 
Table 3-4:  A comparison of the characteristics of cases (N=72) and controls (N=42) that had 
plasma cfDNA extracted and quantified. 
3.3.3.5 Circulating cell-free DNA total levels were higher in cases compared to controls 
The median cfDNA level of all cases (treated and untreated) (N=72) was significantly higher 
than the cfDNA level of controls (N=42) (7.93 ng/ml (range 1.57- 545.10 ng/ml) vs 4.32 ng/ml 
(range 1.25- 33.99 ng/ml), p<0.0001 Mann Whitney U test) (Figure 3-7).  There were four 
cases with very high cfDNA levels (185 ng/ml, 295 ng/ml, 545 ng/ml and 540 ng/ml).  Of these 
cases, two had a histological diagnosis of SCLC and two had a diagnosis of NSCLC 
(adenocarcinoma and NOS).  All four had stage IV disease with distant spread to at least one 
metastatic site.  One case with cfDNA levels of 540 ng/ml had palliative radiotherapy prior to 
blood withdrawal, whilst the other three cases had received no treatment.  The median time 
of plasma storage for controls was 6.6 years (range 2.8-9.6 years) compared to 5.7 years 
(range 1.2-8.9 years) for cases (p=0.054 Mann Whitney U test). 
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Figure 3-7:  A Box plot displaying cfDNA levels in ng/ml for all lung cancer cases (N=72) and 
controls (N=42). 
The median cfDNA level for cases was 7.93 ng/ml (range 1.57- 545.10 ng/ml) vs 4.32 ng/ml 
(range 1.25- 33.99 ng/ml).  **** p<0.0001, Mann Whitney U test.  Median, IQR, maximum 
and minimum values are shown. 
 
3.3.3.6 Treated cases had higher circulating cell-free DNA total levels compared to 
untreated cases 
Anticancer therapy may influence cfDNA levels (129, 272), and therefore the characteristics 
and cfDNA levels of treated and untreated cases were compared.  Twenty lung cancer cases 
had ongoing or had recently completed cancer treatment prior to their blood withdrawal.  
Of these cases, eleven had palliative chemotherapy, four palliative radiotherapy, one 
palliative chemotherapy and radiotherapy, one complete excision of a solitary brain 
metastasis and no disease elsewhere, one radical surgery with incomplete excision, one 
radical chemo-radiotherapy and one case was treated with the bisphosphonate zoledronate.  
A comparison of the characteristics of treated and untreated cases are displayed in Table 
3-5.  There was no significant difference between the treated and untreated cases for gender 
(p=0.80 Chi-squared test), age (p=0.85 Mann Whitney U test), stage of disease (p=0.24 Chi-
squared test for trend), performance status (p=0.88 Chi-squared test for trend), smoking 
status (p=0.70 Chi-squared test) and length of time that plasma was stored (p=0.23 Mann 
Whitney U test).  There were higher cfDNA levels in the treated cases compared to the 
untreated cases, 11.2 ng/ml (range 2.4-540.1) vs 6.9 ng/ml (range 1.6-545.1) (p=0.05 Mann 
Whitney U test). 
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Characteristic Untreated 
N=52 
Treated 
N=20 
P value 
(statistical test) 
Gender Male 26 (50%) 9 (45%) p=0.80 
(Chi-squared 2x2) Female 26 (50%) 11 (55%) 
Age in years Median 
(Range) 
57.4 
(34.6-70.1) 
57.05 
(37.8-78.5) 
p=0.85 
(Mann Whitney U) 
Stage I 5 (10%) 0 (0%) p=0.06 
(Chi-squared test 
for trend, unknown 
excluded) 
II 9 (17%) 1 (5%)    
(incomplete 
excision) 
III 14 (27%) 6 (30%) 
IV 24 (46%) 12 (60%) 
Unknown 0 1 (5%) 
Performance 
Status (PS) 
0 16 (31%) 4 (20%) p=0.88 
(Chi-squared test 
for trend, unknown 
excluded) 
1 25 (48%) 13 (65%) 
2 6 (12%) 3 (15%) 
3 3 (6%) 0 (0%) 
Unknown 2 (4%) 0 (0%)  
Smoking Status  Current 17 (33%) 6 (12%) p=0.70 
(Chi-squared 2x4) Ex 25 (48%) 8 (15%) 
Never 3 (6%) 1 (5%) 
Unknown 7 (13%) 5 (25%) 
Length of plasma 
storage in years 
Median 
(Range) 
5.5 
(1.2-8.9) 
6.0 
(3.5-8.4) 
p=0.23 
(Mann Whitney U) 
CfDNA levels 
ng/ml 
Median 
(Range) 
6.9  
(1.6-545.1), 
11.2 
(2.4-540.1) 
p=0.05 
(Mann Whitney U) 
Status as of 
August 30th 2016 
Alive 12 (23%) 0 (0%) p= 0.03 
(Chi-squared 2x2) Dead 40 (77%) 20 (100%) 
Table 3-5:  A comparison of the characteristics of treated (N=20) and untreated cases (N=52). 
 
3.3.3.7 Circulating cell-free DNA total levels in untreated lung cancer cases and controls  
Given the results above, suggesting that treatment is associated with increased cfDNA levels, 
treated cases were excluded from further analyses to avoid bias in results due to treatment 
effect. 
 
3.3.3.7.1 Circulating cell-free DNA total levels increased with advancing disease stage in 
untreated cases 
In our selected subset, it was established whether cfDNA levels increased with advancing 
disease stage.  For the 52 untreated lung cancer cases, cfDNA levels differed between early 
stage (I-IIIA, N=21) and advanced stage disease (IIIB-IV, N=31) (median 4.74 ng/ml (range 
1.57-21.61 ng/ml) vs 10.34 ng/ml (range 2.39-545.1 ng/ml), p=0.0009 Mann Whitney U test).  
There was a significant trend of increasing cfDNA levels with increasing disease stage 
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(p=0.001 Non-parametric test for trend) (Figure 3-8).  There was a wide distribution of cfDNA 
levels for cases with stage IV disease from 2.34ng/ml to 545.1ng/ml.  Figure 3-9  displays 
cfDNA levels for untreated stage IV cases (N=24) according to histological subtype.  Median 
cfDNA levels were higher for SCLC cases in comparison to cases with adenocarcinoma 
(p=0.019), squamous (p=0.024) or other NSCLC subtypes (p=0.026 Mann Whitney U test). 
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Figure 3-8:  CfDNA levels according to the disease stage of untreated cases (N=52). 
Median and IQR are shown.  Non-parametric test for trend, p=0.001. 
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Figure 3-9: CfDNA levels according to the lung cancer histological subtype of stage IV 
untreated cases (N=24). 
Median and IQR are shown. * P<0.05. 
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3.3.3.7.2 Circulating cell-free DNA total levels were higher for untreated lung cancer cases 
compared to combined high and low risk controls 
Next, comparisons of untreated lung cancer cases (N=52) and controls aged 50 to 75 years 
old (N=40) (to match the age of participants screened in the UKLS lung cancer screening 
study), were explored.  CfDNA levels of untreated cases (median 6.86 ng/ml (range 1.57-
545.15 ng/ml), N=52) were significantly higher than combined high and low risk controls 
(median 4.43 ng/ml (range 1.25-33.99 ng/ml), N=40) p=0.0021 Mann Whitney U test). 
 
3.3.3.8 Log10 cell-free DNA levels were significant predictors of case or control status in 
univariable and multivariable analysis when comparing untreated cases and controls 
A logistic regression model was used to understand whether cfDNA levels predicted case 
(N=52) or control status (N=40) (see Section 2.20.3.1).  As cfDNA levels were positively 
skewed, a log10 transformation was applied.  Consistent with our preliminary analysis, for 
univariable analyses the factors log10 cfDNA levels (Odds Ratio (OR) 2.25, p=0.02), years of 
plasma storage (OR 0.78, p=0.02), age (OR 0.84, p=0.002), and smoking status (never vs 
ex/current) (OR 4.67, p=0.03) were significant, but gender (OR 1.5, p=0.34) was not.  In 
multivariable analyses, log10 cfDNA levels (OR 3.11, p=0.008), smoking status (never vs 
ex/current) (OR 17.45, p=0.02), age (OR 0.78, p<0.001) and gender (OR 4.14, p=0.02) were 
significant factors when adjusting for years of plasma storage (Table 3-6). 
 
 Odds ratio (95% CI) P value 
Univariable analysis    
Log10 cfDNA ng/ml 2.25 (1.14-4.44) 0.02 
Smoking (never vs ex/current) 4.67 (1.17-18.56) 0.03 
Length of plasma storage at -80°C 0.78 (0.64-0.96) 0.02 
Age at study registration 0.84 (0.75-0.94) 0.002 
Gender (male comparator) 1.5 (0.65-3.47) 0.34 
Multivariable analysis   
Log10 cfDNA ng/ml 3.11 (1.34-7.21) 0.008 
Smoking (never vs ex/current) 17.45 (2.44-124.90) 0.02 
Length of plasma storage at -80°C 0.95 (0.69-1.30) 0.76 
Age at study registration 0.78 (0.68-0.90) 0.001 
Gender (male comparator) 4.14 (1.25-13.67) 0.02 
Table 3-6: Univariable and multivariable logistic regression for untreated lung cancer cases 
(N=52) compared to controls (N=40) to determine significant predictors of case or control 
status. 
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ROC curve analysis based on the logistic regression predicted probabilities was carried out 
to establish potential evidence for the suitability of log10 cfDNA levels to discriminate the 
different groups (Figure 3-10).  ROC curves were generated for log10 cfDNA levels alone and 
after adjusting for the predicted probabilities of important variables from multivariable 
logistic regression (see above).  There was fair discriminatory ability for log10 cfDNA levels 
alone (AUC 0.69 (95% CI 0.58-0.78)) and very good discriminative ability after adjustment for 
smoking, length of plasma storage, age and gender (AUC 0.86 (95% CI 0.78-0.94). 
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i. Univariable model log10 cfDNA levels (AUC 0.69 (95% CI 0.58-0.78))  
 
ii. Multivariable model including age, gender, log10 cfdna levels, length of plasma 
storage and smoking (AUC 0.86 (95% CI 0.78-0.94). 
Figure 3-10:  ROC analyses for univarible and multivariable models for untreated lung cancer 
cases (N=52) and controls (N=40) to establish the role of log10cfDNA levels in predicting case 
or control status  
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3.3.3.9 Circulating cell-free DNA total levels for untreated early cancer cases and high risk 
controls were not significantly different and levels did not predict case or control 
status 
To be useful as a screening tool, cfDNA levels need to distinguish early stage cancer from 
high risk controls.  However, there was no significant difference in the levels of cfDNA 
between untreated early stage cancer (stage I-IIIA) (N=21) and high risk controls (N=30) 
(median 4.74 ng/ml (range 1.57-21.61 ng/ml) vs 4.63 ng/ml (range 1.25-33.99 ng/ml) 
respectively, p=0.73 Mann Whitney U test) (Figure 3-11).  As noted above for all cases the 
high risk controls (N=30) were older with a higher proportion of current smokers compared 
to untreated early stage cases (N=21) since they have been selected for high risk LLP risk 
model scores (Table 3-7). 
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Figure 3-11:  A comparison of cfDNA levels ng/ml between early (I-IIIA) (N=21) and late stage 
(IIIB-IV) (N=31) untreated lung cancer cases and high risk (N=30) and low risk controls (N=10). 
*** p<0.001 Mann Whitney U test.  Median and IQR shown.   
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Characteristic Untreated early 
stage cancer  
(I-IIIA) (N=21) 
High risk 
(N= 30) 
P value 
(statistical test) 
Gender Male 9 (43%) 21 (70%) p=0.08 
(Fisher’s exact) Female 12 (57%) 9 (30%) 
Age in years at 
registration   
Median 
(Range) 
56.3 
(40.0-65.2) 
61.9 
(57.1-72.6) 
p<0.0001 
(Mann Whitney U) 
Age at diagnosis Median 
(Range) 
56.2 (40.0-65.2) - - 
Smoking status Current 6 (29%) 24 (80%) p=0.002 
(Chi-squared 2x2) Ex 11 (52%) 6 (20%) 
Never 0 0 
Unknown 0 0 
Status as of 
August 30th 2016 
Dead 11 (52%) 1 (3%) p<0.0001 
(Fisher’s exact) Alive 10 (48%) 29 (97%) 
Length of plasma storage in yrs 6.0 (1.2-8.3) 6.4  
(2.8-9.6) 
p=0.27 
(Mann Whitney U) 
CfDNA ng/ml Median 
(Range) 
4.7 
(1.6-21.6) 
4.6  
(1.2-34.0) 
p=0.73 
(Mann Whitney U) 
Table 3-7:  A comparison of the characteristics of early stage lung cancer cases (I-IIIA) (N=21) 
and high risk controls (N=30). 
 
To determine whether certain factors were predictive of early case vs high risk control status, 
logistic regression was performed.  Smoking was not tested because in this subset all early 
cancer cases and high risk controls had a smoking history.  Log10 cfDNA levels were not a 
statistically significant predictor of case or control status in univariable analysis, neither was 
length of plasma storage or gender (Table 3-8). 
 
 Odds ratio (95% CI) P value 
Univariable analysis    
Log10 cfDNA ng/ml 0.95 (0.43-2.09) 0.91 
Length of plasma storage at -80°C 0.82 (0.65-1.04) 0.11 
Age at study registration 0.60 (0.43-0.84) 0.003 
Gender (male comparator) 3.11 (0.96-10.09) 0.06 
Table 3-8:  Univariable logistic regression for untreated early cancer cases (N=21) and high 
risk controls (N=30) to evaluate predictive factors to determine case or control status. 
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3.4 Discussion 
 Extraction of circulating cell-free DNA from plasma 
In this study, three methods of plasma cfDNA extraction were evaluated.  There was no 
significant difference in the mean percentage of DNA recovered from 1 ml of healthy 
volunteer plasma spiked with tumour DNA for the QIAamp® blood mini kit (Qiagen) 
compared to the phenol chloroform method.  However, the CNA kit (Qiagen) outperformed 
the QIAamp® blood mini kit (Qiagen) with a higher percentage recovery of DNA from 3 mls 
of plasma (20.4% vs 7.0%).  This finding was consistent with the results of other studies, 
which are discussed in detail below (135, 273).  It was hypothesised that the QIAamp® blood 
mini kit (Qiagen) was developed for whole blood, and therefore optimised for the extraction 
of intact higher molecular weight DNA, compared to the CNA kit (Qiagen) developed 
specifically for short DNA fragments (273). 
 
Tumour DNA from FFPE sections was chosen to spike healthy volunteer plasma as a model 
for cfDNA in cancer patients.  This model was representative because the short degraded 
tumour DNA fragments were consistent with the characteristics of cfDNA in cancer patients 
(see Section 1.2.3.1).  However, the recovery of tumour FFPE DNA spiked into pooled healthy 
volunteer plasma was low in this study.  Although, DNA recovery improved with larger 
volumes of plasma.  The percentage of DNA recovery with the QIAamp® blood mini kit 
(Qiagen) from 3 mls of plasma was 7.0% (range 4.6%-9.2%) compared to 1.8% (1.3-2.7%) 
from 1 ml.  Higher plasma volumes result in greater cfDNA yield (273).  A linear increase in 
cfDNA yield was demonstrated up to 3 mls when DNA was extracted with the CNA kit 
(Qiagen) (273).  In order to increase DNA yields further a higher volume of plasma could be 
used, the CNA kit (Qiagen) is validated for up to 5 mls of plasma. 
 
The recovery of DNA can vary according to the type of DNA added to plasma.  Higher levels 
of DNA have been recovered from plasma spiked with alternative DNA sources (135, 140, 
273).  In one study, 1 ml of commercial pooled plasma was spiked with λ/HindIII DNA in a 
tenfold serial dilution from 50 ng/ml to 0.05 ng/ml (135) and two fragment sizes were 
quantified by Taqman PCR.  The QIAamp® blood mini kit (Qiagen) and CNA kit (Qiagen) had 
similar but broad range of percentage recovery for the 23kb fragment (20-70%) but the CNA 
kit had a higher percentage of recovery of the 564 bp fragment (90-100%).  In another study 
that compared the CNA kit (Qiagen) with the QIAamp® blood mini kit (Qiagen), the CNA kit 
(Qiagen) consistently demonstrated higher yields and a higher percentage of extracted 
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lineralised ADH plasmid fragments (>80%) sized 115 bp, 461 bp and 1448 bp (273).  The very 
low recovery achieved may be due to the spiking material tumour FFPE DNA.  Tumour DNA 
may be of poor quality due to damage by formalin fixation and paraffin embedment (274).  
Commercial reference standards of sheared engineered human cell line DNA are available to 
add to plasma in different fractions and can also be used to assess the sensitivity/specificity 
and lower limit of detection of cfDNA genetic profiling (275). 
 
Furthermore, the percentage of DNA recovery reported will be affected by the method of 
quantification.  Amplifiable DNA fragments of plasma-extracted cfDNA were quantified by 
PCR amplification of GAPDH (see Section 2.9.2.1).  Tumour DNA was quantified by nanodrop 
spectrophotometry (see Section 2.10.1.2).  Tumour DNA samples had high 230/260nm ratios 
suggesting the presence of RNA.  The nanodrop lacks specificity and is likely to have 
overestimated the tumour DNA concentration by measuring all nucleic acids.  Thus, the 
percentage recovery are likely to be underestimated.  Extracted plasma DNA was quantified 
by measuring GAPDH a housekeeping gene of length 81 bp with SYBR green RT-qPCR.  One 
study used SYBR green RT-qPCR to quantify seven different housekeeping genes and showed 
that the chosen gene influenced cfDNA yields and suggested averaging the obtained yields 
to increase accuracy  (273).  However, this increases cost. 
 
The CNA kit (Qiagen) has surpassed the QIAamp® blood mini kit (Qiagen) as the most 
common method of plasma DNA extraction (135, 273).  Both the QIAamp® blood mini kit 
(Qiagen) and CNA kit (Qiagen) were easy to use and plasma DNA extraction was completed 
in less than three hours.  In comparison, the phenol chloroform method was labour intensive, 
taking two days, and involved toxic compounds.  Furthermore, the phenol chloroform 
method had steps that required greater operator skill and therefore there was a higher risk 
of poor reproducibility.  In contrast, the QIAamp® blood mini and CNA kit (Qiagen) have the 
potential for automation, an important factor when considering standardisation and 
implementation in a large number of laboratories.  In our study, the CNA kit (Qiagen) gave 
the best yield and recovered 20% of spiked tumour DNA.  For these reasons, the CNA kit 
(Qiagen) is now the preferred method of plasma DNA extraction in our laboratory. 
 
Accurate quantification of cfDNA is important because an insufficient amount of cfDNA can 
lead to assay failure and inability to identify cfDNA genomic mutations.  To overcome this 
limitation the whole DNA genome can be amplified to increase the amount of DNA prior to 
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analysis (276).  Whole genome amplification (WGA) was required to obtain adequate 
quantities of cfDNA (2.5µg) for array comparative genomic hybridisation to detect cfDNA 
CNAs in prostate cancer cases (176).  However, suitable controls must be utilised to 
determine any aberrations that can be introduced by amplification bias or errors (276, 277) 
and amplification sensitivity and efficacy needs to be evaluated after downstream processing 
of the WGA product.  Negative controls must be included to assess for contamination to 
avoid false positive results.  Contaminating amplified DNA is notoriously difficult to eliminate 
and can hamper the purity of further amplification reactions.  The use of WGA was avoided 
for these reasons. 
 
Only 4% of recruited cases in the ReSoLuCENT study had surgically resected specimens 
available.  This highlights the importance of developing a non-invasive test or ‘liquid biopsy’ 
to greater understand the development and progression of lung cancer in order to improve 
patient outcomes.  CfDNA levels have been examined in this regard in many studies. 
 
 Circulating cell-free DNA total levels as a screening tool in lung cancer 
Similar to other studies, it was found that cfDNA levels were raised in lung cancer cases 
compared to controls and increased in late stage lung cancer compared to early stage (202).  
However, to be useful as a screening tool a marker needs to differentiate between early lung 
cancer cases and high risk controls.  In this study, cfDNA levels were not significantly different 
between early stage (I-IIIA) lung cancer cases and high risk controls defined by an LLP score 
≥2.5%.  There was a substantial overlap in the distribution of cfDNA levels leading to poor 
discrimination. 
 
The poor discriminatory ability of cfDNA levels in this study contrasts with reported AUC 
values in the literature ranging from 0.63 to 0.94 (see Table 1-3).  In addition, the median 
cfDNA level for lung cancer cases with advanced disease was lower than other reported 
studies (Table 1-3).  The range of values reported could be because of subject differences 
such as cancer stage and co-morbidities or due to variation in study methods (278).  Not all 
studies match patients to controls for age, sex, co-morbidities and smoking history, which 
can introduce bias and limits comparisons between studies.  Furthermore, the many pre-
analytical and analytical factors that can effect cfDNA yield make comparisons between 
studies difficult (158).  The handling and processing of blood can influence cfDNA levels due 
to the unwanted release of genomic DNA from lysed white blood cells (134, 140).  In addition, 
 
 
108 
 
other methodological factors such as the method of cfDNA extraction and quantification can 
also effect cfDNA levels (273)(see Section 1.3.1).  For these reasons, it is important that 
studies report method details to include the type of blood collection tube, time between 
processing and withdrawal of blood, storage conditions and the speed and number of blood 
spins to obtain plasma. 
 
ReSoLuCENT was a multi-centre study and samples from seven different centres were 
utilised in this study.  Each centre followed the same strict standard operating procedures 
for collecting, processing and storing samples; however, it is not possible to eliminate bias 
introduced by intercentre variability. 
 
It has been suggested that biomarker levels could add further information about the risk of 
indeterminate lung nodules and therefore reduce over-investigation and over-diagnosis 
(202, 279).  However, raised cfDNA levels are not specific to cancer.  Raised cfDNA levels 
have been found in many other conditions including sepsis (105), inflammatory conditions 
(103), myocardial infarction (280), obstructive sleep apnoea (104) and even after exercise 
(102).  Alternative tumour specific associated genetic changes may have greater ability to 
discriminate between early lung cancer and disease free cases (281).  Furthermore, cfDNA 
levels may not be helpful in detecting slow growing tumours which are more likely to be 
detected by CT screening (200). 
 
Interestingly, higher cfDNA levels were found for treated lung cancer cases compared to 
untreated cases.  Eighteen of 20 (90%) treated cases had disease stage III or IV cancer whilst 
38 of 52 (73%) of untreated cases had disease stage III or IV.  However, date of the last 
treatment is not known neither is information regarding disease response to treatment or 
pre-treatment cfDNA levels. 
 
In this study, higher cfDNA levels were found in cases with advanced stage disease compared 
to early stage disease.  CfDNA levels have previously been shown to correlate with advanced 
tumour stage, LDH (138) and age (152) but no consistent correlation has been found relating 
cfDNA levels with stage, histology, age, smoking status, sex (152, 157, 202, 204, 205, 208), 
number of metastatic sites, performance status (282) or pulmonary inflammatory conditions 
(204).  On the other hand, more specific to tumour cell turnover ctDNA levels do correlate 
with disease stage in a number of different cancer subtypes to include lung cancer (161).  
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Most studies now focus on ctDNA levels due to enhanced specificity compared to total cfDNA 
levels. 
 
 Liverpool Lung Project Cancer Risk model 
The LLP risk model utilises age, gender, smoking duration, family history of lung cancer, 
previous history of pneumonia, previous diagnosis of cancer and history of asbestos 
exposure and has been validated in large National and International studies (13).  
Interestingly, an LLP score ≥2.5% correctly identified just 21% of our cases and incorrectly 
identified 15% of controls.  In a large validation study, a score of ≥2.5% correctly identified 
67% of lung cancer cases and incorrectly identified 33.4% of controls (248).  In that study, 
the mean age of cases was older compared to our study, 66.4 years (SD ±9.1) compared to 
55.3 years (SD ±5.5) respectively.  In contrast, the mean age of controls in our study was 
younger, 60.3 years (SD ±9.0) compared to 63.0 years (SD ± 4.3).  A blood biomarker may 
compliment current screening strategies to maximise the likelihood of detecting cancer in 
younger patients or those with a strong family history of lung cancer. 
 
3.5   Summary and Conclusion 
Pre-analytical and analytical methods of plasma DNA extraction can affect the quantity of 
DNA obtained from blood samples (134, 149).  The standardisation and validation of a 
method of plasma DNA extraction is a vital step towards establishing the use of cfDNA as a 
potential cancer biomarker.  The QIAamp® Circulating Nucleic acid (CNA) kit (Qiagen) was 
tested with the standard operating procedure provided by Professor Shaw, University of 
Leicester and this method was validated in our laboratory as the optimal method of plasma 
DNA extraction.  Improvements in cfDNA yield, even if small, will enhance the utilisation of 
cfDNA as a potential clinical biomarker by increasing the sensitivity of downstream analysis 
and reducing the chance of assay failure. 
 
Screening tools must be discriminating, reproducible and robust.  These data suggest that 
total cfDNA levels do not discriminate early lung cancer cases from high risk controls.  Due 
to lack of specificity and standardised methods of quantification cfDNA levels are not 
recommended as a screening tool in lung cancer either alone or as part of a CT screening 
programme.  However, they may be useful in combination with other markers as a screening 
tool. 
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4 Low coverage sequencing to identify copy number aberrations in cell-
free DNA 
4.1 Introduction  
The non-invasive detection of somatic genetic alterations in cfDNA has the potential to 
differentiate between lung cancer cases and controls and therefore aid early lung cancer 
detection.  NSCLC and SCLC have a high number of genetic alterations relative to other cancer 
subtypes reflecting greater genetic diversity (283) and CNAs are commonly identified in both 
subtypes (see Section 1.1.5.2.1).  Therefore, a genomic instability score based on the number 
and magnitude of CNAs may aid the molecular stratification of individuals in a lung cancer-
screening programme by detecting tumour-derived CNAs in cfDNA samples. 
 
Sequencing to a low read depth across the whole genome is called low coverage sequencing, 
and reduces cost because a higher number of samples can be multiplexed and sequenced 
together in one sequencing run (for a definition of coverage see Section 2.18.5).  CNAs were 
identified by the read depth method from just 5 ng of tumour FFPE DNA with low coverage 
sequencing (X0.1 coverage), and an approximate test cost of £70 per sample (262).  Tumour 
FFPE DNA is degraded and consists of DNA fragments that are short and of similar length to 
cfDNA fragments, therefore this approach may be suitable for the detection of CNAs in 
cfDNA. 
 
In this Chapter, two published geomic instability scores, namely the Plasma Genomic 
Abnormality (PGA) score (265) and the Whole Genome Summed Z (WGS) score (178) were 
adapted (see Section 2.19) and tested.  The PGA was chosen because after sequencing cfDNA 
at low coverage (0.53X), the score differentiated between early lung cancer cases (N=8) and 
normal controls (N=8) but the WGS score did not (265).  Nevertheless, the WGS score 
performed well in a study that differentiated prostate cancer cases from healthy controls 
(178).  With the WGS score, genome instability is measured across the whole genome rather 
than focusing on measuring aberrations with the highest copy number ratio.  This is a less 
selective approach to be able to capture both large amplitude aberrations and large numbers 
of small aberrations. 
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4.2 Aims and Hypotheses 
This Chapter describes the work carried out to optimise methods for the detection of CNAs 
by low coverage whole genome sequencing with Illumina HiSeq 2500.  A commercial kit was 
used to prepare DNA for sequencing from DNA samples collected in the ReSoLuCENT study.   
It was hypothesised that more tumour derived CNAs would be present in cfDNA samples of 
lung cancer cases compared to high risk controls and therefore quantifying the number and 
magnitude of CNAs by a genomic instability score may aid lung cancer detection.  Higher 
genomic instability scores would be expected in lung cancer cases compared to high risk 
controls.  In addition, it was hypothesised that a higher genomic instability score would be 
predictive of a shorter survival time for lung cancer cases. 
 
The aims and objectives were 
 To evaluate the analytical performance of low coverage whole genome sequencing 
in detecting tumour-derived CNAs in cfDNA samples and to validate detection of 
CNAs. 
a. To optimise DNA library preparation for cfDNA samples by comparing library 
quantities and detection of copy number ratios with different input amounts 
of cfDNA ng/ml and PCR cycles as well as two different PCR mastermixes. 
b. To determine the lower limit of detection for identifying CNAs by low 
coverage whole genome sequencing of cfDNA samples by adding tumour 
FFPE DNA in known quantities to extracted cfDNA from the pooled plasma 
of healthy volunteers. 
c. To determine test reproducibility across sequencing runs by comparing the 
detection of copy number ratios in cell line DNA. 
d. To determine the lower limit of detection for the CNA score by adding 
tumour FFPE DNA and H69 cell line DNA in known quantities to extracted 
cfDNA from the pooled plasma of healthy volunteers. 
e. To determine the reproducibility of the CNA score across sequencing runs by 
comparing the detection of copy number ratios in cell line DNA. 
f. To describe quality control steps that ensured DNA libraries were of good 
quality and sequencing runs were optimal. 
g. To demonstrate the identification of tumour-derived CNAs in cfDNA samples 
of lung cancer cases collected in the ReSoLuCENT study by low coverage 
whole genome sequencing.  The objectives were to compare cfDNA CNAs to 
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those detected in matched tumour FFPE DNA.  In addition, to compare 
cfDNA CNAs to CNAs known to be common to the three main subtypes of 
lung cancer. 
 
 To evaluate the clinical validity of low coverage whole genome sequencing of cfDNA 
samples to calculate genomic instability scores based on the identification of CNAs 
in selected lung cancer cases and controls recruited in ReSoLuCENT. 
a. To explore the sreeening value of two genomic instability scores based on 
the number and magnitude of CNAs identified in cfDNA samples.  The two 
tested scores were the PGA2 score (see Section 2.19.1) and the CNA score 
(see Section 2.19.2).  The objectives were to compare scores between 
selected lung cancer cases and high risk controls and to perform logistic 
regression and ROC curve analyses to establish preliminary evidence for 
discriminatory ability. 
 
 To assess the relationship between genomic instability score and survival to assess 
potential as a prognostic tool by calculating Kaplan Meier survival curves to compare 
the outcomes of individuals with scores above or below the median value and cox 
regression survival analyses to determine prognostic value of the score alone and in 
combination with other variables. 
 
4.3 Results 
 Analytical performance and validation 
4.3.1.1 Optimising DNA library preparation for low coverage sequencing 
4.3.1.1.1 Optimising library preparation for cell-free DNA samples 
CfDNA samples from ReSoLuCENT cases 1518 and 1106 were used for optimisation studies 
because multiple CNAs were detected and cfDNA yield was high.  The input amounts of 
cfDNA, and numbers of amplification cycles during library preparation were optimised to 
minimise DNA loss, and to maximise library quantities available for sequencing. 
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4.3.1.1.1.1 A high number of PCR amplification cycles led to loss of DNA during library 
preparation  
It was important to optimise input cfDNA levels and numbers of amplification cycles to obtain 
adequate library quantities for sequencing, and avoid over-amplification, which can lead to 
the loss of DNA (described in the paragraph below).  To compare libraries prepared with 
different amounts of cfDNA and different numbers of amplification cycles, the quality and 
quantity of prepared libraries were assessed using the Agilent Tapestation 2100 (see Section 
2.10.2.1). 
 
For 5 ng of cfDNA, low library quantities were obtained with 8 (793 pg/µl) and 10 (1820 pg/µl) 
amplification cycles.  In comparison, higher library quantities were obtained with 12 (5250 
pg/µl) and 16 (4060 pg/µl) cycles.  Two peaks were often observed on electrophenogram 
profiles displaying the size of DNA fragments following amplification (Figure 4-1).  The first 
peak may represent the amplification of mono-nucleosome cfDNA fragments, whilst the 
second peak may represent the amplification of di-nucleosome cfDNA.  The second peak was 
unexpected because a peak for DNA fragments of approximately 300 bp in baseline cfDNA 
samples was not observed (see Section 4.3.1.6.1.1) and this is likely to be because the 
amount of DNA present was too small to be detected by the Agilent Tapestation 2200. 
 
For 50 ng of cfDNA, 10 cycles gave good library quantities (6610 pg/µl) without signs of over 
amplification.  However, when 50 ng were amplified by 16 cycles, the quantity of library 
fragments decreased (2070 pg/µl).  This was due to the exonuclease activity of the DNA 
polymerase in the NebNEXT® Ultra PCR mastermix leading to DNA loss, as well as the 
concatenation of fragments demonstrated by the appearance of high molecular weight DNA 
on the corresponding electropherogram.  In addition, for 16 cycles the second fragment peak 
flattened, indicating over amplification.  Representative gel images and electropherogram 
profiles are displayed in Figure 4-1. 
 
Table 4-1 summarises input DNA levels and the chosen number of amplification cycles to 
create sequencing libraries with high quantities whilst minimising over amplification.  Two 
nanograms of cfDNA was amplified best by 16 cycles (6840 pg/µl) and 10 ng of cfDNA by 12 
cycles (8940 pg/µl) rather than 10 cycles (3510 pg/µl) or 16 cycles (2540 pg/µl).  
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Figure 4-1: DNA libray quantity and quality when the number of PCR cycles and the cfDNA 
input amounts from one lung cancer case (1518) were varied, demonstrated by Agilent 
Tapestation 2200 High Sensitivity Gel images and corresponding electropherograms. 
DNA libray quantity and quality was poor when 5ng of cfDNA was amplified by 8 and 10 PCR 
cycles and library quantity and quality deteriorated for 50ng after 12 cycles. 
  
 Input 
cfDNA 
ng 
No. of 
amplification 
cycles 
Library 
quantities 
pg/µl 
A1 5 8 793 
B1 5 10 1820 
C1 5 12 5250 
D1 5 16 4060 
E1 50 8 3040 
F1 50 10 6610 
G1 50 12 8490 
H1 50 16 2070 
 
F1/50ng 10 cycles  
A1/5ng 8 cycles   B1/5ng 10 cycles  
D1/5ng 16 cycles  C1/5ng 12 cycles 
E1/50ng 8 cycles 
G1/50ng 12 cycles H1/50ng 16 cycles 
Low quantity 
Flat second peak 
Good quantity  
Good second peak 
Good quantity 
Second peak flattens 
Low quantity  
Flat second peak 
Good quantity 
Good second peak 
Good quantity 
Good second peak 
Good quantity 
Second peak flattens 
Low quantity 
Flat second peak 
Upper marker 
Lower marker 
High 
molecular 
weight DNA 
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m
p
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n
si
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 (
FU
) 
Fragment size in base pairs (bp) 
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CfDNA levels No. of amplification cycles 
≥ 2ng < 5ng 16 
≥ 5 ng < 25 ng 12 
≥ 25 ng ≤ 50ng 10 
Table 4-1:  CfDNA levels and the optimimal number of amplification cycles chosen to form 
DNA libraries for sequencing. 
 
4.3.1.1.1.2 The input cell-free DNA quantities and number of PCR cycles did not influence 
the detection of copy number ratios 
To determine whether the detection of CNAs by low coverage whole genome sequencing 
were affected by different cfDNA quantities and number of PCR cycles to amplify cfDNA 
during library preparation, copy number ratios were determined for 1 Mb windows and 
segments (see Section 2.18.6). 
 
Copy number ratios were highly correlated across runs independent of input cfDNA 
quantities and number of PCR cycles utilised when preparing libraries for sequencing from 
cfDNA samples (Table 4-2).  The median Spearman’s rank correlation coefficient was 0.98 
(range 0.95-0.99) for case 1518 and 0.98 (range 0.97-0.998) for case 1106. 
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Case 1518 
cfDNA (N=2085) 
50 ng 5 ng 
16 
cycles 
12 
cycles 
10 
cycles 
8 
cycles 
16 
cycles 
12 
cycles 
10 
cycles 
8 
cycles 
50ng  16 cycles 1.00 
       
12 cycles 0.98 1.00 
      
10 cycles 0.95 0.97 1.00 
     
8 cycles 0.97 0.98 0.96 1.00 
    
5ng  16 cycles 0.98 0.99 0.96 0.98 1.00 
   
12 cycles 0.96 0.98 0.97 0.98 0.98 1.00 
  
10 cycles 0.96 0.98 0.97 0.97 0.98 0.990 1.00 
 
8 cycles 0.97 0.98 0.96 0.98 0.98 0.98 0.98 1.00 
 
Case 1106  
cfDNA (N=2021) 
  
10 ng 5 ng 2ng 
16 
cycles 
12 
cycles 
10 
cycles 
12 cycles 16 cycles 
10ng 16 cycles 1.00 
    
 12 cycles 0.97 1.00 
   
 10 cycles 0.98 0.96 1.00 
  
5 ng 12 cycles 0.996 0.97 0.98 1.00 
 
2 ng 16 cycles 0.993 0.96 0.98 0.998 1.00 
Table 4-2:  Spearman’s rank correlations for copy number ratios to evaluate the effect of 
different cfDNA quantities and number of PCR cycles during library preparation for two lung 
cancer cases (1106 and 1518). 
All comparisons were significantly correlated with p value <0.0001.  N= number of copy 
number ratio values per sample. 
 
4.3.1.1.2 Optimising library preparation for genomic DNA samples 
Agilent Tapestation 2200 electropherogram profiles were similar when libraries were made 
from 100 ng of genomic DNA and amplified with seven, eight or nine cycles.  Generally, higher 
library quantities were obtained with increasing cycle number (data not shown).  Seven 
amplification cycles were used to amplify genomic DNA samples during library preparation. 
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4.3.1.1.3 There was no significant difference between the NEBNext® Q5 hot start HiFi PCR 
master mix and the NEBNext® High-Fidelity PCR master mix  
To amplify barcode-adaptor ligated DNA fragments during library preparation the NEBNext® 
master mix containing DNA polymerase, dNTPs, Mg2+ and a propriety buffer was utilised.  The 
NEBNext® Q5 Hot Start HiFi PCR master mix replaced the NEBNext® High-Fidelity PCR master 
mix, and it contained a more efficient DNA polymerase that was also inactive at room 
temperature.  To compare the two NEBNext® master mixes, libraries for sequencing were 
prepared using both kits for matched cfDNA and genomic samples from case 1106. 
 
Copy number ratios for individual windows and segments were highly comparable when 
libraries were prepared from the same cfDNA sample with the old (NEBNext® High-Fidelity 
PCR) and new (NEBNext® Q5 Hot Start HiFi PCR) master mix (Figure 4-2).  The Bland Altman 
test was used to plot the difference in the copy number ratios for old and new kits for 
individual 1 Mb windows or segments and compare it to the average of the paired 
measurements for the old and new kit.  The bias or average of the differences for all 
comparisons was close to zero for both samples indicating that the old and new kit produced 
similar results.  Furthermore, as the average increased the difference in the method did not 
increase, indicating that results were consistent between methods across a range of copy 
number ratios.  These data were not normally distributed as determined by the D’Agostino-
Pearson omnibus K2 normality test and therefore results must be interpreted with some 
caution because the Bland Altman test is for normally distributed data. 
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A      B 
Figure 4-2:  A comparison of the NEBNext® Ultra DNA old (NEBNext® High-Fidelity PCR) and 
new (NEBNext® Q5 Hot Start HiFi PCR) mastermix by using Bland Altman plots to compare 
copy number ratios (A) and segments (B) identified by low coverage sequencing of 10ng of 
cfDNA from lung cancer case 1106. 
A: comparison of copy number ratios (N=2045) of 1 Mb windows after 12 PCR cycles: Bias -
0.004, 95% limits of agreement -0.04- +0.05.  Each dot represents the differences between 
the copy number ratios for the old and new master mixes plotted against the average copy 
number ratio of the two methods. 
B: A comparison of segmental copy number ratios (N=2086) after 12 PCR cycles: Bias 0.0008, 
95% limits of agreement -0.03- +0.05.  Each dot represents the differences between the 
segmental copy number ratios for the old and new master mixes plotted against the average 
segmental copy number ratio of the two methods. 
 
4.3.1.2 The limit of detection for tumour-derived copy number aberrations was between 10-
20% by visual inspection 
To test the lower limit for the detection of tumour-derived copy number aberrations, tumour 
FFPE DNA from case 261 was added at known proportions to extracted cfDNA from the 
pooled plasma of healthy volunteers (see Section 2.2.1).  Segmental copy number ratios and 
copy number ratios for individual 1 Mb windows were compared for each dilution to 
establish the limit of detection for CNAs. 
 
Figure 4-3 displays scatter diagrams comparing segmental copy number ratios detected for 
100% tumour FFPE DNA (10ng) and descending proportions.  As the tumour DNA fraction 
reduced, both the correlation coefficients of segmental copy number ratios and the 
correlation coefficients of copy number ratio values of individual 1 Mb windows were 
reduced.  Upon performing the experiment for a second time in a different sequencing run, 
the Spearman’s rank correlations were less for both segmental and individual copy number 
ratio values of 1 MB windows (Table 4-3).  In summary, visual inspection shows that tumour 
 
 
119 
 
derived CNAs were detected with tumour FFPE DNA fraction of 10%-20% (the lower limit of 
detection was examined further through a CNA score in Section 4.3.1.4). 
 
Copy number ratios were significantly correlated between cfDNA extracted from pooled 
healthy plasma with no added tumour FFPE DNA and 100% tumour FFPE DNA.  This could be 
due to sequencing artefact.  For example in Figure 4-3 a copy number loss of chromosome 
19 was observed in all cfDNA samples spiked with tumour FFPE DNA as well as the cfDNA 
sample without tumour FFPE DNA.  Alternatively, cfDNA extracted from pooled healthy 
control plasma may have become contaminated by tumour FFPE DNA during library 
preparation. 
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50% Tumour FFPE DNA 50% cfDNA  
20% Tumour FFPE DNA 80% cfDNA  
10% Tumour FFPE DNA 90% cfDNA 
5% Tumour FFPE DNA 95% cfDNA  
0% Tumour FFPE DNA 100% cfDNA 
Figure 4-3:  Copy number profiles and scatter diagrams to demonstrate the lower limit of detection of copy number ratios and segments 
when tumour FFPE DNA was spiked into healthy volunteer control cfDNA in descending proportions. 
All correlations were significant with p<0.0001 unless otherwise stated (N=2072).  The y-axis of the copy number profile graphs shows copy 
number ratio on the left and estimated ploidy on the right with the x-axis showing chromosome position.  The y-axis of the scatter diagram shows 
the copy number ratios of 100% tumour FFPE DNA and the x-axis shows the copy number ratios for samples spiked with different proportions of 
tumour FFPE DNA. 
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Proportion of 
tumour FFPE 
DNA compared 
to cfDNA 
Spearman’s Rank correlations for 
Experiment 1 (cfDNA 10ng) 
Spearman’s Rank correlations for 
Experiment 2 (cfDNA 10ng) 
copy number 
ratios from 
segments 
copy number 
ratios from 
1Mb windows 
copy number 
ratios from 
segments 
copy number 
ratios from 
1Mb windows 
50% (5ng) 0.82 (N=2072) 0.89 (N=2044) 0.81 (N=2072) 0.85 (N=2040) 
20% (2ng) 0.58  (N=2072) 0.61 (N=2044) 0.40 (N=2072) 0.55 (N=2044) 
10% (1ng) 0.38 (N=2072) 0.51 (N=2044) 0.21 (N=2055) 0.28 (N=2044) 
5% (0.5ng) 0.28 (N=2072) 0.34 (N=2044) 0.03 (N=2072) 
p=0.19 
0.17 (N=2044) 
0% (0 ng) 0.14 (N=2072) 0.10 (N=2044) -0.03 (N=2072) 
p=0.07 
0.06 (N=2044) 
p=0.01 
Table 4-3:  Spearman’s Rank correlations to test the identification of tumour derived CNA 
with different proportions of tumour FFPE DNA from lung cancer case 261. 
All correlations were significant with p<0.0001 unless otherwise stated. 
 
4.3.1.3 There was good reproducibility for copy number ratios between sequencing runs 
There is potential for bias to be introduced when performing multiple sequencing runs.  
Reproducibility was evaluated by determining the agreement between sequencing runs of 
segmental copy number ratios from DNA extracted from the SCLC cell line H69 (see Section 
2.20.2).  There was strong agreement between sequencing runs when comparing the copy 
number ratios of segments when consecutive runs were analysed with the Bland Altman 
statistic (Table 4-4).  It must be noted that these data are not normally distributed. 
 
Run  CNV 4   
   10 ng  
CNV 5 
 10 ng 
CNV 6 
10 ng 
CNV 7 
10 ng 
CNV 8 
10 ng 
CNV 9 
10 ng 
CNV 3 
100ng   
Bias % -0.79 -1.14 -0.93 -0.97 -0.94 -0.90 
 SD % 3.4 3.4 4.4 6.2 6.0 6.7 
 95% CI -7.5- 
+5.9 
-7.7- 
+5.4 
-9.4- 
+7.6 
-13.1-
+11.2 
-12.8-
+10.9 
-14.1-
+12.3 
Table 4-4:  Bland Altman statistic to compare sequencing runs for copy number ratios from 
segments for cell line DNA H69 (N=2069). 
 
4.3.1.4 The lower limit of detection for the Copy Number Aberration score may be 5%  
To gain a preliminary measure of the lower limit of detection for the CNA score, CNA scores 
were calculated for descending proportions of tumour DNA from case 261 (N=2) and sheared 
cell-line DNA H69 (N=1) spiked into cfDNA extracted from the pooled plasma of healthy 
volunteers (see Section 2.2.1)(Figure 4-4)(Table 4-5).  The reduction in the CNA score from 
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100% DNA to 50% DNA was greater for tumour FFPE compared to cell-line DNA.  This is 
consistent with the dilutional effect being more for poor quality DNA due to damage by 
formalin fixation and paraffin embedment.  The CNA score was higher when 5% of DNA was 
spiked into healthy control plasma compared to 0% for all three experiments, suggesting that 
the limit of detection may be 5% (although smaller proportions were not tested)(copy 
number profiles are shown in Appendix F).  The CNA scores for cfDNA extracted from pooled 
healthy volunteer plasma were higher (415 and 325) compared to the median score of high 
risk controls of 252, although the range of CNA scores in the high risk group was very broad 
from 149 to 7122. 
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Figure 4-4:  CNA scores for different proportions of tumour FFPE (N=2) and H69 cell-line DNA 
(N=1) spiked into extracted cfDNA from the pooled plasma of healthy volunteers. 
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Proportion of 
tumour FFPE or 
cell-line DNA 
compared to 
cfDNA 
CNA scores for 
Experiment 1 tumour 
FFPE DNA   
CNA scores for 
Experiment 2 
tumour FFPE DNA 
CNA scores for 
H69 cell-line 
DNA  
100% (10ng) 63455 63390 83029 
50% (5ng) 2412 1553 29962 
20% (2ng) 756 448 4883 
10% (1ng) 637 248** 1430 
5% (0.5ng) 514 334 453 
0% (0 ng) 415 325* 325* 
Table 4-5:  Copy number aberration scores for different proportions of tumour FFPE and cell-
line DNA spiked into extracted cfDNA from the pooled plasma of healthy volunteers. 
* these samples were sequenced in the same sequencing run and therefore the 0% value 
was used for both FFPE DNA and H69 DNA experiments.   
** the low CNA score for 10% tumour FFPE DNA in experiment two may be explained by a 
pipetting error. 
 
4.3.1.5 There was good reproducibility for the Copy Number Aberration score between 
sequencing runs  
The median CNA score for cell-line H69 DNA across seven independent sequencing runs was 
83073 (range 82675-84661) (Table 4-6).  The relative variability across sequencing runs 
measured by the coefficient of variance (CV) was 0.94% and was calculated by determining 
the relative difference between the standard deviation of the seven CNA scores divided by 
the mean. 
 
CNA Run CNV 3 
100 ng 
CNV 4 
10 ng 
CNV 5 
10 ng 
CNV 6 
10 ng 
CNV 7 
10 ng 
CNV 8 
10 ng 
CNV 9 
10 ng 
H69 CNA 
score 
84457 83029 84661 83073 82849 83366 82675 
Table 4-6:  Copy number aberration scores of cell-line H69 DNA across seven sequencing runs. 
 
4.3.1.6 Low coverage whole genome sequencing of lung cancer cases and controls 
A pilot study was carried out to determine whether CNAs would be detected in cfDNA of lung 
cancer cases and controls by low coverage whole genome sequencing.  Selected lung cancer 
cases and controls from the ReSoLuCENT study that had cfDNA levels quantified by SYBR 
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green RT-qPCR (N=114) (see Section 3.3.3) were chosen for low coverage whole genome 
sequencing. 
 
Of the 114 individuals, 12 were eliminated from further analyses.  Three cases and one 
control had cfDNA levels less than 2 ng and were not sequenced and seven cases had no 
cfDNA available after targeted sequencing was performed in a different study.  One further 
case did not have adequate coverage of matched genomic DNA despite re-extraction of DNA 
from the buffy coat layer, and was not included in analyses.  Thus, sequencing data is 
presented for cfDNA and matched genomic DNA samples for 62 lung cancer cases (51 
untreated and 11 treated), 30 high risk and 10 low risk controls (N=102). 
 
The characteristics of the analysed cases and controls (N=102) were consistent with the 
characteristics of the selected subjects described in Section 3.3.3.3.  Similar to the findings 
in Section 3.3.3.2, the median age at diagnosis of selected cases (N=62) compared to non-
selected cases (N=618) was older (median 57.4 years (range 40.0-74.5 years) vs 56.0 years 
(range 20.7-83.1 years) (p=0.03, Mann Whitney U test).  Furthermore, and as expected, the 
characteristics of controls selected by LLP risk score and analysed for CNAs (N=40) were 
statistically significantly different from non-selected controls (N=399) for gender (p=0.005, 
Chi-squared test), age (p<0.0001, Mann Whitney U test) and smoking status (p=0.005, Chi-
squared test).  The histology and stage of cases (N=62) selected for copy number analyses 
are shown in Table 4-7. 
 
 NSCLC SCLC Total 
Stage  Adenocarcinoma Squamous Not 
otherwise 
specified 
other  
I               4 1 - - - 5 (8%) 
II 4* 4 1 1 - 10 (16%) 
III 6* 6** 4 - 2* 18 (29%) 
IV 9* 6** 6** 1 7* 29 (47%) 
Total 23 (37%) 17 (27%) 11 (18%) 2 (3%) 9 (15%) 62 
Table 4-7:  Histology and stage of cases (N=62) selected for copy number aberration analysis. 
*one treated case in the sub-group.  ** two treated cases in the sub-group. 
 
Consistent with findings in Section 3.3.3.5, median cfDNA levels ng/ml were significantly 
higher in cases (N=62) compared to controls (N=40), 8.0 ng/ml (range 1.6-545.1 ng/ml) vs 4.4 
ng/ml (range 1.2-34.0 ng/ml) (p<0.0001 Mann Whitney U test).  In addition, treated cases 
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(N=11) had significantly higher cfDNA levels compared to untreated cases (N=51), median 
17.1 ng/ml (range 4.7-540.1 ng/ml) vs 7.2 ng/ml (range 1.6-545.1 ng/ml) (p=0.03 Mann 
Whitney U test).  The characteristics of untreated early stage cancer cases (N=21) and high-
risk controls (N=30) are shown in Table 3-7. 
 
4.3.1.6.1 Quality control 
4.3.1.6.1.1 DNA parameters prior to library construction 
DNA was extracted from matched genomic (N=102), tumour FFPE (N=10), and plasma 
samples (N=102) and quantified by the methods described in Section 2.9.  Genomic DNA was 
sheared by ultrasonic acoustic waves to form short fragments of target length 200 bp to form 
DNA libraries for sequencing (see Section 2.14.1.1).  CfDNA was not sheared because cfDNA 
fragments are typically <200 bp.  Prior to DNA library construction, cfDNA and fragmented 
genomic DNA samples were run on the Agilent 2100 Tapestation.  This was important to 
check for uniformity of fragment size and to ensure the adequate shearing of genomic DNA 
samples (see Section 2.10). 
 
The median peak fragment size for cfDNA was 147 bp (mean 148 bp, range 118-185 bp, 
N=84).  The median peak fragment size for sheared genomic DNA was 225 bp (mean 227 bp, 
range 169-338 bp, N=93).  Representative examples of gel images from the Agilent 
Tapestation 2100 for cfDNA and genomic DNA are shown in Figure 4-5.  Higher molecular 
weight DNA of more than 500 bp was present in most samples of cfDNA tested on the 
Tapestation. 
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Figure 4-5:  Representative gel images demonstrating the fragment sizes of cfDNA and 
sheared genomic (lymphocyte) DNA from the Agilent Tapestation 2100. 
NCI-H69 SCLC cell line DNA.(A5): cfDNA samples (B5-G6) and genomic DNA (lower panel H2-
H3).  A0- hyperladder.  C5-failed run.   
The blue arrow shows the expected size of cfDNA fragments at 160 bp.  The red arrow shows 
200 bp the target length for sheared genomic DNA. 
 
For cfDNA samples, the peak fragment length was available for 84 of 102 participants.  The 
median cfDNA peak fragment length was significantly longer for low risk controls (N=10) 
compared to high risk controls (N=26) and lung cancer cases (N=48), 158 bp (range 152-170 
bp) vs 146 bp (range 128-167 bp) (p=0.0002 Mann Whitney U test) and 146 bp (range 118-
185 bp) (p=0.0005 Mann Whitney U test), respectively (Figure 4-6). 
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Figure 4-6:  The peak fragment size of cfDNA for cases (N=48), high risk controls (N=26) and 
low risk controls (N=10) prior to DNA library construction. 
*** p<0.001.  Median and IQR are shown.  
 
In this pilot study, libraries were prepared from cfDNA (N=102), genomic (N=102) and 
tumour FFPE DNA (N=10) for low coverage whole genome sequencing with Illumina HiSeq 
2500 to establish the presence of CNAs.  A standard protocol was followed to prepare DNA 
samples for sequencing using the NebNEXT® Ultra DNA library preparation kit (see Section 
2.14.1).  DNA libraries were prepared from as much cfDNA as was available, up to a maximum 
of 50 ng of cfDNA.  The median cfDNA quantity to prepare libraries for low coverage 
sequencing was 20 ng (N=62, range 5.5- 50 ng) for cases and 11.5 ng for controls (N=40, range 
3- 50 ng) (p <0.0001, Mann Whitney U test). 
 
4.3.1.6.1.2 DNA library quality control  
An assessment of DNA library quality was important to rule out library contamination by 
adaptor-dimers or primer-dimers, and to achieve optimal cluster formation during 
sequencing to maximise sequencing efficiency with the Illumina HiSeq 2500.  Library quality 
was assessed by running libraries from all samples on the Agilent Tapestation 2100 to 
determine the size and concentration of DNA fragments prior to sequencing (see Section 
2.15.1). 
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4.3.1.6.1.3 No prepared DNA libraries were contaminated by adaptor- dimers or primer-
dimers 
Electropherograms for all samples from the Agilent Tapestation 2100 were reviewed to 
assess library fragment size and concentration.  No fragments less than 125 bp or less than 
60 bp were observed and therefore there was no contamination of libraries by adaptor-
dimers or primer dimers respectively (Figure 4-7). 
 
The median DNA fragment size of the main peak for the cfDNA library was 292 bp (range 
268-302 bp N=102) and 301 bp for genomic DNA (range 257-337 bp, N=102).  For cfDNA, 
there was often a second peak with a higher molecular weight between 400-500 bp (Figure 
4-7).  The median library quantity determined by the Agilent Tapestation 2100 was 7.24 ng/µl 
(mean 6.96 ng/µl, range 1.07-13.70 ng/µl, N=102) for cfDNA and 2.65 ng/µl (mean 3.18 ng/µl, 
range 0.50-10.40 ng/µl, N=102) for genomic DNA.  The size of library DNA fragments were 
longer than input DNA fragments due to the ligation of barcodes and sequencing adaptors 
and therefore the libraries passed quality control (see Section 2.15). 
 
 
A B  
Figure 4-7:  Representative gel images from the Agilent Tapestation 2100 showing fragment 
sizes for DNA libraries prepared for sequencing. 
cfDNA (A: A5-H6) and genomic DNA libraries (B:H2-E3). 
 
4.3.1.6.1.4 Sequencing quality control 
Low coverage whole genome sequencing was carried out with the Illumina HiSeq 2500 (see 
Section 2.17).  Nine sequencing runs were performed in total.  All clusters of amplified DNA 
fragments passed quality control measures to assess the strength and reliability of the 
emitted fluorescence signal intensity (see Section 2.18.1).  A maximum of 24 samples were 
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sequenced per lane of the flow cell resulting in low genome coverage for each sample.  Each 
run contained a mixture of cfDNA, genomic DNA and tumour DNA libraries.  Table 4-8 
summarises important quality control parameters for each sequencing run. 
 
Run No. of 
samples 
Pooled 
library 
concentraion  
pM 
Cluster density 
K/mm2 
Median 
Q30 base 
quality 
scores 
(range) 
Median data 
output per 
sample (GB) 
(range) 
Lane 1 Lane 2 
CNV 1 24 10 830 - 88 (87-90) 732 (237-1,959) 
CNV 2 24 10 1167 - 91 (88-92) 1,127 (784-
3,880) 
CNV 3 
(Lane 1)  
24 12.5 1090 - 92 (89-93) 1,199 (945-
4,855) 
CNV 3 
(Lane 
2)* 
2 12.5 - 1085 93 (91-94) 17,311  
(17,186-17,436)  
CNV 5 48 11 1150 1158 91 (87-92) 1,048 (97-6,602) 
CNV 6 44 11 1125 1147 91 (88-92) 1,446 (962-
5,106) 
CNV 7 48 11 1182 1190 90 (72-95) 1,218 (0-7,632) 
CNV 8 46 10 1074 1088 96 (92-96) 1,636 (0-6,528) 
CNV 9 43 10 907 910 97 (94-98) 1,436 (0-6,528) 
Table 4-8: Important quality control parameters for each sequencing run on the Illumina 
HiSeq 2500. 
*For Run 3 two samples were separated into a different lane to obtain higher coverage and 
therefore potentially increase the sensitivity for the detection of CNAs. 
 
The data for each sequencing run was processed through a bioinformatics pipeline to obtain 
sequences of bases or reads that were then grouped by their barcodes into their originating 
samples (de-multiplexed) (see Section 2.18.2).  For each sample, reads were aligned or 
mapped to the human reference genome and poorly mapped or duplicate reads were 
discarded (see Section 2.18.3 and 2.18.4). 
 
4.3.1.6.1.5 Samples were sequenced at low coverage  
The coverage was calculated by determining the number of bases sequenced (total number 
of mapped reads x read length) divided by the size of the human genome, 3 billion bases 
(256) (see Section 2.18.5).  The median coverage was highest for cfDNA at 0.49X (range 
0.20X-0.63X, N=102), followed by genomic DNA with a coverage of 0.28X (range 0.12X-0.63X, 
N=102) and tumour FFPE DNA with a median coverage of 0.18X (range 0.07X-0.32X, N=10) 
(Figure 4-8). 
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4.3.1.6.1.6 Approximately 90% of reads mapped to the reference genome for each sample 
Approximately 10% of reads were unmapped for each sample and these reads were 
discarded.  These included duplicate reads with identical start and stop positions, and reads 
that mapped to multiple sites of the genome.  The median percentage of duplicate reads for 
all samples was 0.0075% (range 0.0027%-0.014%).  There were fewer mapped reads for 
tumour FFPE DNA (N=10) compared to cfDNA (N=102) (p<0.0001) and genomic DNA (N=102) 
(p<0.0001 Mann Whitney U test) (Figure 4-8). 
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Figure 4-8:  Important sequencing parameters for sheared genomic (N=102), cfDNA (N=102) 
and sheared tumour FFPE DNA (N=10). 
Box plots show the median, IQR and minimum and maximum values. **** p<0.0001, Mann 
Whitney U test.  A: Sample coverage.  B: Percentage of reads aligning to the reference human 
genome. 
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4.3.1.6.1.7 There were some chromosomal regions with no calculated copy number ratios 
There were no mapped reads and therefore no copy number ratio values established for nine 
chromosomal regions varying in size from 1 Mb to 19 Mb.  These regions tended to be within 
or close to centromeres or telomeres (Table 4-9).  There were no copy number ratios 
calculated for the short arm of chromosome 13 or 14.  Genomic positions were identified 
from the UCSC genome browser (284).  The total size of the genomic regions with no 
calculated copy number ratios was approximately 100 Mb, which is equivalent to 3% of the 
whole genome. 
 
Chromo Window 
Start 
position 
Window End position Size 
in Mb 
Approximate location 
1 123000001 142000001 19 1p36.21 
9 46000001 59000001 13 within 3MB of a centromere 
(9q11-12) 
13 1 17000001 17 13p 
14 1 17000001 17 14p 
14 107000001 108000001 (end position of 
chromosome 107043718) 
< 1 Telomere  
15 1 16000001 16 Telomere and 15p13-11.2 
16 39000001 45000001 6 within 3Mb of a centromere 
(16q11.2) 
21 1 4000001 4 Telomere and 21p13 
22 1 9000001 9 Telomere and 22p13-12 
Table 4-9:  Chromosomal regions with no copy number ratio values obtained for sequenced 
samples (N=102). 
4.3.1.7 Validation of copy number profiles determined by low coverage sequencing 
4.3.1.7.1 Tumour FFPE DNA copy number profiles processed in Sheffield were similar to the 
profiles previously established in the Wood laboratory in Leeds 
Tumour FFPE DNA copy number profiles were comparable between laboratories in Sheffield 
and Leeds, despite independent DNA library preparation and sequencing methods.  There 
were a similar pattern of copy number gains and losses demonstrated (Figure 4-9) (N=3). 
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Figure 4-9:  A comparison of copy number profiles for tumour FFPE DNA independently 
processed, sequenced and analysed in Leeds and Sheffield for three different lung cancer 
cases. 
The X and Y profiles have been removed from the Sheffield data.  The left axis shows estimated 
ploidy and the right axis is the copy number ratio.  Dots represent copy number ratios of windows 
and black lines represent segments or windows with similar copy number ratios.  Orange or red 
denotes potential copy number gains and blue denotes copy number losses. 
Leeds: case 52 
Leeds: case 261 
Leeds: case 539 
Sheffield: case 539 
Sheffield: case 261 
Sheffield: case 52 
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4.3.1.7.2 Tumour FFPE copy number aberrations were detected in matched circulating cell-
free DNA samples 
Tumour FFPE DNA CNAs were detected in matched cfDNA for some but not all lung cancer 
cases.  Ten matched tumour FFPE DNA and cfDNA pairs were available for comparison.  Five 
cases had tumour tissue available from a primary bronchial biopsy and the other five cases 
had tumour tissue available following surgical resection of the primary lung tumour.  The 
median time from the tissue sample to blood withdrawal was 30 days (range 0-273 days). 
 
Similar copy number profiles between tumour FFPE and cfDNA were obtained for two lung 
cancer cases (20%) (52 and 203) (Figure 4-10).  For these cases, tumour-derived copy number 
chromosomal gains and losses were identified in the matched profiles of cfDNA by visual 
inspection, albeit at lower magnitude, due to dilution of ctDNA by wild type host cfDNA in 
the blood.  For 6 cases (60%) (146, 261, 527, 539, 800 and 805), CNAs were detected for 
tumour FFPE DNA but not cfDNA (Figure 4-11).  Two cases (20%) (240 and 806) had few CNAs 
detected in both tumour FFPE DNA and cfDNA (Figure 4-12).  CfDNA of lung cancer cases 800 
and 240 were sequenced at higher coverage (4.26X and 4.18X respectively).  However, the 
detection of CNAs in cfDNA did not improve (data not shown).  The clinical characteristics of 
each case are shown in Table 4-10. 
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 52 CfDNA 
52 Tumour FFPE DNA 
203 CfDNA 
  
203 Tumour FFPE DNA 
   
Figure 4-10:  Similar copy number profile graphs for tumour FFPE DNA and matched 
cfDNA for two lung cancer cases. 
Dots represent copy number ratios of 1 Mb windows and black lines represent 
consecutive windows with similar copy number ratios.  Orange denotes copy number 
gain and blue copy number loss.  Y-axis shows estimated ploidy and x-axis chromosomal 
position. 
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Figure 4-11:  Differing copy number profile graphs for three cases with multiple copy number 
aberrations identified in tumour FFPE DNA but not matched cfDNA.  
 
539 CfDNA 
539 Tumour FFPE DNA 
146 CfDNA 
146 Tumour FFPE DNA 
805 CfDNA 
805 Tumour FFPE DNA 
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Figure 4-12:  Copy number profile graphs for two cases with few copy number aberrations 
identified in matched tumour FFPE and cfDNA. 
  
806 CfDNA 
806 Tumour FFPE DNA 
240 CfDNA 
240 Tumour FFPE DNA 
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Tumour FFPE DNA and matched cfDNA copy number profiles were further compared by 
comparing the copy number ratios of segments and copy number ratios of 1 Mb windows 
(Table 4-10).  Two cases had good correlation between tumour FFPE DNA and matched 
cfDNA (203 and 52).  This was consistent with the similar pattern of copy number gains and 
losses observed in copy number profiles.  The high number of correlated points >2000 led to 
high statistical significance for most cases. 
 
Case CfDNA 
ng/ml 
Length 
of 
plasma 
storage 
in years 
Days from 
tissue 
sample to 
blood 
collection 
Prior 
treatment 
to blood 
collection 
Stage  Histology Tumour 
FFPE DNA vs 
cfDNA for 
copy 
number 
ratio 
segments 
Tumour 
FFPE DNA 
vs cfDNA 
for copy 
number 
ratio 1 Mb 
windows 
52 4.7 8.3 273 zometa IV NSCLC-SQ 0.68 
N=2070 
0.63 
N=2043 
146 15.6 7.5 231 recurrence IV NSCLC-AC -0.20 
N=2054 
-0.17 
N=2044 
203 47.3 7.5 17 chemo IIIB SCLC 0.76 
N=2070 
0.78 
N=2045 
240 12.1 7.6 12 no IV NSCLC-NOS 0.09 
N=2084 
0.10 
N=2044 
261 4.7 7.0 0 (same 
day as 
surgery) 
no I NSCLC-AC 0.27 
N=2070 
0.17 
N=2045 
527 6.4 5.6 187 recurrence IV NSCLC-AC 0.22 
N=2072 
-0.05 
(p=0.04) 
N=2046 
539 2.4 5.5 0 (same 
day as 
surgery) 
no IIIA NSCLC-SQ -0.15 
N=2084 
-0.32 
N=2040 
800 9.8 5.0 22 no IV NSCLC-SQ -0.09 
N=2084 
-0.23 
N=2044 
805 13.9 4.9 38 chemo IV SCLC 0.42 
N=2086 
0.33 
N=2044 
806 17.1 4.9 153 SRS to brain IV NSCLC-
mixed 
-0.04 
(p=0.071) 
N=2087 
-0.29 
N=2046 
Table 4-10:  Spearman’s Rank correlations of copy number ratios from 1 Mb windows and 
segments for the copy number profiles of matched tumour FFPE DNA and cfDNA (N=10). 
Unless stated all correlations were significant with p<0.0001.  Chemo: chemotherapy. SRS: 
stereotactic radiosurgery. 
  
 
 
138 
 
4.3.1.7.3 Common copy number aberrations found in lung cancer tumours were detected 
in circulating cell-free DNA samples 
Next, it was explored whether common lung cancer CNAs were identified in cfDNA samples 
by low coverage whole genome sequencing (Table 4-11).  The largest studies analysing 
tumour CNAs for squamous cell carcinoma (N=484) (69), adenocarcinoma (N=660) (69) and 
small cell carcinoma (N=110) (53) were reviewed to identify the top most common regions 
of copy number gains and losses.  Tumour cell derived cfDNA is further diluted in the blood 
compared to the tumour due to a background of wild type cfDNA therefore, a copy number 
ratio greater than 1.10 was chosen to define copy number gain and a copy number ratio less 
than 0.90 to define copy number loss. 
 
For small cell lung cancer (N=9), 7 out of 9 cases were found to have loss of 3p, which contains 
the genes FHIT and ROBO1 (53).  In addition, gain of 3q (4 of 9) and 5p (7 of 9) and focal loss 
of 13q (7 of 9) harbouring RB1 were common CNAs detected.  Common CNAs were detected 
in the cfDNA of squamous cell carcinoma and adenocarcinoma lung cancer cases but at lower 
proportions compared to small cell lung cancer (Table 4-11). 
 
Interestingly, across all samples there were a high number of chromosome 19 deletions 
observed to include 25 of 51 untreated cases (49%), 16 of 30 high risk controls (53%) and 2  
of 10 (20%) low risk controls (Appendix F).  This deletion was not present in H69 cell line DNA 
but it was present in 2 of 10 (20%) FFPE DNA tumour samples, both of which had multiple 
aberrations detected (Appendix F)(Figure 10, 
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Figure 4-11, Figure 4-12)  
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Squamous cell carcinoma 
(N=17) 
Adenocarcinoma  
(N=23) 
Small cell carcinoma  
(N=9) 
Chromosomal 
position of CNA 
No. 
cases 
with 
CNA 
detected 
in cfDNA 
Chromosomal 
position of CNA 
No. 
cases 
with 
CNA 
detected 
in cfDNA 
Chromosomal 
position of CNA 
No. 
cases 
with 
CNA 
detected 
in cfDNA 
Copy number loss 
9p 0-43000000 1 9p 0-43000000 0 3p 0-
90900000 
7 
8p 0-45200000 2 4q 50000000-
190214555 
4 3q 90900000-
198295559 
7 
2q 93900000-
242193529 
0 22q 17400000-
50818468 
1    
10q 39800000-
133797422 
1 1p 0-
123400000 
1 
   
5q 48800000-
181538259 
0 15q 19000000-
101991189 
0 
   
1p 0-
123400000 
0 16q 36800000-
90338345 
0 
   
3p 0-90900000 2 11q 53400000-
135086622 
1 
   
19p 0-26200000 3 13q 17700000-
114364328 
0 
  
18q 21500000-
80373285 
2 
      
Copy number gain 
3q 90900000-
198295559 
0 14q 17200000-
107043718 
0 5p 0-
48800000 
7 
8p 0-45200000 1 8q 45200000-
145138636 
1 3q 90900000-
198295559 
4 
11q 53400000-
135086622 
0 5p 0-48800000 1 4q 50000000-
190214555 
0 
8q 45200000-
145138636 
1 1q 123400000-
248956422 
2 18q 21500000-
80373285 
5 
7p 0-60100000 0 12p 0-35500000 2 18p 0-
80373285 
4 
4q 50000000-
190214555 
0 12q 35500000-
133275309 
2 8q 45200000-
145138636 
1 
2p 0-93900000 0 11q 53400000-
135086622 
1 8p 0-
45200000 
1 
9p 0-43000000 1 3q 90900000-
198295559 
0 
   
19q 26200000-
58617616 
1 7p 0-60100000 1 
  
1q 123400000-
248956422 
0 
      
Table 4-11:  The most significant CNAs identified from SNP array data in large genomic studies 
and the number of lung cancer cases with the same CNAs detected in cfDNA samples for the 
three most common histological subtypes. 
CNAs are shown in descending order of significance (determined by q value based on the 
magnitude and frequency of the aberration across tumour samples). 
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The mean and standard deviation of the copy number ratio of each 1 Mb window for 49 lung 
cancer cases were plotted against chromosomal position for chromosomes that were known 
to commonly have CNAs for the three most frequent lung cancer subtypes.  Small cell lung 
cancer cases (N=9) had a greater number and magnitude of CNAs compared to squamous 
cell carcinoma (N=17) and adenocarcinoma cases (N=23) (Figure 4-13).  Although no case 
with adenocarcinoma had a copy number loss identified for 13q with a copy number ratio 
less than 0.90, the mean copy number ratio in this region was less than 1.0. 
 
A: Adenocarcinoma (N=23) 
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B: Squamous cell lung cancer (N=17) 
 
C: Small cell lung cancer (N=9) 
Figure 4-13:  The identification of common copy number aberrations in cfDNA for the three 
most frequent histological subtypes of lung cancer. 
The mean and standard deviation of the copy number ratio of each 1 Mb window was plotted against 
chromosomal position for chromosomes known to commonly have CNA.  The green line denotes the 
position of the centromere.  The red line highlights the copy number ratio of 1.0 (or ploidy of 2.0). 
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 Clinical Validation of circulating cell-free DNA genomic instability scores 
Low coverage whole genome sequencing of cfDNA and lymphocyte genomic DNA samples 
was performed with Illumina HiSeq 2500 (see Section 2.17.1).  The sequencing data for 102 
selected lung cancer cases and controls was analysed to determine whether two tested 
genomic instability scores distinguished between lung cancer cases and controls.  Selection 
and characteristics of lung cancer cases and controls are described in Section 3.3.3.  Treated 
cases were removed from analyses because of concerns about introducing bias due to the 
potential confounding effect of treatment on circulating tumour DNA levels and therefore 
genomic instability score (see Section 3.3.3.6). 
 
4.3.2.1 The Plasma Genomic Abnormality 2 (PGA2) score 
The adapted PGA score (PGA2) was calculated by summing the 95th to 99th centile squared 
copy number ratio Z scores from 1 Mb sized windows.  This adaptation of the Xia et al. 
method (266) converts gains and losses to positive values to allow both extremes of the 
distribution to be examined (see Section 2.19.1). 
 
Figure 4-14 displays the copy number ratio profiles, corresponding histogram for copy 
number ratios and scatter diagram for ranked squared copy number ratios for each 1 Mb 
window.  Low magnitude multiple copy number aberrations were detected for case 249 and 
the PGA score was 362.  In comparison, the copy number profile for case 254 was relatively 
flat but there were a number of 1 Mb windows with more extreme copy number ratio values 
and the PGA score was 357. 
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i) Case 254 stage IIIA NSCLC with few cfDNA CNAs and PGA score 357  
 
ii) Case 249 extensive stage SCLC with multiple cfDNA CNAs and yet the PGA score was 
362  
Figure 4-14:  Two lung cancer cases with similar cfDNA PGA2 scores yet different observed 
copy number profiles. 
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4.3.2.1.1 The log10 PGA2 score does not correlate with log10 circulating cell-free DNA levels  
The relationship between the PGA2 score and cfDNA levels was explored on a log10 scale 
because the distribution of the PGA2 score was negatively skewed (see Section 3.3.3.8 for 
establishment of log10 cfDNA levels) for cases (N=51) and controls (N=40) (Figure 4-15).  The 
Pearson’s correlation coefficient was -0.06 (p=0.59) indicating that there was no correlation 
between the log10 PGA2 scores and log10 cfDNA levels. 
Figure 4-15:  A scatter diagram to compare log10 PGA2 scores and log10 cfDNA levels ng/ml. 
Pearson’s correlation coefficient R=-0.06 (p=0.59) (N=91). 
 
4.3.2.1.2 There was no difference in PGA2 scores across different disease stages  
To assess whether PGA2 scores differed according to disease stage the distribution of scores 
were compared.  There was no significant difference between PGA2 scores across different 
lung cancer disease stages (p=0.97 Non-parametric test for trend) (Figure 4-16). 
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Figure 4-16:  PGA2 scores according to the stage of lung cancer. 
Non-parametric test for trend, z=0.03 p=0.97 N=51.  Median and IQR shown. 
 
4.3.2.1.3 The PGA2 score for high risk controls was higher than the PGA2 score for untreated 
lung cancer cases and low risk controls 
To determine whether the PGA2 score distinguished between untreated lung cancer cases 
and high risk controls the distribution of scores were compared.  The median PGA2 score of 
the high risk controls (N=30) was significantly higher than the PGA2 score for the low risk 
controls (N=10), 509 (range 329-628) vs 446 (range 244-570), p= 0.02 Mann Whitney U test.  
Unexpectedly and against our hypothesis, the median PGA2 score for high risk controls 
(N=30) was significantly higher than the score for cases with untreated stage I-IIIA (N=21), 
460 (range 299-555), p=0.04 Mann Whitney U test, and untreated stage IIIB-IV lung cancer 
(N=30), 442 (range 173-655), p=0.01 Mann Whitney U test.  There was no difference in the 
median PGA2 score for low risk controls compared to advanced lung cancer cases (p=0.77 
Mann Whitney U test) (Figure 4-17). 
 
Summing the 95th to 99th percentile Z score copy number ratios of 1 Mb windows to form a 
PGA2 score did not perform as expected in our sample set and therefore this score was not 
further evaluated. 
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Figure 4-17:  PGA2 score for low (N=10) and high risk controls (N=30) and lung cancer cases 
of stage I-IIIA (N=21) and stage IIIB-IV (N=30). 
* p < 0.05.  Median and IQR shown. 
 
4.3.2.2 The Copy Number Aberration score  
An adapted Whole Genome Summed Z score (WGS) (which is now refered to as a Copy 
Number Aberration (CNA) score) was explored as an unselected measure of genomic 
instability across the whole genome.  Z scores of copy number ratios for each 1 Mb window 
were created and then the squared Z scores were summed for each 1 Mb window across the 
genome to create a CNA score (see Section 2.19.2).  Since the CNA score was not normally 
distributed, for most analyses log10 CNA was used (see Section 3.3.3.8 for establishment of 
log10 cfDNA levels). 
 
4.3.2.2.1 Reference control group 
To calculate Z score statistics for each 1 Mb window a reference control group was used.  Ten 
un-related healthy controls at low risk for lung cancer development, with LLP score <2.5%, 
were used as the reference group.  The characteristics of the reference group are displayed 
in Table 4-12 and their selection from the ReSoLuCENT cohort is described in Section 3.3.3.1. 
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Characteristic Low risk controls 
N=10 
Male  3 (30%) 
Female 7 (70%) 
Age at recruitment Median (Range)  55.8 years (48-68) 
Ethnicity White British 10 (100%) 
Smoking Status  Current 0 
Ex 0  
Never 10 (100%) 
Unknown 0 
Status as of August 30th 2016   Alive 9 (90%) 
Dead 1 (10%) 
Table 4-12: The characteristics of the low risk healthy control group (N=10). 
 
4.3.2.2.2 Copy Number Aberration scores and circulating tumour DNA allele fractions 
determined by Ion Torrent targeted sequencing  
Six treated cases (222, 291, 338, 765, 1117, 1324) had CNA scores and cfDNA samples that 
underwent targeted sequencing with the Ion AmpliSeqTM Colon Lungv2 22 gene cancer panel, 
as part of another project carried out in collaboration with Professor Jacqui Shaw’s group at 
the University of Leicester (see Appendix E for methods(285-288).  Five cases had 
chemotherapy prior to blood withdrawal and one case had palliative radiotherapy to the 
bone. 
 
Mutations were identified as somatic if they were unique to cfDNA samples and not present 
in matched genomic DNA after bioinformatics processing.  Allele fractions quantify the levels 
of tumour-derived cfDNA in the circulation (ctDNA) and it was hypothesised that higher CNA 
scores would be associated with higher ctDNA allele fractions. 
 
4.3.2.2.2.1 Identified somatic mutations in circulating cell-free DNA samples with Copy 
Number Aberration scores 
TP53 missense mutations were the most commonly identified variant unique to cfDNA 
samples, found in four of six lung cancer cases with allele fractions varying from 1.9% to 
77.5%.  Two cases had an intronic low frequency SNP identified in ERBB4 and one case with 
adenocarcinoma had an additional EGFR substitution coding a silent mutation identified 
(Table 4-13). 
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Interestingly, one advanced metastatic NSCLC case with a TP53 allele fraction of 77.5% had 
very high cfDNA levels (299 ng/ml) and also a very high CNA score of 169,039.  Another case 
with a ctDNA allele fraction of 1.9% (case 338), had a high CNA score of 2696.  Although case 
numbers were very small (N=6), there was no significant correlation between log10 CNA 
scores and allele fraction (Spearman’s Rank correlation coefficient R=0.26, p=0.66)(Figure 
4-18). 
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Table 4-13:  Clinical characteristics, CNA scores and detected cfDNA mutations using the Ion 
Torrent Platform for six lung cancer cases. 
COSMIC: Catologue of Somatic Mutations in Cancer (60).  MAF: mutant allele fraction.  * this 
case was treated with palliative radiotherapy to the bone prior to blood withdrawal. 
 
Figure 4-18:  Scatter diagram for log10 CNA scores and allele fraction determined by Ion 
Torrent targeted sequencing. 
Spearman’s Rank correlation coefficient R=0.26 p=0.66  
Case  Stage Path CfDNA 
ng/ml  
Unique 
variants 
to 
cfDNA 
Gene COSMIC 
mutation 
CtDN
A 
MAF 
Description CNA 
score 
222 IIIA SQ 6.4 2 TP53 99647 
M1441 
2.4% Substitution
-missense 
983 
ERBB4 - 11.3% Intronic low 
frequency 
SNP 
 
291* IV NOS 299 1 TP53 43635 
H179L 
77.5% Substitution
-missense 
169,039 
338 IV SQ 10.7 1 TP53 9022 
R175H 
1.9% Substitution
-missense 
2696 
765 IV AC 10.1 2 ERBB4 - 4.6% Intronic low 
frequency 
SNP 
4808 
EGFR - 5.2% Substitution
-coding 
silent 
 
1117 IIIB AC 17.1 1 TP53 44142 
Y126S 
2.3% Substitution
-missense 
1377 
1324 IIIA SQ 13.8 1 TP53 Novel 
CG>GA 
R248E 
3.5% In-frame 
dinucleotide 
change. 
Missense 
2187 
0 2 0 4 0 6 0 8 0 1 0 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0
1 0 0 0 0 0
1 0 0 0 0 0 0
M u t a n t  a l l e l e  f r a c t i o n  %
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0
 
C
N
A
 
s
c
o
r
e
R=0.26 
p=0.66 
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4.3.2.2.3 Log10 Copy Number Aberration scores and log10 circulating cell-free DNA levels 
were correlated 
To explore the relationship of log10 CNA and log10 cfDNA levels they were correlated for cases 
(N=51) and controls (N=30).  Log10 CNA were positively correlated with log10 cfDNA levels 
ng/ml (Pearson’s correlation coefficient R=0.58, p<0.0001)(Figure 4-19). 
   
Figure 4-19:  A scatter diagram to show the correlation of log10 CNA scores with log10 cfDNA 
levels ng/ml for lung cancer cases (N=51) and controls (N=30). 
R=0.58, p<0.0001 Pearson’s correlation coefficient 
4.3.2.2.4 Copy Number Aberration scores were higher for advanced stage cancer compared 
to early stage cancer cases  
To assess whether CNA scores increased with tumour burden the distribution of scores 
across disease stages were compared.  The median CNA score differed significantly across 
disease stages for untreated lung cancer cases from stage I to stage IV (p<0.001 Non-
parametric test for trend)(Figure 4-20).  The median CNA score for lung cancer cases with 
stage I disease was 225 (range 117-904) compared to the median CNA score for cases with 
stage IV disease 1389 (range 167-66,869). 
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Figure 4-20:  CNA scores for lung cancer cases according to disease stage (N=51). 
Median and IQR are shown , Non-parametric test for trend z=3.53 p<0.001. 
 
4.3.2.2.5 Small cell lung cancer cases had the highest Copy Number Aberration scores 
compared to other histological subtypes 
The relationship between the CNA score, disease stage and histological subtype were 
explored.  Cases with extensive stage SCLC (N=7) had higher median CNA scores compared 
to cases with advanced non-squamous NSCLC (N=17) and advanced squamous NSCLC (N=6), 
median 35,996 (range 14,277-66,869) vs 592 (range 169-43445), p=0.008 and 1512 (560-
34,275), p=0.03 Mann Whitney U test (Figure 4-21). 
 
The median CNA score was significantly higher for non-squamous NSCLC in advanced stage 
cases (N=17) compared to early stage cases (N=14) (median 592 (range 169-43,445) vs 369 
(range 117-15,373), p=0.04 Mann Whitney U test).  There was a borderline statistically 
significant difference for the higher median CNA score for advanced squamous NSCLC cases 
(N=6) compared to the median CNA score for early stage cases (N=7) (median 1512 (range 
560-34,275) vs 520 (range 192-6757), p=0.05 Mann Whitney U test). 
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Figure 4-21:  CNA score according to histological subtype and disease stage. 
Early: stage I-IIIA.  Late: stage IIIB-IV. Mann Whitney U test. * p <0.05, ** p<0.005, *** 
p<0.0005.  Median and IQR are shown. 
 
4.3.2.2.6 Copy Number Aberration scores were higher for lung cancer cases compared to 
high risk controls 
To establish whether CNA scores differentiated between lung cancer cases (N=51) and high 
risk controls (N=30), the distribution of scores were compared.  The median CNA score for 
lung cancer cases (stage I-IV, N=51) was significantly higher than the median CNA score for 
high risk controls (N=30), 559 (range 117-66,869) compared to 252 (range 149-7122), p 
value=0.0002 Mann Whitney U test (Figure 4-22). 
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Figure 4-22:  CNA score for high risk controls (N=30) and lung cancer cases (N=51). 
*** p<0.001.  Median and IQR are shown. 
 
4.3.2.2.7 Log10 Copy Number Aberration scores predicted status for lung cancer cases and 
high risk controls in univariable and multivariable analyses  
Univariable and multivariable logistic regression were carried out to establish whether the 
CNA score predicted case-control status for lung cancer cases (N=51) and high risk controls 
(N=30) (see Section 2.20.3.1).  Only 3 out of 51 cases had no history of smoking and all high 
risk controls were ex or current smokers, therefore smoking was not included as a variable 
in this analysis. 
 
In univariable analysis, the variables log10 CNA (OR 1.89 p=0.004), log10 cfDNA levels (OR 2.01 
p=0.04) and age at study registration (OR 0.71 p=0.002) were significant.  Whilst, length of 
plasma storage (OR 0.81 p=0.06) and gender (OR 2.42 p=0.07) were of borderline 
significance.  In multivariable analysis, after adjusting for length of plasma storage and log10 
cfDNA levels, log10 CNA (OR 2.16 p=0.03), age at study registration (OR 0.64 <0.0001) and 
gender (OR 5.41 p=0.02) were significant variables (Table 4-14).  Similar to results described 
in Section 3.3.3.8, younger age and being female were associated with higher lung cancer 
risk in multivariable analysis.  This is a consequence of the eligibility criteria for ReSoLuCENT. 
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 Odds ratio (95% CI) P value 
Univariable analysis    
Log10 CNA score 1.89 (1.23-2.88) 0.004 
Log10 cfDNA ng/ml 2.01 (1.05-3.85) 0.04 
Length of plasma storage at -80°C 0.81 (0.65-1.00 0.06 
Age at study registration 0.71 (0.57-0.88) 0.002 
Gender (comparator male) 2.42 (0.93-6.34) 0.07 
Multivariable analysis    
Log10 CNA score 2.16 (1.07-4.34) 0.03 
Log10 cfDNA ng/ml 2.46 (0.95-7.16) 0.10 
Length of plasma storage at -80°C 1.07 (0.71-1.62) 0.74 
Age at study registration 0.64 (0.50-0.82) <0.0001 
Gender (comparator male) 5.41 (1.26-23.21) 0.02 
Table 4-14:  Univariable and multivariable logistic regression analyses for lung cancer cases 
stage I-IV (N=51) and high risk controls (N=30) to evaluate the relationship of different factors 
for predicting case-control status. 
 
The relationship between log10 CNA score and lung cancer was explored by grouping this 
variable into quintiles.  When univariable logistic regression was carried out, the chance of 
detecting a lung cancer case broadly increased with quintile except for individuals ranked in 
the fourth quintile (rank 49-64).  However, there remained a significant difference between 
the fourth quintile compared to the reference group (1-16) with the lowest ranked log10 CNA 
scores (Table 4-15). 
 
 Odds ratio (95% CI) P value 
Univariable analysis    
Log10 CNA score five groups (comparator 1-16)   
17-32 2.2 (0.52-9.30) 0.28 
33-48 6.6 (1.40-31.05) 0.02 
49-64 4.84 (1.09-21.58) 0.04 
65-81 16.5 (2.69-101.33) 0.002 
Multivariable analysis    
Log10 CNA score five groups (comparator 1-16)   
17-32 1.82 (0.31-10.66) 0.51 
33-48 3.27 (0.49-21.92) 0.22 
49-64 8.31 (1.13-61.34) 0.04 
65-81 12.03 (0.45-322.93) 0.14 
Log10 cfDNA ng/ml 2.32 (0.77-7.07) 0.14 
Length of plasma storage at -80°C 1.06 (0.75-1.49) 0.75 
Age at study registration 0.64 (0.48-0.87) 0.004 
Gender (comparator male) 5.42 (1.31-22.43) 0.02 
Table 4-15:  Univariable and multivariable logistic regression carried out for ranked and 
grouped log10 CNA scores (N=81) to evaluate the relationship of different factors for 
predicting case-control status. 
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When multivariable logistic regression was performed for log10 CNA subdivided into two 
ranked groups (based on the significance of the p value in univariable analysis), log10 CNA 
score (OR 5.19 p=0.023), age (OR 0.66 p=0.005) and gender (OR 4.55 p=0.036) were 
significant predictors.  However, log10 cfDNA levels (OR 2.31 p=0.13), length of plasma 
storage (OR 1.06 p=0.72) were not significant predictors of case or control status (Table 
4-16). 
 
 Odds ratio (95% CI) P value 
Univariable analysis    
Log10 CNA score two groups 1-32 compared to 
33-81 
5.85 (2.17-15.77) <0.0001 
Multivariable analysis    
Log10 CNA score groups 1-32 compared to 33-81  5.19 (1.26-21.45) 0.023 
Log10 cfDNA ng/ml 2.31 (0.78-6.78) 0.13 
Length of plasma storage at -80°C 1.06 (0.76-1.48) 0.72 
Age at study registration 0.66 (0.49-0.88) 0.005 
Gender 4.55 (1.11-18.71) 0.036 
Table 4-16:  Univariable and multivariable logistic regression carried out for ranked and 
grouped log10 CNA scores based on the p value of univariable quintile analyses (N=81) to 
evaluate the relationship of different factors for predicting case-control status. 
 
ROC curve analyses using the predicted probability of being a case (based on the logistic 
regression) were performed to compare AUC for the discriminatory ability of the log10 CNA 
score as a continuous variable to distinguish between high risk controls (N=30) and untreated 
lung cancer cases (N=51) (Figure 4-23).  The log10 CNA score had good discriminatory ability 
to differentiate high risk controls (N=30) and untreated lung cancer cases with stage I-IV 
disease (N=51).  The univariable AUC was 0.74 (95% CI: CI 0.63-0.85).  The AUC for the log10 
CNA was greater than the AUC for log10 cfDNA levels, which was 0.67 (95% CI: 0.54-0.79), 
although the 95% confidence intervals overlapped.  The AUC was not improved by the 
combination of log10 cfDNA levels and log10 CNA scores (AUC 0.74 95% CI 0.63-0.85).  The 
AUC for the multivariable model was very high 0.91 (95% CI 0.86-0.97), demonstrating 
excellent discriminative ability when multiple variables were combined (Figure 4-23). 
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i: Univariable model log10 CNA (AUC 0.74 95% CI 0.63-0.85) 
 
ii: Multivariable model including log10 CNA, age, gender, log10 cfdna levels, length of plasma 
storage (AUC 0.91 95% CI 0.86-0.97) 
 
Figure 4-23:  ROC curves for univariable and multivariable models for untreated lung cancer 
cases (N=51) compared to high risk controls (N=30) to establish the role of log10 CNA in 
predicting case or control status 
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4.3.2.2.8 Identifying a cut off for the log10 Copy Number Aberration score for untreated lung 
cancer cases and high risk controls 
To evaluate the potential clinical usefulness of the CNA score different cut offs were explored 
to determine the chance that individuals scoring above the cut off were correctly identified 
as cases (sensitivity) and that individuals scoring below the cut off were correctly identified 
as controls (specificity).  The ROC AUC was 0.74, indicating good discriminatory ability for 
untreated lung cancer cases (N=51) and high risk controls (N=30).  A log10 CNA score cut-off 
of 6.03 gave the best balance of sensitivity 71% and specificity 73% (Table 4-17).  A lower 
cut-off of 5.35 increased sensitivity to 90% and therefore a higher proportion of cases with 
cancer would be correctly identified, but at the cost of reducing the specificity to 37% and 
therefore increasing the false positive rate.  For our screening test, a high sensitivity is 
preferred to reduce the false negative rate and therefore minimise the chance of missing a 
true case. 
 
Log10 CNA score cut-
off 
Sensitivity % Specificity % Likelihood ratio 
5.25 92 20 1.15 
5.35 90 37 1.42 
5.73 78 60 2.00 
6.03 71 73 2.65 
6.33 51 77 2.18 
6.70 42 83 2.47 
6.82 37 87 2.79 
7.24 37 90 3.73 
7.96 33 93 5.00 
Table 4-17:  Examples of different cut-offs for the log10 CNA score and corresponding 
sensitivity, specificity and likelihood ratio values (N=81). 
The likelihood ratio defines how much more likely it is that an individual that tests positive 
has cancer compared to an individual that tests negative. 
 
4.3.2.2.9 There was no difference between the Copy Number Aberration score for early 
stage cancer cases and high risk controls 
To be useful as a potential screening tool, the CNA score needs to differentiate between early 
lung cancer cases and high risk controls and therefore the distribution of CNA scores were 
compared between the two groups.  There was no significant difference between the median 
CNA score for high risk controls (N=30) and cases with early stage (I-IIIA, N=21) cancer, 252 
(range 149-7122) vs 398 (range 117-15,373), p=0.25 Mann Whitney U test.  Advanced stage 
(IIIB-IV, N=30) cases had a higher median CNA score compared to high risk controls (N=30), 
 
 
159 
 
2256 (range 169-66,869) compared to 252 (range 149-7122) respectively p<0.0001 Mann 
Whitney U test (Figure 4-24). 
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Figure 4-24:  CNA score calculated from 1 Mb windows for high risk controls (N=30) and early 
(stage I-IIIA N=21) and advanced (stage IIIB-IV N=31) lung cancer cases (N=51). 
*** p <0.001, **** p<0.0001.  Median and IQR are shown. 
 
4.3.2.2.10 Log10 Copy Number Aberration scores were not predictive of early lung cancer 
cases compared to high risk controls in univariable analysis 
Logistic regression was carried out to evaluate whether log10 CNA scores predicted case or 
control status when early cancer cases (stage I-IIIA, N=21) and high risk controls (N=30) were 
compared.  The log10 CNA score was not a significant predictive factor in univariable analysis 
(OR 1.25 (95% CI 0.74-0.21) p=0.40), and neither were, length of plasma storage (OR 0.82 
(95% CI 0.65-1.04) p=0.82) or log10 cfDNA levels (OR 0.95 (95% CI 0.42-2.16) p=0.91).  Age at 
diagnosis was a significantly significant predictive factor (OR 0.60 (95% CI 0.43-0.84 p=0.003) 
and gender was a borderline significant factor (OR 3.11 (95% CI 0.96-10.09), p=0.06). 
 
Consistent with these results, ROC analysis showed that there was poor discriminatory ability 
when only considering the log10 CNA scores of lung cancer cases with early stage (I-IIIA) 
disease (N=21) compared to the CNA scores of high risk controls (N=30), AUC 0.60 (95% CI 
0.43-0.76).  Combining log10 CNA scores with log10 cfDNA levels did not improve 
discriminatory ability and resulted in an AUC of 0.57 (0.40-0.75)(Figure 4-25)(Table 4-18). 
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i: Log10 CNA (AUC 0.60 95% CI 0.43-0.76) 
 
ii. Log10 CNA and log10 cfDNA (AUC 0.57 95% CI 0.40-0.75) 
Figure 4-25:  ROC curves for log10 CNA alone and combined with log10 cfDNA for untreated 
early lung cancer (I=IIIA, N=21) compared to high risk controls (N=30) to establish their role 
in predicting case or control status. 
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Factor  ROC-AUC for 
stage I-IV  
(N=51) (95% CI) 
ROC-AUC for 
early stage I-IIIA 
(N=21) (95%CI) 
ROC-AUC for 
late stage IIIB-
IV (N=30) 
(95%CI) 
Log10 CNA  0.74 (0.63-0.85) 0.60 (0.44-0.72) 0.84 (0.73-0.93) 
Log10 cfDNA ng/ml 0.67 (0.54-0.79) 0.53 (0.38-0.67) 0.76 (0.64-0.87) 
Log10 CNA and log10 cfDNA ng/ml 0.74 (0.63-0.85) 0.57 (0.40-0.75) 0.84 (0.74-0.94) 
Table 4-18:  ROC analyses demonstrating area under the curve for high risk controls (N=30) 
and untreated lung cancer cases (N=51). 
 
 Log10 Copy Number Aberration score as a prognostic tool 
To evaluate whether the log10 CNA score was a prognostic biomarker for lung cancer, HSCIC 
data with medical record information was used to determine the date that a patient was last 
known to be alive or date of death, and analyses were adjusted according to time from 
diagnosis to blood sampling (see Section 2.20.4).  All untreated cases were included (N=51), 
with the exclusion of two cases for whom the date of disease recurrence was unknown.  
Smoking was not assessed as a prognostic variable because only 3 of 49 cases had never 
smoked. 
 
4.3.3.1 Lung cancer cases with a log10 Copy Number Aberration score higher than the 
median score had shorter survival 
Survival time was shorter for lung cancer cases (N=49) with a log10 CNA score greater than 
the median score of 6.38 compared to cases with log10 CNA score less than the median, 38.01 
months (95% CI 9.83-not available) vs 11.11 months (95% CI 4.70-15.02) respectively.  The 
hazard ratio for death (logrank) was 3.13 (95% CI 1.54-6.35), p=0.0009.  The Kaplan-Meier 
survival curve is displayed in Figure 4-26. 
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Time in 
months 
0 20 40 60 80 100 
No. at risk 
log10  CNA 
<6.38 
24 14 8 6 3 2 
No. at risk 
log10 CNA 
>6.38 
25 5 1 0 0 0 
Figure 4-26:  Kaplan-Meier survival curve for untreated lung cancer cases (N=49) with log10 
CNA greater or less than the median CNA value of 6.38.   
 
4.3.3.2 Log10 CNA score was a prognostic factor in univariable but not multivariable analyses 
Cox regression survival analyses were carried out to establish the prognostic value of 
important variables (see Section 2.20.4.1).  The following variables were significant 
predictors of survival in univariable analysis; disease stage (early I-IIIA or late IIIB-IV) (HR 5.10 
(95% CI 2.28-11.37) p<0.001), log10 CNA score (HR 1.22 (95% CI 1.05-1.42) p=0.008), gender 
(HR 0.48 (95% CI 0.25-0.94) p=0.03) and log10 cfDNA levels (HR 1.38 (95% CI 1.02-1.86) 
p=0.04).  Whilst, performance status (0/1 or 2/3) (HR 2.43 (95% CI 0.93-6.36) p=0.07), age at 
diagnosis (HR 1.05 (95% CI 1.00-1.12) p=0.07), were of borderline significance and, length of 
plasma storage (HR 1.11 (95% CI 0.95-1.31) p=0.18) and histology (NSCLC non squamous vs 
NSCLC squamous vs SCLC (HR 1.15 (95% CI 0.52-2.51) p=0.74 and HR 1.82 (95% CI 0.89-3.74) 
p=0.30) were not significant in univariable analysis.  Variables with p value <0.25 were 
included in the final multivariable model. 
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Disease stage (early I-IIIA or late IIIB-IV)(HR 9.12 p<0.001) and performance status (0/1 or 
2/3)(HR 6.79 p=0.002) were significant predictors for death in multivariable analyses after 
adjusting for gender, log10 CNA score, log10 cfDNA levels and age at diagnosis (Table 4-19).  
There were no significant interactions that required adjustment for in the multivariable 
models, and the assumption of proportional hazards was met. 
 
Factor  Hazard Ratio (95% CI) P value 
Log10 CNA score 0.91 (0.73-1.15) 0.45 
Log10 cfDNA ng/ml 1.15 (0.76-1.75) 0.52 
Length of plasma storage 1.11 (0.92-1.33) 0.27 
Age at diagnosis 1.01 (0.92-1.10) 0.15 
Gender (comparator male) 0.52 (0.25-1.07) 0.08 
Stage (comparator early stage) 9.12 (2.96-27.98) <0.001 
Performance status (comparator PS 0 or 1) 6.79 (2.03-22.71) 0.002 
Table 4-19:  Hazard Ratios for variables tested in multivariable cox regression survival 
analyses of untreated lung cancer cases (N=49). 
 
The relationships between log10 CNA scores were explored by grouping the variable into 
quintiles.  When cox regression survival analyses were carried out after ranking and grouping 
cases into five subgroups, the hazard ratios increased as the log10 CNA scores increased but 
the hazard ratio was only statistically significant for the two groups with the highest ranked 
log10 CNA scores, suggesting that only very high scores impact on survival (Table 4-20). 
 
When cases were split into two subgroups according to the statistical significance of the 
ranked quintile group log10 CNA score, for univariable analysis the hazard ratio was 2.14 
p=0.02.  However, in multivariable analysis when adjusting for gender, age at diagnosis, 
length of plasma storage and log10 cfDNA levels, log10 CNA (HR 0.66 p=0.48) remained non-
significant and disease stage (HR 8.80 p<0.001) as well as performance status (HR 6.97 
p=0.002) remained significant prognostic factors (Table 4-20). 
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 Hazard Ratio  
(95% CI) 
P value 
Univariable analysis   
Ranked and grouped by quintile log10 CNA score 
(comparator 1-10) 
  
11-20 1.80 (0.51-6.35) 0.36 
21-30 2.55 (0.89-7.29) 0.08 
31-40 2.81 (1.06-7.47) 0.04 
41-49 4.46 (1.54-12.89) 0.006 
Multivariable analysis   
Log10 CNA score grouped by quintile (comparator 1-10)   
11-20 1.61 (0.42-6.17) 0.49 
21-30 1.23 (0.40-3.83) 0.72 
31-40 1.08 (0.33-3.48) 0.90 
41-49 0.75 (0.17-3.21) 0.70 
Log10 cfDNA ng/ml 1.14 (0.78-1.68) 0.49 
Length of plasma storage 1.13 (0.92-1.38) 0.23 
Age at diagnosis 1.00 (0.93-1.07) 0.94 
Gender (comparator male) 0.58 (0.26-1.32) 0.20 
Stage (comparator early stage) 9.97 (2.17-45.71) 0.003 
Performance status (comparator PS 0 or 1) 7.20 (1.75-29.61) 0.006 
Univariable analysis   
Ranked and grouped log10 CNA score (comparator 1-30)  
31-49 
 
2.14 (1.15-3.97) 
 
0.02 
Multivariable analysis   
Log10 CNA score (comparator 1-30) 
31-49 
 
0.66 (0.21-2.05) 
 
0.48 
Log10 cfDNA ng/ml 1.15 (0.75-1.76) 0.52 
Length of plasma storage 1.14 (0.94-1.38) 0.19 
Age at diagnosis 1.00 (0.91-1.09) 0.93 
Gender (comparator male) 0.53 (0.26-1.08) 0.08 
Stage (comparator early stage) 8.80 (2.91-26.42) <0.001 
Performance status (comparator PS 0 or 1) 6.97 (2.05-23.74) 0.002 
Table 4-20:  Hazard ratios for ranked and grouped log10 CNA scores for univariable and 
multivariable cox regression analyses for untreated lung cancer cases (N=49). 
 
  
 
 
165 
 
4.4 Discussion 
In this pilot study, CNAs were detected in cfDNA of lung cancer cases by low coverage whole 
genome sequencing with Illumina HiSeq 2500, an unbiased and cost effective method.  
CfDNA samples were included from the three most common histological types of lung cancer 
to mimic the general lung cancer population.  As expected, a higher number of CNAs with 
greater magnitude were identified in SCLC cfDNA samples compared to adenocarcinoma and 
squamous cell carcinoma cfDNA samples. 
 
 Analytical performance and validation 
4.4.1.1 Tumour FFPE and circulating cell-free DNA samples 
For the three main histological subtypes of lung cancer, known common tumour CNAs in 
cfDNA samples were identified for some but not all cases.  Tumour-derived cfDNA is diluted 
by wild type DNA in the blood (115).  Copy number gain and loss were defined by setting an 
arbitrary copy number ratio threshold (see Section 4.3.1.7.3).  CNAs may have been missed 
if the set threshold was too high but a lower threshold may increase false positives.  
Alternatively, Z scores of targeted regions could be calculated to more accurately define copy 
number gains and losses.  This approach still relies on setting a threshold but takes into 
account population differences by comparison to a healthy control group (168, 178).  Even 
though only a small number of copy number aberrations exceeded the set threshold, the 
mean copy number ratio for a certain genomic region was often less than or greater than 
1.0.  Furthermore, resolution to identify focal CNAs in our samples was limited and focal 
aberrations are more common in NSCLC compared to SCLC (66). 
 
CNAs detected in tumour FFPE DNA showed good correlation with CNAs detected in matched 
cfDNA samples for two out of ten cases.  A number of factors may explain the poor 
correlation of CNAs in matched tumour and cfDNA samples.  Anti-cancer treatment prior to 
blood withdrawal may affect the identification of plasma CNAs by reducing tumour bulk and 
therefore the shedding of tumour DNA into the circulation (129).  Of the ten cases with 
matched tumour FFPE DNA and cfDNA, four had treatment prior to blood withdrawal.  In 
hierachial cluster analysis, the cfDNA CNA profile of a patient treated with neoadjuvant 
chemotherapy grouped with the profiles of healthy controls rather than untreated lung 
cancer cases (265).  Tumour-derived cfDNA levels in the circulation are dynamic; levels can 
increase with disease progression and reduce in response to anticancer therapy (129, 131). 
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Tumour evolution may be an important factor to explain discrepancies between CNAs 
detected in tumour DNA and matched cfDNA samples.  Tumour evolution results in the 
development of major clones and subclones of cells that can be spatially separated within 
tumours and between primary and metastatic sites (289).  CNAs identified in tumour DNA 
from both primary and metastatic sites have been detected in cfDNA samples (113).  
Furthermore, CNAs from a case with synchronous primary ovarian and breast tumours were 
detected in cfDNA samples (290).  Four of our cases had more than five months pass from 
tumour sampling to blood withdrawal and new genetic alterations in the tumour may have 
developed in this time. 
 
Genetic heterogeneity is a characteristic of lung tumours and therefore evaluating only a 
small sample of tumour tissue taken by a single biopsy can lead to sampling bias (196, 291).  
CfDNA may be more representative of tumour heterogeneity than a tumour biopsy, because 
cfDNA comprises of DNA from different clonal populations of tumour cells (106).  In a multi-
region whole exome/whole genome sequencing study of seven early stage NSCLC primary 
tumours (adenocarcinoma and squamous cell carcinoma), there were CNAs unique to one or 
two tumour regions and intra-tumour heterogeneity varied from 4% to 63% (292).  However, 
less than 5% of the tumour was sampled and therefore intra-tumour heterogeneity may have 
been underestimated (196).  In another study of four patients with early stage lung cancer, 
43% of ubiquitous (predicted to occur early in tumour evolution and therefore be clonal) and 
heterogenous (predicted to occur late in tumour evolution and therefore be subclonal) single 
nucleotide variants (SNVs) identified in tumours were identified in plasma (107).  The allele 
fraction of ubiquitous SNVs ranged from 0.15% to 23.25% whilst the range for heterogenous 
SNVs was 0.28% to 1.17% (107).  TRACERx is a longitudinal study that will provide greater 
understanding of tumour heterogeneity and evolution in NSCLC by sequencing of tumour, 
cfDNA and ctDNA (293). 
 
Another possible explanation for the poor correlation of CNAs between tumour FFPE DNA 
and cfDNA samples could be the introduction of artefact due to repetitive regions, PCR or 
sequencing errors and poor quality DNA.  This can cause false positives and negatives.  To 
reduce false positives from repetitive regions, any window that overlapped regions 
blacklisted by ENCODE were removed (see Section 2.18.6.2).  Furthermore, normalisation of 
cfDNA and tumour FFPE DNA read profiles against genomic DNA read profiles to create copy 
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number ratios may help to reduce error from sequencing artefact if present in both samples 
as well as eliminate inherited aberrations (see Section 2.18.6.1).  The coverage of tumour 
FFPE DNA samples was significantly lower than the coverage of cfDNA samples X0.18 vs 
X0.49, this may reflect poor quality tumour DNA that has been damaged by formalin fixation 
and paraffin embedment (274).  Deletion of chromosome 19 was identified in cfDNA samples 
spiked with tumour FFPE DNA, control cfDNA sample (0% FFPE DNA) and control tumour 
FFPE DNA (100% FFPE DNA).  This observation may be an artefact related to the fragmented 
nature of cfDNA and FFPE DNA and is further discussed in Section 4.4.2.1. 
 
Tumour clones and subclones when diluted by wild type DNA in the circulation may be 
present at too low an allele fraction to be detected by low coverage whole genome 
sequencing.  The detection of tumour-derived CNAs in cfDNA is dependent on the fraction 
of ctDNA in the circulation (178, 290) and sample coverage (178).  Higher ctDNA fractions in 
the plasma were associated with a higher proportion of tumour associated CNAs in cfDNA 
samples (290).  In silico analyses showed that when the fractional DNA concentration 
reduced a higher number of reads were required to detect CNAs (290).  In addition, the 
magnitude and size of CNAs also influences detection (290).  Two copy gains were detected 
with higher sensitivity than one copy gain or loss (290).  The detection of ctDNA is also 
dependent on the number of ctDNA molecules recovered from plasma, highlighting the 
importance of efficient plasma extraction methods (169).  In addition, the short half-life of 
cfDNA may explain how some patients with advanced cancer have no measurable mutant 
fragments because cfDNA is rapidly cleared from the circulation (179). 
 
4.4.1.2 The limit of detection of copy number aberrations in circulating cell-free DNA with 
low coverage sequencing 
The limit of detection by visual inspection for the identification of CNAs was shown to be 
approximately 10-20%, which was determined by adding tumour FFPE DNA to control plasma 
at different proportions.  This may be an underestimate because tumour FFPE DNA can be 
of poor quality due to the DNA damage that occurs during formalin fixation and paraffin 
embedment (274).  DNA quality is an important factor to ensure that sequencing results are 
reliable and accurate.  The mutant allele fraction may give a more specific measure of ctDNA 
but is reliant on the tested allele being mutated in the tumour.  Furthermore, tumour 
aneuploidy is not taken into account neither is the  increase or decrease in the numbers of 
circulating mutant copies caused if a mutation is present in a region of copy number gain or 
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loss (294).  Low coverage whole genome sequencing (0.1X) detected tumour-derived CNAs 
in patients with advanced breast cancer in cfDNA samples with mutant allele fraction greater 
than 10% (178).  In other studies, CNAs were detected in cfDNA samples by whole genome 
sequencing with mutant allele fractions between 3.7% to 5% (167, 179, 290).  Although, the 
numbers of cases with mutant allele fractions and CNA scores were small, these results 
compare well to the mutant allele fractions observed for our cases with high CNA scores (see 
Section 4.3.2.2.2). 
 
With high coverage sequencing, in silico analysis showed that a cfDNA mutant allele fraction 
of 0.75% had a sensitivity greater than 90% and specificity greater than 99% for the detection 
of chromosomal arm cfDNA CNAs (167).  In silico analyses may not be representative of real 
values and confirmatory experiments are required.  The presence of longer DNA fragments 
have been associated with a higher detection rate of CNAs, emphasising the need for good 
quality DNA (179). 
 
Commercial reference standards may more accurately determine analytical sensitivity and 
specificity and the lower limits of detection.  Human cancer cell line DNA has been sheared 
to 160 bp to produce commercial reference standards with known fractions of mutant alleles 
and copy number variants (275).  Using visual inspection is not a very precise measure for 
determining the lower limit of detection.  Neither is using correlation because the optimal 
cut-off is unknown.  Furthermore, there was correlation of copy number ratios between 
100% tumour DNA and cfDNA without any tumour DNA added.  This may be due to 
sequencing artefact for example chromosome 19 loss was demonstrated in both 100% 
tumour FFPE DNA and cfDNA without spiked tumour FFPE DNA.  To get a more precise 
estimate of the lower limit of detection the circulating mutant allele fraction with Ion Torrent 
targeted sequencing was explored (see Section 4.3.2.2.2). 
 
4.4.1.3 Fragment size of circulating cell-free DNA samples  
The baseline median cfDNA fragment length was significantly longer for low risk controls 
(158 bp) compared to high risk controls (146 bp) and cases (146 bp).  This may represent 
differences in the mechanism of cfDNA release into the circulation.  One-hundred and forty 
six bp is equivalent to the size of a mono-nucleosome and 158 bp is more consistent with the 
size of a mono-nucleosome plus linker protein (115).  Heitzer et al 2013, reported slightly 
longer peak fragment lengths for cfDNA in healthy controls compared to patients with 
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advanced colorectal cancer when cfDNA fragments were size separated by electrophoresis 
by Agilent Bioanalyser (113).  There was a higher proportion of smaller cfDNA fragments 
(<145 bp and <100 bp) identified by PCR in the blood of colorectal cancer patients compared 
to healthy controls (108).  DNA fragment size differences are important to understand to 
ensure accurate quantification and mutation analysis by using primers of an appropriate 
length (295).  Furthermore, differences in the size of DNA fragments may aid the 
differentiation of cases and controls (114). 
 
The baseline cfDNA profiles for both cases and controls in this study contained DNA greater 
than 500 bp in size.  Larger fragments may represent DNA secreted directly from tumour 
cells into the blood or DNA released by macrophages after the necrotic death of tumour cells 
rather than the small fragments expected after apoptotic cell death (179).  PCR selectively 
amplifies small DNA fragments and therefore longer DNA fragments in these samples may 
have been lost during library preparation and sequencing. 
 
The bioanalyser profiles of cfDNA libraries often had a peak fragment size around 290 bp and 
a second smaller peak around 450 bp.  This may represent di-nucleosome fragments that 
became visible because of amplification during library preparation.  Baseline cfDNA bi-phasic 
profiles of advanced stage colorectal cancer patients (N=32) were associated with higher 
cfDNA total levels, higher levels of mutant KRAS and higher proportion of copy number 
aberrations after array CGH (median 10% vs 22%), compared to cases without a bi-phasic 
profile (113).  Similar findings were identified for patients with advanced breast cancer 
(N=35), whereby a bi-phasic profile was associated with higher number of CNAs after low 
coverage sequencing (78% vs 7.7%) (179).  A saturation of cfDNA degradation mechanisms 
may occur due to very high cfDNA levels resulting in the release of longer DNA fragments 
(179).  None of our cfDNA baseline profiles were bi-phasic.  The biology and dynamics of 
cfDNA release from tumour cells requires further study across different cancer types, 
between individuals and within the same individual to assess variation. 
 
 Clinical validation  
4.4.2.1 Genomic instability scores as a screening tool in lung cancer 
In this pilot study, the use of two genomic instability scores based on the detection of 
tumour-derived CNAs were explored in cfDNA samples of untreated lung cancer cases and 
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high risk controls.  The CNA score had good discriminative ability between lung cancer cases 
and high risk controls with AUC 0.74.  However, when only early stage (I-IIIA) cases were 
considered there was poor ability to discriminate, with AUC 0.60. 
 
It is more difficult to detect tumour-derived cfDNA in the blood of patients with early stage 
compared to advanced stage disease due to lower tumour volume and therefore lower 
number of tumour cells that can potentially release DNA into the blood (160).  A test with 
high analytical sensitivity has a greater chance of detecting tiny amounts of tumour-derived 
cfDNA (ctDNA) diluted by wild type DNA in the circulation (161).  Low coverage whole 
genome sequencing provides a non-selective approach requiring no prior knowledge of the 
tumour alterations.  In comparison, a personalised approach aims to detect genetic 
alterations known to be present in matched tumour samples and is tailored to each 
individual (161).  With this approach, highly sensitive technologies such as digital droplet PCR 
can be used (161) or genomic regions can be targeted at very high coverage to enhance 
sensitivity of next generation sequencing methods (296) (see Table 1-2).  The disadvantages 
of a personalised approach are that it takes longer, is more costly and that a tumour sample 
must be available with sufficient quantities of extracted DNA for genetic testing so a repeat 
biopsy may be required (161).  Most importantly, a personalised approach cannot be applied 
to a screening programme. 
 
Compared to whole genome sequencing to establish CNAs, targeted approaches reduce the 
proportion of the genome sequenced, therefore the depth of coverage can be increased and 
analytical sensitivity enhanced.  Kirkizlar et al 2015, amplified 3168 SNPs across five genomic 
regions using massively multiplex PCR (mmPCR) to obtain amplicons of 75 bp (294).  
Amplicons were sequenced with Illumina HiSeq 2500 and reads were counted to determine 
CNAs.  Clonal and subclonal tumour-derived cfDNA CNAs were detected in 73% of breast 
cancer cases with stage II disease with an analytical sensitivity of 0.5% (N=11).  The average 
allelic imbalance (AAI) was calculated across specific regions to calculate the proportion of 
abnormal DNA in a cfDNA sample.  CNAs were detected with an AAI between 0.8% and 5.3%.  
To calculate the allelic imbalance of a region, the number of reads for a heterogenous allele 
were compared to the total number of reads for both alleles at the same locus.  Therefore, 
this method requires haplotype information for each individual warranting a combinatory 
biomarker approach (294). 
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A one-unit increase in the log10 CNA score led to a 2.16 (95% CI 1.07-4.34) increased chance 
of lung cancer after adjusting for log10 cfDNA levels, age, gender and length of plasma 
storage.  Generally lower log10 CNA scores were associated with lower total cfDNA levels, 
indicating less ctDNA in the blood stream.  Tumour burden generally correlates with ctDNA 
levels (160).  Some studies (110, 118) but not all studies (138, 152, 209) correlate tumour 
burden with total cfDNA levels.  As discussed in Section 3.4.2, the discrepancy is because 
total cfDNA levels are not specific to cancer and are raised in other medical conditions (102-
105, 280). 
 
There are many potential reasons for not detecting CNAs in cancer cases, such as inadequate 
circulating ctDNA fractions, poor test sensitivity and biological and technical differences 
(discussed in Section 4.4.1.1).  In contrast, some high risk controls had unexpectedly raised 
CNA scores and visual inspection of copy number profiles demonstrated the presence of 
segmental copy number gains and losses despite normalisation to matched genomic DNA 
and elimination of germline aberrations (Appendix F). 
 
Similar to this study, other studies have reported the presence of abnormal DNA in cfDNA 
samples of controls (114, 160, 171, 297).  For example, TP53 mutations were identified by 
Ion Torrent targeted deep sequencing (5000X) in approximately 10% of matched controls 
attending hospital for a non-cancerous medical condition (N=225)(297). 
 
All of our high risk controls were current or ex heavy smokers and genetic alterations may 
have accumulated in cells secondary to prolonged carcinogen exposure or be a sign of 
increasing age (171).  Somatic CNAs were detected in DNA extracted from bronchial biopsy 
specimens sampled at different sites along the airways of cases with more than a 20-pack 
year history of smoking and pre-invasive lung lesions, this is consistent with a ‘field 
characterisation’ effect (298).  However, the tiny fractions of cfDNA released into the 
circulation from pre-invasive lesions (<0.1% (296) or benign cells (299) is unlikely to be 
detected by low coverage whole genome sequencing and therefore may not explain the 
detection of CNA in our high risk controls. 
 
To our knowledge, none of the high risk controls in our study subsequently developed cancer 
that could have explained the presence of non-germline CNAs in the blood.  The median 
length of follow up for high risk controls in our study was approximately seven years (range 
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four to ten years).  In a large international prospective study, TP53 and KRAS mutations were 
identified in 3% and 1% of cfDNA samples of healthy controls that did not subsequently 
develop cancer (median follow up 75.4 months) and 5.5% and 3.8% of controls that 
developed cancer at a later date (median time to event 20.8 and 14.3 months respectively) 
(300).  However, in this study TP53 and KRAS mutations in germline DNA were not 
established.  The clinical impact of detecting abnormal DNA in the blood of individuals 
without cancer needs to be understood to avoid patient anxiety and unnecessary medical 
interventions (301).  Large longitudinal prospective studies with prolonged follow up are 
required to establish the significance of detecting non-germline cfDNA abnormalities in the 
blood of non-cancer cases.  It would be useful to repeat library preparation and sequencing 
for high risk controls in our study to determine if our results are reproducible.  Mapping, PCR 
or sequencing artefacts or errors could lead to false positives, or samples may have been 
cross contaminated. 
 
Deletion of chromosome 19 was a common finding observed across copy number profiles of 
lung cancer cases and high risk controls.  This observation may be related to the fragmented 
nature of cfDNA and be a sequencing artefact as it was also present in a small proportion of 
tumour FFPE DNA copy number profiles but not in H69 cell line DNA copy number profiles.  
 
CNA scores were higher when 5% cell line DNA was spiked into pooled healthy control cfDNA 
compared to samples with no DNA spike.  However, the mutant allele fraction would be 
expected to be a more accurate measure of analytical sensitivity.  CfDNA mutant allele 
fractions were available for six treated lung cancer cases with CNA scores.  The cfDNA mutant 
allele fraction describes the proportion of mutant alleles compared to the total number of 
alleles.  One advanced NSCLC case with a very high CNA score, was found to have a circulating 
TP53 mutant allele fraction of 77.5%, a likely clonal mutation due to its high abundance.  For 
another case despite a relatively low circulating TP53 mutant allele fraction of 1.9%, the CNA 
score was higher than the median CNA score of advanced cases.  It would be useful to know 
the ctDNA allele fraction and AAI score for all untreated cases and controls, to establish the 
relationship with CNA scores and to determine whether ctDNA could be detected. 
 
The PGA2 score was calculated by summing squared copy number ratio Z scores ranked in 
the 95th to 99th percentile.  However, this score did not behave as expected in our cohort.  
The PGA2 score was independent of log10 cfDNA levels and did not increase with advancing 
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disease stage.  Furthermore, high risk controls had significantly higher PGA2 scores 
compared to lung cancer cases.  These results contrast with previous findings by Xia et al. 
2015, whereby the PGA score differentiated between early stage adenocarcinoma cases and 
normal controls (265).  The PGA2 score did not capture the multitude of small aberrations 
present in copy number profiles.  Despite eliminating the top 1% of scores, sequencing 
artefact may still have been present accounting for our results.  Normalisation of each 1 Mb 
copy number ratio calculated to the mean copy number ratio values for the equivalent 1 Mb 
window of a healthy control group may further aid the elimination of sequencing artefact by 
subtracting background noise. 
 
Another copy number aberration score that has been evaluated in cfDNA samples of breast 
and colorectal cancer cases is the Plasma Aneuploidy (PA) score (167).  This score sums the 
Z scores of the top five chromosomal arms with the largest CNAs.  To calculate the PA score, 
first the numbers of reads mapping to a chromosome arm were compared to the total 
number of reads to obtain a genomic representation (GR) score.  A Z score was calculated by 
subtracting the mean GR score of a group of normal controls from the observed GR score 
and dividing this by the standard deviation of the GR score of the normal controls.  The top 
five Z scores for the chromosomal arms were converted to P values and the negative sum of 
the logarithms of the P values were summed (167).  A small change in a Z score equates to a 
large change in a P value and therefore P values can be a better discriminator particularly at 
the extreme ends of a distribution.  Then, the PA score was calculated by taking the observed 
summed log P values and subtracting the mean of the summed log P values of the normal 
controls and dividing by the standard deviation of the summed log P values of the normal 
controls (167).  A cut off greater than 5.84 had a specificity of 99% for the detection of CNAs 
in cfDNA (167).  All controls (N=10) had a PA score less than 5.84 and all cancer cases (N=10) 
had a score higher than 5.84.  The two lowest PA scores for cases had the lowest ctDNA 
fractions (1.4% and 4.7%, overall range 1.4%- 47.9%) (167). 
 
Comparisons of scores between studies is difficult because of differences in the 
characteristics of study participants and methodology.  Furthermore, most studies have 
included only a small number of cases and controls (167, 178, 179, 265).  There are variations 
in methods for blood collection and processing and extraction of cfDNA from plasma.  In 
addition, there are differences in methods of library preparation, sequencing techniques and 
machinery and bioinformatics pipelines.  In this study, the number of reads in a 1 Mb window 
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for cfDNA were compared to matched genomic lymphocyte DNA to obtain copy number 
ratios.  Other studies to obtain copy number ratios, compare the number of reads for cfDNA 
to the mean number of reads of a group of healthy controls.  However, little information is 
given about control groups and they are mostly unmatched to cases for age and gender.  
Furthermore, details regarding smoking history of controls, lung cancer risk, or previous 
history of cancer are absent.  These clinical parameters may be important confounding 
factors. 
 
The use of genomic DNA as a comparative to cfDNA has the advantage of eliminating germ-
line aberrations.  Nevertheless, test cost could be halved if matched genomic DNA was not 
required to be sequenced.  Instead of genomic DNA, the number of reads in cfDNA samples 
could be compared to the mean number of reads from a control group for each 
corresponding 1 Mb window.  A larger control group would increase the number of reads 
across the genome, reduce read variability and therefore increase the chance of detecting a 
true CNA by reducing background noise (169).  However, matching to genomic DNA is a more 
accurate way to reduce false positives and is an advantage of our method compared to other 
genomic instability scores that do not use genomic DNA (178, 266). 
 
4.4.2.2 Circulating cell-free DNA genomic instability scores as a prognostic tool 
Lung cancer cases with a log10 CNA score above the median value lived for significantly less 
time compared to cases with a score below the median value (11 vs 38 months).  However, 
the log10 CNA score was an independent prognostic factor in univariable but not 
multivariable analyses.  This may be due to small sample size and therefore poor power to 
observe a significant difference when additional factors are included in the model or could 
be caused by bias introduced by the interaction of increasing log10 CNA score with increasing 
disease stage.  Consistent with disease stage being a strong prognostic indicator, disease 
stage was found to have the highest hazard ratio and it was the most significant factor 
affecting survival in both univariable and multivariable analyses. 
 
There is minimal data published regarding the prognostic value of cfDNA genomic instability 
scores in cancer cases and larger studies are required.  In a study of twenty prostate cancer 
patients, higher PGA scores were associated with shorter survival in pre-treatment and post-
treatment cfDNA samples (266). 
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 Study limitations  
It would be useful to validate the detection of CNAs in tested plasma and tumour samples by 
an alternative method such as array CGH or Affymetrix 6.0 SNP array.  However, due to the 
mostly low quantities of cfDNA extracted whole genome amplification would be required, 
which may introduce bias.  The identification of CNAs in cfDNA samples with array CGH data 
has been shown to be concordant with low coverage sequencing data (178). 
 
For data analysis,the window size was fixed to 1 Mb and therefore focal CNAs less than 1Mb 
in size or point mutations were not decteced due to inadequate resolution.  In addition, nine 
chromosomal regions had no mapped reads and therefore no coverage.  These regions 
tended to be close to repetitive regions such as telomeres and centromeres and therefore 
there can be difficulty with the alignment of short reads.  There were no reads aligned to the 
short arm of chromosome 13 or 14 but these regions do not contain common CNAs 
important in lung cancer. 
 
This was a retrospective study, although blood samples were collected specifically for cfDNA 
genetic analyses with optimised methods (140).  Different pre-analytical factors and their 
effect on the CNA score were not assessed.  It has been reported that variations in pre-
analytical factors can influence the detection of somatic mutations and that pre-analytical 
factors should be optimised by assessing their impact on the detection of tumour-derived 
cfDNA (135). 
 
Although our sample set is representative of the general lung cancer population for disease 
stage and histological subtype, it is a heterogenous group and the statistical analysis of sub-
groups is limited due to small case numbers. 
 
To establish the CNA score it was assumed that DNA reads obtained after sequencing were 
mapped to the genome without bias and were therefore equally distributed across 
chromosomes.  However, nine chromosomal regions had no aligned reads for all samples 
and this issue is discussed in Section 4.4.3.  The magnitude of copy number losses are limited 
and therefore a copy number loss may not score as high as a copy number gain.  Weighting 
of copy number losses may eliminate this bias for cases with multiple copy number losses 
compared to gains. 
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4.5 Summary and Conclusion 
This pilot study provides preliminary evidence for the detection of CNAs in cfDNA samples of 
lung cancer cases by low coverage whole genome sequencing.  For some but not all lung 
cancer cases, good correlation was found between tumour FFPE and cfDNA copy number 
ratios.  Low coverage whole genome sequencing of cfDNA samples was specific and known 
common tumour CNAs were identified for the three main histological sub-types of lung 
cancer.  The limit of detection for segmental CNAs by visual inspection was 10%-20%.  Many 
factors can influence the detection of cfDNA CNAs.  These include anti-cancer treatment 
prior to blood withdrawal, the fraction of circulating tumour-derived cfDNA, depth of 
coverage, the size of the aberration and biological and technical differences. 
 
To our knowledge, this is the largest study to explore genomic instability scores based on the 
detection of cfDNA CNAs in lung cancer cases and high risk controls.  The PGA2 score did not 
perform as expected in our cohort and was not further evaluated.  The CNA score had good 
discriminatory ability to differentiate between high risk controls and lung cancer cases with 
advanced stage IIIB-IV but not early stage I-IIIA disease.  Low coverage whole genome 
sequencing did not detect the small fractions of tumour-derived cfDNA in the blood when 
cases had low tumour volumes.  A targeted approach that sequences a smaller proportion 
of the genome combined with a high depth of coverage is predicted to increase analytical 
sensitivity whilst maintaining cost effectiveness.  In a screening programme, tumour DNA is 
not available and therefore The Cancer Genome Atlas (TCGA) could be used to identify 
recurrent focal CNAs important in NSCLC and SCLC and these regions could be targeted to 
maximise the potential of detecting aberrations in patients with early stage disease.  Any 
genomic instability score will require validation in a large independent prospective screening 
study.  Low coverage whole genome sequencing may have greater clinical utility in patients 
with advanced cancer to identify CNAs that may predict treatment response and identify 
mechanisms of treatment resistance.  
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5 Discussion and Future work 
Lung cancer causes the highest number of cancer related deaths in the UK and worldwide 
because most cases present with advanced disease that is not amenable to curative 
treatment (302).  The aim of this study was to develop a non-invasive biomarker to aid early 
lung cancer detection.  For clinical utility, such a molecular biomarker test should be based 
on a sample that is easy to obtain, (e.g. blood), be easy to perform in an NHS lab, 
reproducible, cost-effective, and have high diagnostic sensitivity.  The hypothesis was that 
cancer cases would have higher levels of tumour-derived cfDNA (and therefore higher total 
levels of cfDNA), and greater genomic instability scores compared to high risk controls. 
 
To be useful as a screening tool a biomarker needs to differentiate between early lung cancer 
cases and high risk controls.  In this study, cfDNA levels were not significantly different 
between early stage (I-IIIA) lung cancer cases (N=21) and high risk controls defined by an LLP 
score ≥2.5% (N=30).  There was a substantial overlap in the distribution of cfDNA levels in 
these two groups, leading to poor discrimination, with a ROC AUC of 0.53. 
 
More specific to cancer than measuring total cfDNA levels, tumour-derived genetic 
alterations are detected in cfDNA samples of lung cancer cases (167, 195).  To our knowledge, 
this is the largest study to explore genomic instability scores based on the detection of cfDNA 
CNAs in lung cancer cases (N=51) and high risk controls (N=30).  Our approach was designed 
to detect CNAs across the whole genome by low coverage sequencing and therefore enable 
the detection of aberrations across different lung cancer histological subtypes without prior 
knowledge of any aberrations that may be present in a tumour.  This is an essential 
characteristic for a potential screening tool.  Furthermore, by reading only a small proportion 
of the genome at low depth of coverage, more samples could be multiplexed together in one 
sequencing run, thus reducing test cost.  Low coverage sequencing data was available for 51 
untreated cancer cases, 30 high risk and 10 low risk controls. 
 
The PGA2 score was calculated by summing the ranked 95th to 99th percentile squared copy 
number ratio Z score from 1 Mb windows.  There was no association between the PGA2 score 
and total cfDNA levels and the PGA2 score did not increase with increasing lung cancer stage.  
The PGA2 score was not explored further because contrary to our hypothesis, PGA2 scores 
were higher for high risk controls compared to lung cancer cases and low risk controls.  By 
selecting, the 95th to 99th percentiles to capture large amplitude CNAs, smaller amplitude 
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CNAs were missed and genomic instability was only measured across a small proportion of 
the genome. 
 
The CNA score assessed genomic instability across the whole genome and was established 
by summing the squared copy number Z scores for each 1 Mb window, based on the mean 
and standard deviation of the low risk control group.  The log10 CNA score was correlated 
with log10 total cfDNA levels.  Furthermore, the CNA score increased with increasing disease 
stage.  The distribution of CNA scores was higher in lung cancer cases compared to high risk 
controls.  Log10 CNA scores had good discriminative ability in distinguishing between all lung 
cancer cases and high risk controls, with AUC 0.74.  However, when the log10 CNA score was 
adjusted for age, gender, disease stage, log10 cfDNA levels and length of plasma storage the 
AUC improved to 0.91.  Yet, when only early stage cases were compared to high risk controls 
the discriminatory ability was poor with AUC 0.60. 
 
The discriminative ability of the CNA score was affected by an overlap of scores between 
lung cancer cases and high risk controls and this is discussed in detail in Section 4.4.1.1 and 
4.4.2.1.  It is not clear why some high risk controls had high CNA scores.  Other studies have 
reported the detection of genetic alterations in cfDNA of controls (114, 171, 297, 300) and 
this possess a significant challenge to the development of cfDNA screening tests (297, 301).  
In contrast, some lung cancer cases had unexpectedly low CNA scores.  Highly sensitive tests 
are required to detect ctDNA in the plasma, particularly for early stage cancer cases with low 
tumour bulk (159, 160).  Tumour clones and subclones when diluted by wild type DNA in the 
circulation may be present at too low an allele fraction to be detected by low coverage whole 
genome sequencing (107).  
 
The CNA score alone is not recommended for further evaluation as a potential lung cancer 
screening tool, but it may be useful in combination with other genomic biomarkers, or be 
useful to monitor quantitative changes longitudinally because it would be expected that with 
greater cancer burden the CNA score would increase (but remain unchanged in controls 
without cancer). 
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5.1 Study limitations 
 Pre-analytical factors 
Retrospective analyses was performed of plasma and genomic DNA samples.  It has been 
reported that cfDNA levels decline by approximately one third for every year in storage (201).  
Yet, the screening performance of cfDNA levels did not change and cfDNA levels continued 
to have very good ability to distinguish between lung cancer cases and controls (201).  Plasma 
samples in this study had been stored at -80°C for between one and nine years prior to cfDNA 
extraction.  Work carried out in our laboratory has shown that cfDNA yields at two points 
seven years apart were well correlated (Pearson’s R= 0.78, p<0.0001) and there was a 
median yield drop of 2.8 ng/ml (IQ range 0.59-6.2 ng/ml) (Prof Cox personal comment).  To 
minimise the effect of variable lengths of storage this factor was adjusted for, in logistic 
regression and cox regression survival analyses.  In this study, length of plasma storage was 
not a significant factor in logistic regression or survival analyses suggesting that this is not a 
major issue here and vindicates the consistent collection, processing and storage procedures 
defined in the ReSoLuCENT protocol.  However, it may be important to carry out a large 
prospective study with analysis of cfDNA levels within three months of plasma storage to 
eliminate bias potentially caused by degradation. 
 
Higher plasma volumes may be necessary to increase the number of ctDNA genome copies 
present to enable detection.  Just one mutant genome may be present in 5 mls of plasma 
(195).  Up to 3 mls of plasma were used in this study, in other studies up to 20 mls of plasma 
have been collected (167).  Automated cfDNA extraction methods may be necessary to deal 
with high plasma volumes on a large scale. 
 
Much work has been carried out into blood collection, processing and plasma storage (134).  
The aim is to preserve plasma and avoid white blood cell lysis that increases genomic DNA 
and further dilutes tumour-derived cfDNA.  However, little is known about the optimal 
physiological condition of the host for cfDNA testing.  In this study, the colour of the plasma 
was highly variable from clear to cloudy and pale yellow to dark yellow/orange.  High lipid 
plasma levels may interfere with cfDNA binding to the column and result in lower cfDNA 
yields.  It is not known whether improved cfDNA yields are seen after overnight fasting. 
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 Case and control selection 
The design of ReSoLuCENT to enrich the study sample for cases with inherited changes has 
introduced bias into this study.  Lung cancer cases were selected to be of a younger age (<60 
years old) unless there was a strong family history of lung cancer.  This led to a lower 
distribution of ages with a median age of participants of 56 years compared to an unselected 
lung cancer population when it is expected that half of all lung cancer cases occur in 
individuals >70 years old (303).  Therefore, comparison with the general lung cancer 
population is potentially limited. 
 
In this study, controls were selected to be high risk if they had more than a 2.5% chance of 
developing lung cancer over a five-year period according to the LLP risk model (11).  The LLP 
risk model evaluates seven lung cancer risk factors to include older age and smoking history 
(11).  In this study, the median age of selected controls was higher than the median age of 
selected cases.  The age bias may have affected the results; older controls may have more 
genetic changes related to increasing age.  Due to the methods of choosing cases and 
controls, univariable and multivariable logistic regression analyses showed that younger age 
was associated with greater odds of having lung cancer, when in fact the natural history of 
lung cancer is that risk increases with age (303).  As a result, the LLP score performs poorly 
in our selected sample. 
 
The importance of ethnicity in the pathogenesis of cancer is acknowledged (304).  Samples 
used in this study were from mostly white British cases and controls and therefore the 
findings may not be directly transferable to groups of alternative ethnicity.  However, a 
recent targeted exome sequencing study of 509 non-small cell tumours found there to be no 
difference between mutation frequencies and copy number alterations between matched 
black and white individuals (305). 
 
CtDNA levels reduce in response to anti-cancer treatment (129, 131).  In this study, the focus 
was to select cases that had not received anti-cancer treatment prior to blood withdrawal to 
maximise the chance of detecting tumour-derived cfDNA.  However, the numbers of 
untreated cases were limited in the ReSoLuCENT cohort.  Furthermore, the number of cases 
with early stage cancer were small.  Samples from all 21 untreated early stage cases were 
analysed but to adequately power our study as a guide 30 cases were required to estimate a 
true sensitivity of 0.92 or more with a 95% confidence interval width of 0.2 (306).  
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Furthermore, the inclusion of cases with stage IIIA disease, associated with a worse prognosis 
and potentially greater disease bulk compared to cases with stage I and II disease, may have 
led to an overestimation of results in the early stage group.  This group was included because 
they can be radically treated. 
 
The small numbers of cases and controls and retrospective design limits this pilot study.  On 
the other hand there is no study that has tried to compare these two groups.  Due to the 
selection methods and small numbers of cases and controls eligible for our study, it was not 
possible to match chosen cases and controls for age, gender or smoking history to balance 
the distribution of these potentially confounding factors.  To overcome bias in selection of 
cases and controls, any genetic instability score established in our data set must be validated 
prospectively in a large independent study and be tested in the population where the score 
is intended to be used eg. a high risk population attending lung cancer screening.  Prolonged 
follow up is vital to evaluate whether high risk controls with genetic alterations detected in 
cfDNA subsequently develop cancer and how early these alterations can be detected prior 
to any diagnosis of lung cancer. 
 
5.2 Future work  
 Further analyses of data 
5.2.1.1 Combining the CNA score with DNA fragment length (determined by sequencing) 
Whole genome sequencing enables every DNA insert or fragment length to be defined (114).  
Jiang et al 2015 studied the DNA insert size of sequenced fragments (median 31 million 
reads) from selected chromosomal arms known to have aberrations in hepatocellular 
carcinoma tumours and found that tumour-derived DNA fragments were shorter than non-
tumour derived fragments (114).  Therefore, short fragments were over-represented with 
copy number gain and under-represented with copy number loss.  This resulted in a 
difference in the size of fragments between hepatocellular cases and controls, which can be 
quantified.  A score based on the size of sequenced DNA inserts in combination with a CNA 
score may improve the screening performance of our test. 
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 Further experiments 
The lower limit of detection for CNAs of our low coverage approach was approximated to be 
between 10-20% by visual inspection of copy number profiles and 5% for the CNA score, after 
spiking tumour FFPE DNA at known proportions into cfDNA samples of healthy controls.  This 
may be an underestimate because tumour FFPE DNA is degraded and damaged by tissue 
processing methods, which can reduce sequencing efficiency (274).  Accurate methods to 
improve the estimation of the limits of detection or analytical sensitivity of the technique 
would be to use human cell line DNA with known CNAs sheared to 160 bp and spiked into 
cfDNA samples of healthy controls at known different proportions or to use commercially 
available validated standards (275).  In addition, a set of healthy controls is required to be a 
reference to evaluate whether a CNA score from a spiked sample has a significant aberration 
above a set threshold (for example two standard deviations) to evaluate analytical 
sensitivity. 
 
ReSoLuCENT recruited controls that were co-habiting with lung cancer cases and detailed 
smoking histories were collected from participants.  Therefore, exploring CNA scores in this 
cohort may control for environmental damge to DNA and the role of passive smoking may 
be able to be explored. 
 
 Combinatory biomarker approaches 
The addition of total cfDNA levels did not improve the discriminatory ability of the CNA score 
but alternative combinatory approaches are required.  More specific combinatory 
approaches to detect a multitude of tumour derived genetic alterations are recommended 
to aid early cancer detection.  Further supportive evidence for a combinatory approach to 
enhance specificity is that the oncogenic signatures of tumours can be mutational or copy 
number rich (62).  Tumours with a high number of recurrent mutational events may 
therefore have a low number of recurrent CNAs and low CNA scores.  Genomic data held in 
The Cancer Genome Atlas (TCGA) for 3,299 tumours was analysed to identify recurrent 
genetic alteration signatures for 12 tumour subtypes.  This study demonstrated that lung 
squamous cell tumours were copy number rich in comparison to lung adenocarcinoma 
tumours, which had an equivocal proportion of tumours with copy number rich and 
mutational signatures.  In this study, there was a trend for higher CNA scores for NSCLC cases 
with squamous cell lung cancer compared to non-squamous cell lung cancer.  A combined 
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targeted approach for the detection of SNVs and CNAs has successfully detected driver 
genetic alterations in cfDNA samples of early stage breast cancer cases (294). 
 
In 2018, a grant of which I am a co-applicant was successful and led to an award of 
approximately £50,000 from Weston Park Charity.  The aim of this pilot study is to develop a 
multivariable cfDNA biomarker to aid the detection of lung cancer.  The objectives are to 
establish the sensitivity, specificity and utility of a combined optimised CNA score with 
tumour mutation burden.  The CNA score will be optimised by exploring the addition of DNA 
fragment size to the score (as described in Section 5.2.1.1) as well the impact of recurrent 
CNAs, chromosomal re-arrangements and the presene of chromothripsis (reflecting a 
catastrophic genomic instability event) using established bioinformatics data.  The tumour 
mutation burden will be calculated by identifying common SNVs mutated in NSCLC by high 
coverage (>X500) targeted sequencing of cfDNA samples. 
 
Alternatively, methylation occurs early in lung cancer tumourogenesis (307-309) and 
combined approaches have been developed to identify both CNAs and methylation in cfDNA 
samples (106).  By calculating the percentage of 1 Mb bins that were hypomethylated or 
contained a CNA after whole genome bisulphite cfDNA sequencing (mean 93 million reads), 
cases with hepatocellular carcinoma and cases with hepatitis B and cirrhosis were 
distinguished with a sensitivity of 92% and specificity of 88% (106).  A four gene cfDNA 
methylation signature established by evaluating 96 markers by RT-qPCR had excellent 
discriminatory ability to distinguish NSCLC cases (stage I-IV) from healthy controls with AUC 
0.90 (215).  Furthermore, a DNA hypermethylation index established from tumour tissue was 
prognostic in an independent validation cohort of NSCLC stage I cases (310).  Methylation 
cfDNA profiles warrants further investigation in early lung cancer cases and high risk controls. 
 
 Future considerations in order to establish a circulating cell-free DNA screening 
biomarker 
In order to establish cfDNA as a cancer biomarker, methods for cfDNA blood collection, 
processing, plasma DNA extraction, library preparation, sequencing and bioinformatics must 
be standardised prior to clinical implementation.  International efforts are in progress, such 
as CANCER-ID to evaluate, validate and develop standard operating procedures for ctDNA 
genetic analyses (311).  However, the tiny fractions of ctDNA in the blood of early cancer 
cases may still limit the clinical utility of cfDNA as a screening tool. 
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Despite recent advances in technology, ctDNA is not detected in more than 50% of patients 
with stage I lung cancer (159, 169).  High analytical sensitivity is an important factor for 
detecting ctDNA in early cancer cases because the ctDNA allele fraction can be less than 0.1% 
(169, 296).  A high depth of coverage between 5000X to 10000X is required to detect tiny 
ctDNA fractions in the blood but the number of samples that can be multiplexed are reduced 
and therefore test cost increases (160, 297).  In a recent study, a variant allele fraction of 
0.1% equated to a primary NSCLC tumour volume of 10 cm3 (159).  Yet, much smaller tumour 
volumes can be detected by low dose CT screening (5) necessitating a test that can detect a 
variant allele fraction of 0.00014% (159).  At such tiny fractions, it is vital to understand the 
PCR or sequencing error rate or ‘background noise’ for each genetic alteration in order to 
reduce false positives (160).  Further technological advances are required to increase the 
analytical sensitivity for the detection of abnormal DNA in the blood to aid early lung cancer 
detection and avoid false negatives, whilst maintaining cost-effectiveness. 
 
A greater understanding is required to determine the relationship of tumour evolution and 
cfDNA detected genetic alterations in the blood to maximise clinical impact.  The analysis of 
tumour samples and circulating biomarkers in studies such as TRACERx and PEACE are 
enhancing our understanding of clonal and subclonal events (107).  Most recently, the cfDNA 
profiles obtained by multiplex-PCR NGS for the first 100 TRACERx participants with early 
stage NSCLC were published (159).  Clonal ctDNA SNVs were in greater abundance in the 
plasma compared to subclonal SNVs (159), supporting the generation of a cfDNA screening 
test based on recurrent clonal genomic alterations.  CtDNA was detected in nearly all patients 
with early stage squamous tumours (97%) compared to 19% of cases with adenocarcinoma 
and 71% of cases with other NSCLC subtypes (159).  The release of ctDNA into the circulation 
in early stage lung cancer was associated with more necrotic tumours (159).  In this study, 
independent predictors for the detection of ctDNA, included non-adenocarcinoma, lympho-
vascular invasion and high ki67 proliferation index.  These findings highlight the importance 
of understanding the biology of the release of ctDNA in order to design an appropriate 
biomarker test and implies that cases with slow growing less necrotic and/or 
adenocarcinoma tumours are less likely to have ctDNA detected in the blood.  This is an 
important consideration because adenocarcinoma tumours were the most commonly 
detected tumours when screening high risk groups by low dose CT (8).  This implies that even 
with advances in technologies for ctDNA analyses a ctDNA biomarker may still need to be 
combined with different biomarkers from alternative body sources such as sputum, urine or 
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exhaled metabolites to enhance diagnostic sensitivity and specificity to overcome biological 
differences between tumours.  For a screening test to have clinical utility in the NHS it must 
be cost effective and the more biomarkers that are tested the greater the cost.  Our low 
coverage whole genome sequencing approach had an approximate cost of £120 per sample. 
 
For molecular stratification prior to CT screening, a test with a high diagnostic sensitivity is 
warranted so that the false negative rate is low.  Furthermore, a greater knowledge of 
abnormalities in healthy control and high risk groups is required to enhance analytical 
specificity.  A screening test must distinguish between ‘disease associated cfDNA mutations 
from exposure associated mutations’ (300).  A Pre-Cancer Genome Atlas aims to develop 
understanding of pre-invasive events and the genomic steps required to progress to 
malignancy and may identify new approaches for early detection and prevention (312). 
 
Most biomarker studies carried out to date are case-control studies with a relatively small 
number of participants and the biomarker is not always tested in matched high risk groups.  
A screening prospective study testing a validated biomarker to prove clinical utility is very 
costly due to the large numbers of individuals involved and the need for longitudinal follow 
up to determine the outcome of those that test negative and those that test positive with no 
imaging abnormalities detected.  Hence, any tested biomarker in a large prospective 
screening study must be robust and reproducible with established analytical and clinical 
validity to determine clinical utility (313).  Furthermore, meaningful clinical end-points to 
assess the efficacy of any biomarker must be established, such as reducing the number of 
people having imaging investigations and increasing the detection rate of potentially curable 
lung cancers.  A baseline register of biomarker studies may avoid publication selection bias 
and standard guidelines can aid reporting and comparison of studies (313).  Furthermore, 
the ethical, legal and social implications of any developed biomarker must be considered as 
per the ACCE framework (189) . 
 
In the future, it may be possible to determine the origin of ctDNA based on the methylation 
profile (314) or nucleotide footprint (109), which could indicate the next most appropriate 
imaging modality or investigation.  Recently, RNA was isolated from platelets and sequenced 
in order to test the diagnostic value of RNA within tumour-educated platelets.  For six types 
of cancer, the diagnostic sensitivity was 97% and specificity 94% and the RNA signature 
correctly identified the cancer subtype with 71% accuracy (315).  In this study, the majority 
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of patients tested had advanced cancer and more data is required to test the diagnostic value 
in patients with early stage disease.  These findings could lead to an early detection test for 
all cancer subtypes. 
 
In 2016, 100 million dollars was invested in setting up a new company associated with 
Illumina to identify a blood based pan cancer screening test to aid early detection (316).  With 
technological advancements and reduction in costs a cfDNA blood biomarker test may yet 
have clinical utility in the NHS to aid early cancer detection.  A potential biomarker strategy 
to aid early detection of lung cancer is shown in Figure 5-1. 
  
 
 
187 
 
 
 
 
 
 
 
 
NB  
Individuals aged 50-75 years 
Screening questionnaire eg. LLP model or 
autoantibody test 
(high specificity, maintain acceptable PPV when low 
prevalence of the disease is expected) 
Blood biomarker stratification 
(high sensitivity, if test negative high 
chance no cancer ie. high NPV) 
Essential biomarker 
characteristics 
(application to cfDNA) 
High analytical validity- 
reproducible, reliable, high 
analytical sensitivity and 
specificity, appropriate 
analytical range/limit of 
detection, accuracy, 
linearity (measure serial 
dilutions), precision 
(agreement between 
replicates) 
 
Robust pre-analytical 
SOPs -blood collection and 
processing 
 
Robust analytical SOPs -
DNA extraction and 
quantification, library 
preparation, sequencing 
and data analysis. 
 
Comprehensive 
understanding of 
biological factors- sample 
timing, effect of diet (high 
fats) and exercise 
 
High clinical validity- 
defined diagnostic 
sensitivity and specificity in 
the relevant population in 
the training set and 
validation set in case-
control studies and an 
independent prospective 
cohort 
High clinical utility- 
improved patient 
outcomes are 
demonstrated 
Low dose CT (LDCT) thorax imaging 
High risk Low risk 
no action 
Test positive Test negative 
Low risk no action 
Test 
negative- 
repeat blood 
test at 
intervals 
Test positive Indeterminate 
nodule 
LDCT interval testing 
or ? blood biomarker 
stratification 
stratification 
Intervention 
Test 
positive 
Test negative- repeat blood 
test at intervals +/- LDCT 
Figure 5-1:  A potential biomarker strategy to aid lung cancer screening. 
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5.3 Summary of PhD work and collaborations 
During my PhD, I participated in multiple research projects using blood samples and data 
collected in the Sheffield ReSoLuCENT study (Figure 5-2).  I have collaborated with Prof J 
Shaw’s laboratory at the University of Leicester and Prof C. Dive’s laboratory at the Cancer 
Research UK Manchester Institute to analyse cfDNA samples collected in the clinical trial for 
patients with small cell lung cancer called STOMP. In addition, I continue to be an active 
member of the International Lung Cancer Consortium that has genotyped over 15,000 lung 
cancer cases and controls including 11190 samples collected in ReSoLuCENT. 
  
 
CfDNA low 
coverage whole 
genome 
sequencing to 
detect CNAs
51 untreated lung cancer cases 
and 40 controls
2 published genetic instability 
scores evaluated
This work was carried out 
independently
Manuscript in 
preparation
CfDNA targeted 
sequencing with 
the Ion Torrent 
Platform  
40 lung cancer cases 
Ongoing collaboration with 
Prof J. Shaw in Leicester
I learnt methods by visiting the 
laboratory
Ongoing 
collaboration
I wrote the  
introduction to the 
manuscript and 
contributed to 
results analyses
International 
collaboration* to 
identify lung cancer 
susceptilibility 
genes
I co-ordinated genomic DNA 
extraction and data collection 
for 1119 cases and controls  
Data analysis in progress for 
my accepted proposal to 
analyse polymorphisms in 
bone turnover genes
Delayed results
I am co-supervising 
a PhD student
I am a co-author of 
published 
manuscripts 
CfDNA targeted 
sequencing to 
detect mutations in 
samples collected in 
STOMP
Collaboration with Prof C. 
Dive 
By visiting the laboratory I 
learnt methods for plasma 
DNA extraction, library 
preparation and Illumina 
MiSeq sequencing
Ongoing 
collaboration 
Figure 5-2:  Summary of PhD work and collaborations. 
STOMP: Small cell lung cancer trial of Olaparib following response to first line chemotherapy.  
*ILCCO (International Lung Cancer Consortium) GAME_ON study with genotyping results for 
over 15,000 lung cancer cases and controls. 
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7 Appendix 
Appendix A: Potential clinical applications of cfDNA in lung cancer  
Potential clinical applications 
of cfDNA in lung cancer 
Application in lung 
cancer 
Examples of studies in lung cancer 
Predict treatment response 
to molecular targeted 
therapies in advanced cases 
EGFR-TKI and EGFR 
mutations 
 
Bai 2009 
He 2009 
Yung 2009 
Kimura 2007 
Mack 2009 
Mao 2010 
Taniguchi 2011  
Brevet 2011  
Yam 2012  
Nakamura 2012  
Wang 2014 
Weber 2014  
Yanagita 2016 
Oxnard 2016 
Reck 2016 
Reckcamp 2016 
Kasahara 2017 
Remon 2017 
Zhang 2017 
Muller 2017 
Crizotinib and ALK 
re-arrangements 
Wang 2016 
Cui 2017 
Monitor treatment response 
by tracking mutation profiles 
in advanced cases 
EGFR TKI and EGFR 
mutations  
 
 
 
 
 
 
First line 
chemotherapy 
KRAS mutations 
 
BRAF mutations 
Oxnard 2014 
Wang 2014 
Thress 2016 
Reckcamp 2016  
Piotrowska 2016 
Pecuchet 2016  
Zhu 2017 
 
Wang 2010 
 
Yanagita 2016 
 
Janku 2016 
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Identify treatment resistance 
mechanisms and new 
therapeutic targets in 
advanced cases 
EGFR TKI and EGFR 
mutant lung cancer  
 
Punnoose 2012 
Kuang 2009 
Murtaza 2013 
Oxnard 2014 
Douillard 2014 
Chabon 2016  
Yanagita 2016 
Thompson 2016 
Thress 2016 
Sundaresan 
2016 
Kashahara 2017  
Chabon 2017 
Monitor for minimal residual 
disease and disease relapse 
Allelic imbalances, 
cfDNA levels 
 
Targeted ctDNA 
profiling  
Sozzi 2001 
 
 
Abbosh 2017 
Early detection CfDNA levels Sozzi 2001 2003 
Zhang 2010 
Szpechcinski 2015 
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Appendix D: Bioinformatics scripts for data processing  
 Shell script for creating read profiles 
# Map to human genome GRCh38 with bwa 
./bwa mem -M -t 6 [Human_Genome] R1.fq R2.fq > output.sam 
# convert to bam 
samtools-0.1.19/samtools view -Sb output.sam > output.bam 
# sort bam 
samtools-0.1.19/samtools sort output.bam output_sorted.bam 
# mark duplicates with Picard 
java -Xmx2g –jar MarkDuplicates.jar I=output_sorted.bam 
O=output_sorted_dups.bam M=output_sorted_dups.metrics 
# remove duplicates 
samtools rmdup output_sorted_dups.bam output_sorted.nodups.bam 
# only retain uniquely mappable reads with qual>37 
samtools view -b -q 37 output_sorted.nodups.bam > output_sorted.final.bam 
 
# Bin reads (-w window size, or -r mean number of reads in window)   
perl bam2windows.pl --samtools-path=[path to samtools] -gc 
gc1000Base_38.txt [-r 1000] [-w 1000000]test sorted.final.bam 
ref sorted.final.bam > output.tab 
 
 CNAnorm R script for closest normalisation 
#obtain read copy number count files for analysis 
get_results = function(w,x,y,z)  
{ 
a=read.delim(file=”output.tab”, stringsAsFactors=FALSE, 
check.names=FALSE) set.seed(31) 
CN <- dataFrame2object(a) 
#eliminate Y and X chromosome and mitochondrial DNA 
toSkip <- c(“X”,"Y", "MT") 
#normalisation (GC content, closest normalisation for ploidy and heterogeneity) and eliminate 
outliers 
CN <- gcNorm(CN, exclude=toSkip) 
CN <- addSmooth(CN, lambda=7) 
CN <- peakPloidy (CN, exclude=toSkip, method='closest') 
pdf(w, height=4.27, width=11.69) 
plotPeaks(CN) 
dev.off() 
CN <- validation (CN,ploidy = (sugg.ploidy(CN) - 1)) 
#segmentation of normalised copy number ratios 
CN <- addDNACopy(CN) 
CN <- discreteNorm(CN)  
pdf(x, height=4.27, width=11.69) 
#establish copy number profile graphs 
data(gPar) 
gPar$genome$colors$gain.dot <- 'darkorange' 
gPar$genome$colors$grid <- NULL 
gPar$genome$cex$gain.dot <- .2 
gPar$genome$cex$loss.dot <- .2 
plotGenome(CN, superimpose='DNACopy', show.centromeres=FALSE,gPar=gPar, 
colorful=TRUE) 
dev.off() 
pdf(y, height=4.27, width=11.69) 
plotGenome(CN, superimpose='smooth', show.centromeres=FALSE) 
dev.off() 
exportTable(CN, file=z, show='center') 
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Appendix E: Methods for determining somatic mutations by targeted highly parallel 
genome sequencing with the Ion Torrent Platform 
This work was carried out in collaboration with Professor Jaqui Shaw at the University of 
Leicester.  We supplied and shipped plasma and genomic DNA collected in the ReSoLuCENT 
study to Leicester for Ion Torrent analysis.  I spent time in the laboratory in Leicester to learn 
plasma DNA extraction, library preparation and sequencing methods.  I assisted in result 
analysis and checked variants on the Integrated Genomic Viewer. 
 
The Ion Torrent platform is validated for the detection of genome variants from 10 ng of 
tumour FFPE DNA and was therefore an attractive approach for targeted genome sequencing 
of cfDNA.  There were four main steps required to process samples and identify variants.  
These were, library construction, template enrichment, sequencing and data analysis (Figure 
Appendix E1).  The manufacturer’s instructions for the maintenance and preparation of all 
instruments were carried out.  Standard recommended protocols were followed to prepare 
and sequence samples. 
 
Figure Appendix E1: The four main steps for targeted sequencing with the Ion Torrent 
Platform   
1 Library 
construction
•PCR amplification of target regions with Ion AmpliseqTM primers
•Partial digestion of primer sequences  and end repair by phosphorylation
•Adaptor and barcode ligation to amplicons +/- purification
•Quantification of the library 
2 Template 
preparation
•Library pooling
•Template enrichment
•Library quality check
3 
Sequencing
•Preparation of enriched library for sequencing
•Ion Torrent Chip check
•Ion PGM (personal genome machine) sequencing
4 Data 
analysis
•Torrent Suite analysis software (TVC) to call variants
•Ion Reporter software to annotate variant significance
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1 Library construction 
The Ion AmpliseqTM Library Kit 2.0, Ion XpressTM barcode adaptors and Ion AmpliseqTM 
Colon/Lung cancer panel v2 were used to create amplicon libraries (all Thermo Fisher 
Scientific).  Figure Appendix E2 summarises the library construction process. 
 
  
Figure Appendix E2: Ion AmpliSeqTM Library preparation and quantification.  P1 is a universal 
sequencing adaptor.  X is an adaptor with a unique oligonucleotide barcode for each sample. 
1A) PCR amplification of target regions 
Target regions were amplified by primer pairs in the Colon/Lung cancer panel v2.  In a 200 µl 
tube or 96 well plate, 10 µl of 2X Ion AmpliSeqTM primer pool were added to 4 µl of 5X Ion 
AmpliSeqTM HiFi Master Mix.  Up to 10 ng of cfDNA or genomic DNA were added in a 
maximum volume of 6 µl.  Targeted regions were amplified by PCR with thermocycling 
conditions displayed in Table Appendix E1. 
Step Temp Time 
Enzyme activation 99 °C 2 mins 
Denature DNA 99 °C 15 
secs 
*22-28 cycles for cfDNA dependent on 
the number of primer pairs, 17-22 
cycles for genomic DNA.   Anneal/ Extension 60 °C 4 mins 
Hold 10 °C Hold 
 Table Appendix E1:  Thermocycling conditions for the PCR amplification of target regions.   
  
Library quantification 
 
DNA 
P1 
X 
1B Partial digestion of adaptors and end 
repair 
1C Ligate adaptors 
1A Amplify targets with primer pairs  
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1B) Partial digestion of primer sequences and end repair by phosphorylation 
After PCR amplification, primer sequences were partially digested and amplicon ends were 
repaired by phosphorylation to facilitate barcode adaptor ligation, by addition of 2 µl of FuPa 
Reagent to each sample.  The mixture was incubated in a thermocycler with the following 
conditions, 50 °C for 10 minutes, 55 °C for 10 minutes, 60 °C for 20 minutes and final 10 °C 
hold for up to 1 hour. 
1C) Barcode adapter ligation 
A diluted unique barcode adaptor mix was made for each sample by adding 2 µl of Ion P1 
adapter to 2 µl of a unique Ion Xpress Barcode X and 4 µl of sterile nuclease free water.  2 µl 
of this was added to 4 µl of Switch Solution and the partially digested repaired amplicons, 
followed by 2 µl of DNA ligase.  The mixture was incubated at 22 °C for 30 minutes, 72 °C for 
10 minutes and finally held at 10 °C for up to 1 hour. 
1D) Quantification of barcode adaptor libraries and further library enrichment 
Amplicon libraries were purified, enriched, quantified and finally normalised to 100 pM and 
stored at -20oC.  These processed are described in detail in the following sections. 
i. First purification 
The barcode adaptor libraries were purified using AMPure®XP bead (Beckman Coulter, Inc) 
to remove enzymes, FuPa and PCR inhibitors.  45 µl of AMPure®XP beads were added to 30 
µl of the barcode adaptor ligated amplicons to give a bead to sample ratio of 1.5X.  The 
following amendments were made to the purification method, 150 µl of 70 % ethanol was 
used to wash the pellet, and DNA was eluted in 50 µl of Platinum® PCR SuperMix High Fidelity 
(Thermo Fisher Scientific).  Two microlitres of EquilizerTM primers (Thermo Fisher Scientific) 
were added to the eluate and after mixing 50 µl were transferred into a 200 µl tube for an 
additional amplification step. 
ii. PCR amplification, size selection and second purification 
EquilizerTM primers bind only to adaptor ligated DNA amplicons.  PCR amplification aims to 
achieve a stronger signal from adaptor-ligated amplicons and to reduce the effect of 
amplicon loss during the purification steps.  Thermocycling conditions were 98 °C for 2 
minutes followed by 7 cycles of 98 °C for 15 seconds and 60 °C for 1 minute, and a final hold 
at 10 °C. 
After PCR amplification, AMPureTM beads were used in two steps to size select the amplicon 
products and eliminate impurities.  First, 25 µl of beads were added to 50 µl of sample for a 
bead: product ratio of 0.5X.  This ratio resulted in the separation of large DNA fragments that 
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bound to the beads from the small DNA amplicons that remained in the supernatant.  The 
supernatant was transferred to a clean 200 µl tube and a second clean-up was performed.  
Sixty microlitres of beads were added to 50 µl of sample to give a bead to product ratio of 
1.2X.  This resulted in the barcode adaptor DNA amplicons binding to the beads, whilst the 
primers and other impurities remained in the supernatant, which was discarded.   The 
remaining pellet was washed twice in 150 µl of 70% ethanol, dried for 5 minutes and the 
DNA was eluted in 50 µl of Low T.E (Thermo Fisher Scientific).  Libraries were quantified with 
the Qubit® fluorimeter and library quality was assessed with the Agilent Tapestation 2200 
and the high sensitivity kit. 
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2 Template Preparation 
To prepare constructed libraries for sequencing, libraries were pooled and templates were 
formed and quality checked (Figure Appendix E3).  These processes are explained in greater 
detail in the following sections.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure Appendix E3: Template preparation for Ion Torrent sequencing.  A) One barcode 
adaptor ligated DNA fragment binds to a complementary oligonucleotide on the Ion Sphere 
particle within a water droplet in oil.  B) Emulsion PCR forms a positive template covered in 
millions of clonally amplified DNA fragments.  C)  Positive templates are selected.  D) The 
proportion of positive templates are calculated by establishing the AF647:AF488 ratio. 
 
2A+2B) Library pooling and Template Enrichment by emulsion PCR 
Ten microlitres of each library normalised to 100pM were pooled together prior to 
enrichment.  In the enrichment step, barcode adaptor ligated DNA fragments are amplified 
by emulsion PCR.  Ion Torrent Spheres provide the solid platform for this process.  Adaptor 
ligated DNA fragments bind to the complementary primers attached to the spheres.  To 
create monoclonal templates, it is essential that only one DNA fragment binds to each 
sphere, this is achieved by having an excess of spheres compared to fragments.  Fragment: 
bead complexes are mixed with emulsion oil to create droplets in a reaction filter.  The 
solution containing the droplets passes through the multiple channels of a Ion OneTouchTM 
2 amplification plate that is set at two different temperatures for thermocycling.  The 
solution moves due to peristalsis created by a fluidic pump.  After amplification is completed, 
Ion torrent sphere with B 
primers 
 
Barcode adaptor ligated DNA 
with P1 and X adaptors  Fluorophores 
AF488 
AF488 
Sphere with no attached DNA fragments   Positive template with attached DNA fragment  
DNA insert  B and P1  X barcode 
D 
C 
A B 
AF647 
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each sphere is covered in approximately one million clonally amplified DNA fragments to 
create a positive template.  The emulsion flows into a centrifuging tube along with a 
‘recovery solution’ that contains a detergent.  Upon centrifugation, the emulsion is broken 
down, the spheres are washed and recovered into a collecting tube forming a pellet. 
Library templates were prepared with the Ion PGMTM Template OT2 200 kit (Thermo Fisher 
Scientific).  In brief, an amplification solution was made by mixing 500 µl of Ion PGM 
Template OT2 200 Reagent Mix, 300 µl of PCR Reagent B and 50 µl of Enzyme Mix.  Two 
microlitres of the pooled library were added to the amplification solution, which was then 
vortexed and briefly centrifuged.  Then, 100 µl of re-suspended Ion Sphere Particles (ISPs) 
were added.  After vortexing, the final solution of 1000 µl was immediately injected into the 
Ion PGMTM OneTouch Plus Reaction Filter (Thermo Fisher Scientific) followed by 1500 µl of 
oil.  The filter was inverted carefully and inserted onto the automated Ion OneTouchTM  2 
instrument (Thermo Fisher Scientific).  The programme PGM: Ion PGMTM Template OT2 200 
kit was run. 
2C) Selection of Ion sphere positive templates 
Complementary DNA fragments attached to the positive template spheres have biotin 
incorporated into the P1 adaptor.  The biotinylated positive sphere templates bind to the 
MyOneTM Streptavidin C1 beads and are separated from non-template spheres by magnet 
transfer, this maximises sequencing yield.  The Ion sphere positive templates are then 
washed.  The complementary strand attached to a DNA fragment on the sphere are 
separated by the addition of NaOH but stay bound to the beads.  The beads and therefore 
complementary fragments are removed using a magnet.  Remaining, are single strands 
attached to the Ion positive spheres that are now ready to be used as a sequencing template. 
The collecting tube holding the enriched library product was removed from the Ion 
OneTouchTM  2 instrument.  All but 50 µl of liquid were discarded and the pellet of spheres 
were re-suspended.  Two microlitres of the enriched sphere product were retained to check 
library quality.  The remaining solution was transferred to the automated Ion OneTouchTM 
enrichment system (Thermo Fisher Scientific) for purification and selection of Ion sphere 
enriched templates with Dynabead® MyOneTM Streptavidin C1 beads (Thermo Fisher 
Scientific).  An 8-well strip was inserted into the Ion OneTouchTM  2 enrichment system.  This 
contained in the following order, the enriched library, 130 µl of Dynabeads® MyOneTM 
Streptavidin C1 beads re-suspended in Beads Wash Solution, 3 consecutive wells filled with 
300 µl of Ion OneTouchTM Wash Solution, an empty well, 300 µl of freshly prepared Melt-Off 
Solution and an empty well to collect the final selected product. 
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2D) Library quality check 
The quality of the enriched library was determined by establishing the ratio of positively 
enriched Ion spheres to the total number of spheres.  This was achieved by using two types 
of fluorophore probes.  The Alexa Fluor® 488 is attached to an oligonucleotide chain that is 
complementary to a sequence present in the primers on all spheres and the DNA template.  
The Alexa Fluor® 647 is attached to an oligonucleotide chain complementary to a sequence 
only present in the DNA template.  Therefore, positive templates are distinguished from 
spheres that have no DNA templates and the percentage of positive template can be 
established (Figure Appendix E3). 
In brief, 2 µl of the enriched library were added to 19 µl of annealing buffer and 1 µl of Ion 
fluorophore probes, both from the Ion SphereTM quality control kit (Thermo Fisher Scientific).  
The solution was incubated at 95 °C for 2 minutes and 37 °C for 2 minutes to enable the 
probes to anneal to their targets.  AF647 and AF488 fluorescence was measured with the Ion 
assay on the Qubit® 2.0 fluorometer and the ratio of positively enriched Ion spheres to total 
Ion spheres was calculated using an Ion Torrent excel file.  The optimal result was a library 
with 10% to 30% of enriched positive template spheres because these are most likely to be 
monoclonal due to a significant excess of spheres compared to DNA fragments. 
 
3) Ion Torrent PGM sequencing 
The Ion Torrent Sequencing 200 Kit v2 (Thermo Fisher Scientific) was used to obtain bi-
directional sequencing reads up to 200 bp in length with the Ion Torrent Personal Genome 
MachineTM (PGM). 
3A) Preparation of enriched spheres for sequencing 
Enriched positive template spheres were combined with Ion control spheres that have DNA 
fragments attached whereby the sequence of bases are known.  The Ion control spheres are 
positive controls for the sequencing process and they aid calibration of the Ion Torrent 
PGMTM to ensure accurate base calling. 
Five microlitres of control Ion spheres were combined with the enriched positive template 
Ion spheres, pipette mixed and centrifuged at 15,000 g for 5 minutes.  Next, 15 µl of the 
supernatant surrounding the resultant pellet of spheres were removed and 12 µl of 
Sequencing Primer were added prior to re-suspending the pellet.  To anneal the sequencing 
primers, the mixture was incubated at 95 °C for 2 minutes followed by 37 °C for 2 minutes.  
Three microlitres of Ion PGMTM Sequencing 200v2 Polymerase were added and the mixture 
was incubated at room temperature for 5 minutes. 
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3B) Chip loading 
The Ion 316 v2 semiconductor chip (Thermo Fisher Scientific) with an expected output of 1.9- 
2.5 million reads was chosen to facilitate sample multiplexing whilst maintaining high 
amplicon coverage at a reasonable cost.  The prepared Ion sphere library (30 µl) was loaded 
onto the calibrated Ion 316 v2 chip for sequencing at a rate of 1 µl per second.  Subsequent 
steps of centrifugation and mixing of the sample aimed to lodge one sphere into each well.  
It was important to avoid the introduction of air into the chip because spheres become 
dislodged.  Any residual liquid was removed from the chip prior to sequencing. 
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3C) Targeted Sequencing 
The Ion PGMTM was used for the sequencing of enriched libraries.  During sequencing, each 
of the four nucleotide bases (A, T, C, G) flowed sequentially over the Ion Torrent 
semiconductor chip, which consisted of millions of wells.  Each well contained one bead that 
was covered in approximately one million copies of a single DNA fragment.  In a well, if the 
flowing nucleotide was complementary to the nucleotide of the DNA template attached to 
the sphere it was incorporated by DNA polymerase into a newly synthesised DNA strand, 
resulting in the release of a hydrogen ion.  The resulting change in pH of the solution was 
measured directly by an Ion Sensor, converted to a voltage and the base was called.  A 
different nucleotide then flowed over the chip and the process was repeated.  If no base was 
incorporated there was no change in pH, and no base was called.  If two consecutive bases 
were identical on the DNA template two nucleotides were incorporated, two hydrogen ions 
were released, the voltage was doubled and two of the same bases were called.  Bi-
directional sequencing was carried out because two templates were generated for each 
fragment during initial library construction therefore both ends of an amplicon were 
sequenced with a single read run (147). 
 
 
Figure Appendix A) Ion Semiconductor Sequencing (add labels to sensor and ISP).  Addapted 
from Rothberg et al. 2011 (147) (permission not required by the publisher). 
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4) Ion Torrent Data Analysis 
Automated data analysis optimised for the processing of Ion Torrent sequencing data was 
completed with the Ion Torrent suite software (version 4.0.2) on the Ion Torrent Server.  
Nucleotide bases were called, assigned Phred like quality scores and ordered to form one 
read for every DNA fragment.  Reads were trimmed, filtered and aligned to the human 
reference genome 19 (hg19) to enable the identification of variants.  The data analysis steps 
are outlined in Figure Appendix E4. 
Figure Appendix E4: Data analyses steps to identify variants and their significance  
PH CHANGE WAS RECORDED AS A VOLTAGE
In a well, a change in pH  changes the charge in the Ion sensing plate, which creates a voltage 
that is recorded as a digital output.
•DAT file (data aquisition)
NUCLEOTIDE BASES WERE CALLED
Digital signals were processed into called bases after applying phasing and signal corrections.  
Quality scores were assigned.
•WELLs file
READS WERE FORMED AND PROCESSED
Nucleotide bases were ordered to create reads 
Adaptors and low quality 3'ends were trimmed (Quality score <15)
Low quality reads were removed (polyclonal, <8 bp (adaptor dimer or trimmed reads), low or 
unrecognised signal)
Trimmed and filtered reads were demultiplexed
•Unmapped BAM (Binary aligment map) file
ALIGNMENT TO A REFERENCE
Reads were aligned to the reference human genome hg19 with the Torrent Mapping Alignment 
Program.  Post alignment quality scores were assigned. 
•Mapped BAM file
VARIANTS CALLED
Variants were called in targeted regions in the Torrent Variant Caller Plug in
•VCF (Variant Call Format) file
VARIANT SIGNIFICANCE DETERMINED
The significance of a called variant can be annotated by the 'Torrent Variant Caller Plug in' or 
checked in COSMIC.    
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Ion Torrent Phred like quality scores 
A quality or Phred like score was assigned to each nucleotide to predict the likelihood of the 
called base being correct (325).  This score enabled sequencing quality to be compared 
between experiments and established the accuracy of each individual base call (326). 
Torrent Variant Caller 
Aligned reads were evaluated for base discrepancies from the reference sequence using the 
Torrent Variant Caller Plugin (TVC version).  Somatic low stringency parameters were applied 
to optimise low frequency variant detection but minimise false negatives.  SNVs, MNPs (multi 
nucleotide polymorphisms) and Indels were called in the targeted regions defined by the 
specific Ion Torrent Panelv2 BED files. 
Manual checking of called variants 
The parameters of all called variants were manually checked.  Variants with a quality Phred 
score less than 20 or original amplicon coverage of less than 50 were discarded.  All reads of 
called variants were visualised in the Integrated Genomic Viewer (IGV version 2.3) to 
determine false positives due to PCR artefact, sequencing errors and strand bias.  Variants 
were excluded if the variant allele was called within 10 nucleotide bases of the end of a read 
due to the higher error rate of DNA polymerase.  Figures Appendix E5 and Appendix E6 
display accepted and rejected variant calls. 
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Figure Appendix E5: Example of a read profile of an accepted variant viewed in IGV. Reads in 
red are on the positive/forward strand and reads in blue are on the negative/reverse strand.  
The reference allele is T and the variant allele is C. 
 
 
Figure Appendix E6: Example of a read profile of a rejected variant viewed in IGV.  The 
reference allele is G and the variant allele is A.  The variant allele is called within five bases 
of the end of the reverse/negative strand 3’ end and is most likely an artefact introduced by 
mis-priming during PCR amplification. 
 
Determination of the significance of a called variant 
Targeted sequencing can identify discrepancies between the reference and DNA sequence 
within the length of an amplicon.  It is important to determine whether a variant is somatic 
or germline.  We sequenced lymphocyte genomic DNA and if a variant was identified to be 
present in both germline and cfDNA samples it was eliminated.  All somatic variants were 
checked for their presence in the public database of somatic mutations COSMIC (327). 
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Appendix F: Copy number profiles for cfDNA samples 
Untreated lung cancer cases (age, gender, centre, smoking status, stage, pathology)(N=51) 
(WPH: Weston park hospital Sheffield, NGH: Northern General Hospital, Sheffield, DRI: 
Doncaster Royal Infirmary, AGH: Airedale, VHC: , CHM: Christies Hospital Manchester, SGH:  
P130 (57 years, male, WPH, ex-smoker, stage IV adenocarcinoma) 290 CNA score 
 
P146 (66 years, female, WPH, ex-smoker, stage IV adenocarcinoma) 494 CNA score  
 
P157 (60 years, female, WPH, current, stage III SCLC) 40062 CNA score 
 
P165 (54 years, female, DRI, current, stage IV NSCLC NOS) 266 CNA score 
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P240 (58 years, male, DRI, current, stage IV NSCLC NOS) 660 CNA score 
 
P244 (65 years, female, NGH, current, stage IIA squamous) 211 CNA score 
 
P246 (58 years, female, WPH, never smoked, stage IV adenocarcinoma) 169 CNA score 
 
P249 (60 years, male, WPH, ex-smoker, stage IV SCLC) 28704 CNA score 
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P254 (61 years, female, WPH, ex-smoker, stage IIIA NSCLC NOS) 804 CNA score 
 
P255 (59 years, female, DRI, current, stage IV squamous) 692 CNA score 
 
P261 (59 years, male, NGH, current, stage IA adenocarcinoma) 393 CNA score 
 
P276 (54 years, female, NGH, ex-smoker, stage IIA adenocarcinoma) 268 CNA score 
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P281 (55 years, male, WPH, ex-smoker, stage IIIA adenocarcinoma) 478 CNA score 
 
P288 (60 years, male, NGH, current, stage IA squamous) 904 CNA score 
 
P332 (59 years, female, DRI, ex-smoker, stage IV squamous) 560 CNA score 
 
P434 (57 years, male, NGH, ex-smoker, stage IIB squamous) 192 CNA score 
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P458 (40 years, female, NGH, ex-smoker, stage IIIA adenocarcinoma) 535 CNA score 
 
P483 (57 years old, male, NGH, ex-smoker, stage IIA squamous) 531 CNA score 
 
P493 (49 years, male, NGH, ex-smoker, stage II NSCLC NOS) 344 CNA score 
 
P527 (50 years, male, WPH, unknown, stage IV adenocarcinoma) 556 CNA score 
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P539 (53 years, male, NGH, unknown, stage IIIA squamous) 520 CNA score 
 
P640 (70 years, male, WPH, ex-smoker, stage IV NSCLC NOS) 16458 CNA score 
 
P710 (55 years, male, DRI, ex-smoker, stage IV SCLC) 5454 CNA score 
 
P790 (59 years, female, DRI, current, stage IIIA adenocarcinoma) 398 CNA score 
 
P800 (56 years, female, DRI, never smoked, stage IV squamous) 1635 CNA score 
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P801 (55 years, male, WPH, ex-smoker, stage IV NSCLC NOS) 213 CNA score 
 
P816 (59 years, female, DRI, ex-smoker, stage IIA adenocarcinoma) 167 CNA score 
 
P823 (53 years, female, AGH, current, stage IV adenocarcinoma) 12229 CNA score 
 
P855 (60 years, male, VHC, current, stage IIIA NSCLC NOS) 346 CNA score 
 
 
232 
 
 
P858 (41 years, male, VHC, ex-smoker, stage IIIB, NSCLC NOS) 43445 CNA score 
 
P878 (57 years, female, DRI, current, stage IV, SCLC) 66869 CNA score 
 
P1024 (56 years, male, CHN, Unknown, stage IIIA squamous) 6757 CNA score 
 
P1027 (61 years, female, CHN, never smoked, stage IV NSCLC NOS) 2877 CNA score 
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P1052 (60 years, female, DRI, ex-smoker, stage IIIB NSCLC NOS) 453 CNA score 
 
P1103 (61 years, male, DRI, current, stage IV adenocarcinoma) 813 CNA score 
 
P1106 (51 years, male, DRI, current, stage IV SCLC) 24652 CNA score 
 
P1111 (60 years, female, WPH, ex-smoker, stage IIIB adenocarcinoma) 592 CNA score 
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P1134 (52 years, male, CHM, ex-smoker, stage IV, SCLC) 35996 CNA score 
 
P1151 (61 years, male, WPH, ex-smoker, stage IIIB squamous) 3064 CNA score 
 
P1155 (60 years, male, WPH, unknown, stage IV adenocarcinoma) 415 CNA score 
 
P1156 (59 years, female, DRI, current, stage IIIB, squamous) 34275 CNA score 
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P1165 (58 years, male, WPH, unknown, stage IV squamous) 1389 CNA score 
 
P1182 (51 years, female, NGH, ex-smoker, stage IIB squamous) 430 CNA score 
 
P1271 (60 years, male, WPH, ex-smoker, stage IV SCLC) 14277 CNA score 
 
P1301 (59 years, female, NGH, current, stage IIB adenocarcinoma) 558 CNA score 
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P1353 (60 years, female, SGH, ex-smoker, stage IIIB adenocarcinoma) 4791 CNA score 
 
P1473 (52 years, female, NGH, unknown, stage IIA NSCLC other) 15373 CNA score 
 
P1518 (52 years, male, CHM, current, stage IV adenocarcinoma) 18823 CNA score 
 
P1634 (51 years, female, NGH, unknown, stage IA adenocarcinoma) 225 CNA score 
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P1646 (48 years, female, NGH, ex-smoker, stage IA adenocarcinoma) 117 CNA score 
 
P1767 (53 years, female, NGH, ex-smoker, stage IA adenocarcinoma) 144 CNA score 
 
 
 
Treated lung cancer cases (age, gender, centre, smoking status,stage, pathology)(N=11) 
P52 (53 years, female, WPH, ex-smoker, stage IV Squamous) 2269 CNA score 
 
P203 (60 years, female, WPH, ex-smoker, stage IIIB SCLC) 25760 CNA score 
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P222 (57 years, male, DRI, ex-smoker, stage IIIA Squamous) 983 CNA score 
 
P291 (50 years, female, WPH, current, stage IV NOS) 169039 CNA score 
 
P338 (75 years, male, WPH, ex-smoker, stage IV Squamous) 2696 CNA score 
 
P765 (55 years, female, WPH, unknown, stage IV adenocarcinoma) 4808 CNA score 
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P805 (57 years, female, WPH, current, stage IV SCLC) 551 CNA score 
 
P806 (58 years, male, DRI, ex-smoker, stage IV mixed adeno/squamous) 531 CNA score 
 
P1117 (52 years, female, WPH, current, stage IIIB adenocarcinoma) 1377 CNA score 
 
P1324 (60 years, male, DRI, never smoked, stage IIIA squamous) 2187 CNA score 
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P1367 (69 years, female, DRI, unknown, stage IIA adenocarcinoma) 280 CNA score 
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High risk controls (age, gender, centre, smoking history)(N=30) 
P27 (72 years, female, WPH, current) 842 CNA score 
P38 (64 years, male, WPH, current) 210 CNA score 
P39 (72 years, male, WPH, current) 916 CNA score 
 
P46 (61 years, female, WPH, current) 194 CNA score 
 
 
 
 
 
 
 
242 
 
P98 (62 years, female, WPH, current) 266 CNA score 
 
P107 (63 years, female, WPH, current) 172 CNA score 
 
P154 (64 years, male, WPH, ex-smoker) 649 CNA score   
 
P241 (60 years, male, DRI, current) 170 CNA score  
P247 (63 years, male, DRI, current) 803 CNA score  
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P293 (69 years, male, WPH, current) 280 CNA score 
 
P355 (62 years, male, SGH, current) 6132 CNA score 
P368 (60 years, male, WPH, ex-smoker) 7122 CNA score 
 
P439 (58 years, male, WPH, current) 149 CNA score 
 
 
 
244 
 
P561 (59 years, male, WPH, current) 192 CNA score 
 
P584 (64 years, female, DRI, ex-smoker) 259 CNA score 
 
P589 (60 years, female, DRI, current) 442 CNA score 
 
P769 (59 years, male, WPH, current) 233 CNA score 
 
P778 (61 years, female, AGH, current) 307 CNA score 
 
P798 (73 years, male, WPH, current) 204 CNA score 
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P886 (60 years, male, CHM, ex-smoker) 369 CNA score 
 
P901 (62 years, male, DRI, current) 169 CNA score 
 
P987 (63 years, male, AGH, current) 217 CNA score 
 
P1034 (61 years, male, CHM, current) 392 CNA score 
 
P1053 (62 years, female, DRI, current) 2390 CNA score 
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P1086 (70 years, female, CHM, current) 245 CNA score 
 
P1160 (57 years male, WPH, current) 211 CNA score 
 
P1296 (65 years, male, WPH, ex-smoker) 149 CNA score 
 
P1326 (58 years, male, WPH, current) 411 CNA score 
 
P1332 (68 years, male, WPH, ex-smoker) 205 CNA score 
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P1339 (60 years, male, WPH, current) 156 CNA score 
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Low risk controls (N=10) (age, gender, centre, smoking history) 
P116 (59 years, female, WPH, never smoked) 
 
P185 (48 years, female, DRI, never smoked) 
P369 (49 years, male, WPH, never smoked) 
P388 (59 years, male,WPH, never smoked) 
 
P397 (53 years, female, DRI, never smoked) 
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P413 (68 years, female, WPH, never smoked) 
 
P441 (51 years, female, DRI, never smoked) 
 
P541 (52 years, female, DRI, never smoked) 
 
  
 
 
250 
 
P721 (61 years, male, WPH, never smoked) 
 
P1099 (65 years, female, WPH, never smoked) 
 
Copy number profiles of H69 cell line DNA spiked into pooled healthy volunteer cfDNA at 
varying proportions 
100% H69 DNA 
 
50% H69 DNA  
 
 
 
 
 
251 
 
20% H69 DNA  
 
10% H69 DNA 
 
5% H69 DNA 
 
0% H69 DNA (100% pooled healthy control cfDNA) 
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Tumour FFPE DNA copy number profile 
Tumour FFPE DNA for case 527 
 
Tumour FFPE DNA for case 1106 
 
